Document:

EX-10.54

 EXECUTION VERSION 

Exhibit 10.54 
 ***CERTAIN
MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

LICENSE AND ASSIGNMENT AGREEMENT 

among 
 Velos Biopharma
Holdings, LLC 
 and 

VelosBio Inc. 
 and

 Oncternal Therapeutics, Inc. 

Dated: February 6, 2018 
  

 TABLE OF CONTENTS 

Page 
  

									
	1.	 	 DEFINITIONS
	  	 	1	
			
	2.	 	 LICENSE GRANT; EXCLUSIVITY; ASSIGNMENT OF CERTAIN RIGHTS
	  	 	7	
		 	2.1	  	 License Grant
	  	 	7	
		 	2.2	  	 Sublicense Rights
	  	 	7	
		 	2.3	  	 UCSD License Agreement
	  	 	8	
		 	2.4	  	 Retained Rights
	  	 	11	
		 	2.5	  	 Exclusivity.
	  	 	11	
		 	2.6	  	 Oncternal License and Assignment Agreement
	  	 	13	
		 	2.7	  	 Selexis Sublicense
	  	 	13	
			
	3.	 	 DEVELOPMENT AND COMMERCIALIZATION; REGULATORY
	  	 	13	
		 	3.1	  	 Product Development
	  	 	13	
		 	3.2	  	 Product Commercialization
	  	 	13	
		 	3.3	  	 Companion Diagnostics
	  	 	14	
		 	3.4	  	 Right of Reference.
	  	 	14	
			
	4.	 	 PAYMENT TERMS
	  	 	14	
		 	4.1	  	 Payment Terms
	  	 	14	
		 	4.2	  	 Payment Method
	  	 	17	
		 	4.3	  	 Taxes
	  	 	18	
			
	5.	 	 RECORDS; AUDIT RIGHTS
	  	 	19	
		 	5.1	  	 Relevant Records
	  	 	19	
			
	6.	 	 INTELLECTUAL PROPERTY RIGHTS
	  	 	19	
		 	6.1	  	 Pre-existing IP
	  	 	19	
		 	6.2	  	 Patent Prosecution
	  	 	20	
			
	7.	 	 INFRINGEMENT; MISAPPROPRIATION
	  	 	21	
		 	7.1	  	 Notification
	  	 	21	
		 	7.2	  	 Enforcement Action
	  	 	21	
			
	8.	 	 CONFIDENTIALITY
	  	 	22	
		 	8.1	  	 Definition
	  	 	22	
		 	8.2	  	 Obligations
	  	 	23	
		 	8.3	  	 Exceptions
	  	 	23	
		 	8.4	  	 Right to Injunctive Relief
	  	 	24	
		 		  	 Ongoing Obligation for Confidentiality
	  	 	24	 
		 		  	 Publicity Review
	  	 	24	 
			
	9.	 	 REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	24	 
		 	9.1	  	 Representations, Warranties and Covenants by Each Party
	  	 	24	 

									
		 	9.2	  	 Additional Representations, Warranties and Covenants by LICENSEE
	  	 	25	
		 	9.3	  	 Additional Representations, Warranties and Covenants by LICENSOR.
	  	 	25	
		 	9.4	  	 No Other Warranties
	  	 	27	
			
	10.	 	 INDEMNIFICATION
	  	 	27	
		 	10.1	  	 Indemnification by LICENSEE
	  	 	27	
		 	10.2	  	 Indemnification by LICENSOR
	  	 	28	
		 	10.3	  	 Indemnification Procedure
	  	 	28	
			
	11.	 	 LIMITATION OF LIABILITY
	  	 	28	
		 	11.1	  	 Consequential Damages Waiver
	  	 	28	
		 	11.2	  	 Liability Cap
	  	 	29	
			
	12.	 	 TERM; TERMINATION
	  	 	29	
		 	12.1	  	 Term
	  	 	29	
		 	12.2	  	 Termination for Convenience
	  	 	29	
		 	12.3	  	 Termination for Cause
	  	 	29	
		 	12.4	  	 Termination for Patent Challenge
	  	 	30	
		 	12.5	  	 Termination for a Bankruptcy Event
	  	 	30	
		 	12.6	  	 Effect of Termination or Expiration
	  	 	30	
		 	12.7	  	 Remedies
	  	 	31	
		 	12.8	  	 Survival
	  	 	31	
			
	13.	 	 LICENSEE INSURANCE
	  	 	31	
		 	13.1	  	 Insurance Requirements
	  	 	31	
		 	13.2	  	 Policy Notification
	  	 	32	
		 	13.3	  	 Third Parties
	  	 	32	
			
	14.	 	 DISPUTE RESOLUTION
	  	 	32	
		 	14.1	  	 General
	  	 	32	
		 	14.2	  	 Meeting
	  	 	32	
		 	14.3	  	 Arbitration
	  	 	32	
			
	15.	 	 PRODUCT IP ASSIGNMENT
	  	 	33	
		 	15.1	  	 Transfer of Product IP
	  	 	33	
			
	16.	 	 GENERAL PROVISIONS
	  	 	33	
		 	16.1	  	 Assignment
	  	 	33	
		 	16.2	  	 Severability
	  	 	34	
		 	16.3	  	 Governing Law
	  	 	34	
		 	16.4	  	 Force Majeure
	  	 	34	
		 	16.5	  	 Waivers and Amendments
	  	 	34	
		 	16.6	  	 Relationship of the Parties
	  	 	34	
		 	16.7	  	 Successors and Assigns
	  	 	34	
		 	16.8	  	 Notices
	  	 	35	
		 	16.9	  	 Further Assurances
	  	 	35	
		 	16.10	  	 No Third Party Beneficiary Rights
	  	 	36	

  
 ii 

									
		 	16.11	  	 Entire Agreement
	  	 	36	
		 	16.12	  	 Counterparts
	  	 	36	
		 	16.13	  	 Cumulative Remedies
	  	 	36	
		 	16.14	  	 Interpretation; Waiver of Rule of Construction
	  	 	36	
		 	16.15	  	 Guaranty
	  	 	37	

  
 iii 

 LICENSE AND ASSIGNMENT AGREEMENT 

THIS LICENSE AND ASSIGNMENT AGREEMENT (“Agreement”), dated as of February 6, 2018 (the “Effective
Date”), is entered into among Velos Biopharma Holdings, LLC., a Delaware limited liability company (“LICENSOR”), and VelosBio Inc., a Delaware corporation (“LICENSEE”) and, solely with respect to Sections
2.3, 2.6, 2.7, 3.3, 3.4, 7.1, 16.1, 16.9, 16.15 and Articles 8 and 14, Oncternal Therapeutics, Inc., a Delaware corporation (“Oncternal”). Each of LICENSOR and LICENSEE, and Oncternal solely with respect to the above-referenced
Sections, may be referred to herein as a “Party,” and collectively as the “Parties”). 
 RECITALS 

WHEREAS, LICENSOR has acquired rights to the Licensed Technology and the Product IP (each hereinafter defined) pursuant to that certain
License and Assignment Agreement by and between Oncternal and LICENSOR dated as of even date herewith (the “Oncternal License and Assignment Agreement”) and 

WHEREAS, LICENSEE desires to obtain and LICENSOR has agreed to grant, certain licenses under the Licensed Technology on the terms and
conditions set forth herein. 
 NOW, THEREFORE, in consideration of the mutual agreements and covenants set forth herein and other good and
valuable consideration, the receipt and sufficiency of which the Parties hereby acknowledge, the Parties, intending to be legally bound hereby, agree to the foregoing and as follows: 

 

	1.	 DEFINITIONS 

  

	 	1.1	 “ADC Product” means any product containing or comprising a ROR1 reactive Antibody
conjugated or fused directly or indirectly with a cytotoxic or cytostatic compound or radionuclide (or any other method of delivering a toxic moiety to a cell using an Antibody). For clarity, “ADC Product” includes, but is not limited to,
any Bispecific Product conjugated, fused, or operatively linked directly or indirectly with a cytotoxic or cytostatic compound or radionuclide (or any other method of delivering a toxic moiety to a cell using an Antibody), but excludes a CAR-T Product. 

  

	 	1.2	 “Affiliate” means, with respect to a Person, any other Person that controls, is
controlled by, or is under common control with such first Person. For the purpose of this definition, “control” shall refer to: (a) the possession, directly or indirectly, of the power to direct the management or policies of an
entity, whether through the ownership of voting securities, by contract or otherwise, or (b) the ownership, directly or indirectly, of the Ownership Threshold or more of the voting securities of such entity. Solely for purposes of this
Agreement and appropriately apportioning responsibilities between the Parties, LICENSOR and Oncternal and their controlled Affiliates shall not be deemed Affiliates of LICENSEE or its controlled Affiliates and LICENSEE and its controlled Affiliates
shall not be deemed an Affiliate of LICENSOR or Oncternal. The “Ownership Threshold” means sixty-five percent (65%) solely for purposes of Section 16.15 with respect to LICENSOR and Oncternal, and fifty percent (50%) for all
other purposes hereunder. 

  
 1 

	 	1.3	 “Applicable Laws” means all applicable laws, statutes, rules, regulations and
guidelines, including, without limitation, but only as applicable to a given activity, all good clinical practices, good manufacturing practices and all applicable standards or guidelines promulgated by the appropriate Regulatory Authority.

  

	 	1.4	 “Antibody” means all forms of antibodies, including, but not limited to: murine,
chimeric, primatized, humanized, de-immunized, and human; as well as all intact antibodies and fragments (including, but not limited to, Fab, scFv formats (including diabodies and tandem scFvs), single domain
antibodies (such as nanobodies), and small modular immunopharmaceuticals (SMIPs)). For clarity, an Antibody includes any Antibody whose carbohydrates or Fc region have been chemically or genetically modified, for example, to alter its
pharmacokinetics, or its interactions with immune effector cells or complement components. 

  

	 	1.5	 “Bispecific Product” means any product containing or comprising a ROR1 reactive
Antibody conjugated, fused, or operatively linked to any other moiety such that such product can bind simultaneously one or more epitopes on ROR1 and one or more different targets (e.g., polypeptide, carbohydrate, or lipid). For clarity, Bispecific
Product does not include a CAR-T Product, but does include “multispecific” Antibodies.

  

	 	1.6	 “Business Day” means any day other than a Saturday, a Sunday or a day on which
commercial banks located in New York, New York are authorized or required by law to remain closed. 

  

	 	1.7	 “Calendar Quarter” means a calendar quarter, except that the first (1st) Calendar
Quarter shall commence on the Effective Date and extend to the end of the then-current calendar quarter and the last calendar quarter shall extend from the first day of such calendar quarter until the effective date of the termination or expiration
of this Agreement. 

  

	 	1.8	 “CAR-T Product” means any product that is a
genetically engineered immune effector cell expressing a ROR1 reactive Antibody or the genetic techniques to produce it, or other genetically engineered cellular therapies having an affinity for ROR1. For clarity, a
CAR-T Product can also include additional Antibodies recognizing other cellular targets, or the genetic techniques to produce it, but does not include any Bispecific Product. 

 

	 	1.9	 “Change in Control” means (a) the acquisition of any voting securities of a Party
by any Person other than an Affiliate of such Party, immediately after which such Person has “Beneficial Ownership” (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of more than
fifty percent (50%) of (i) the then-outstanding shares or (ii) the combined voting power of the Party’s then-outstanding voting securities, or (b) the sale to a Person other than an Affiliate of such Party of all or substantially
all of the assets of such Party. Notwithstanding the foregoing, (1) a stock sale to underwriters of a public offering of a Party’s capital stock or other Third Parties solely for the purpose of financing or a transaction solely to change
the domicile of a Party or (2) a shift in the majority of the voting power of a Party as a resulting of a financing in which a Party issues convertible preferred shares or other securities to investors (including existing investors) in an
arm’s length transaction shall not constitute a Change in Control. 

  
 2 

	 	1.10	 “Commencement” when used with respect to a Registration Study, means the first dosing
of the first subject for such trial. 

  

	 	1.11	 “Commercialize” or “Commercialization” means any and all activities
directed to commercialization, including to manufacture for sale (along with any and all activities directed to the manufacture, receipt, incoming inspections, storage, quality control and handling of raw materials and components and the
manufacture, formulation, packaging, storage, handling, assembly, production, processing, labeling, testing, disposition, packaging and quality control of any product, including manufacturing process development,
scale-up and validation), market, promote, distribute, offer for sale and sell (as well as importing and exporting activities in connection therewith). 

 

	 	1.12	 “Commercially Reasonable Efforts” means: (a) with respect to Development of a
Product, the efforts and expenditures required to obtain Regulatory Approval that would be employed by a company in the pharmaceutical or biotechnology industry of similar size and resources to LICENSEE for a product of similar commercial potential
with similar rights; and (b) with respect to Commercialization of a Product, the efforts and expenditures that would be employed by a company in the pharmaceutical or biotechnology industry of similar size and resources to LICENSEE and for a
product of similar commercial potential with similar rights, in each case of (a) and (b) considering all relevant factors at the relevant time, including anticipated and actual competitiveness of the marketplace, proprietary position (e.g.,
patent coverage), regulatory status, supply chain, profitability (including pricing and reimbursement status achieved), relative safety and efficacy of, and other relevant factors, including technical, legal, scientific or medical factors.

  

	 	1.13	 “Control” or “Controlled” means, with respect to any Intellectual
Property Rights, the legal authority or right (whether by ownership, license or otherwise) of a Party to grant a license or, subject to Section 2.2, a sublicense under Intellectual Property Rights, as applicable, to the other Party pursuant to
the terms of this Agreement without breaching an obligation to or other arrangement with a Third Party. Notwithstanding the foregoing, upon a Change in Control of LICENSOR that results in LICENSOR being merged into a Third Party and/or all or
substantially of LICENSOR’s assets being assigned to a Third Party, the term Control shall be limited to only those Intellectual Property Rights that were Controlled by LICENSOR immediately prior to such Change of Control.

  

	 	1.14	 “Cover”, “Covered” or “Covering” means,
with respect to a particular compound and a particular patent (or patent application), that, but for rights granted hereunder, the making, using or selling of such compound would infringe a Valid Claim in such patent (or patent application, as if
such claim had issued). 

  

	 	1.15	 “Develop” or “Development” means to conduct any and all research and
development activities, including manufacturing process development and manufacturing for research and clinical trial purposes. 

  

	 	1.16	 “Dispute” is defined in Section 14.2. 

 

	 	1.17	 “Dispute Resolution Period” is defined in Section 14.2. 

  
 3 

	 	1.18	 “Executive Officers” means the Chief Executive Officer of each Party.

  

	 	1.19	 “Exploit”, “Exploiting” or
“Exploitation” means to Develop, practice any methods, manufacture, have manufactured, market, use, import, export, Commercialize (including to offer for sale, lease, license, sell, distribute, provide technical support for and/or
otherwise dispose of), in each case, directly and indirectly through multiple tiers. 

  

	 	1.20	 “FDA” means the United States Food and Drug Administration, or a successor federal
agency thereto. 

  

	 	1.21	 “Field” means therapeutic, diagnostic and preventive applications in all
indications. 

  

	 	1.22	 “First Commercial Sale” means, with respect to any Product and any country, the first
sale of such Product in such country by LICENSEE or its sublicensees for monetary value for use or consumption by the general public pursuant to a Regulatory Approval in such country. 

 

	 	1.23	 “Fully-Diluted Equity” means all outstanding shares of capital stock of LICENSEE on an
as converted to common stock basis and all options, warrants or other convertible securities, instruments, understandings, or other rights to receive or acquire capital stock (assuming the exercise or conversion in full of such options, warrants or
other convertible securities, instruments or other rights, regardless of whether any such options, warrants, convertible securities or instruments or other rights are then vested or exercisable or convertible in accordance with their
terms).

  

	 	1.24	 “Infringing Product” means any ADC Product or Bispecific Product that (a) contains
the same active ingredient as a Product, (b) is manufactured using the same process as used to manufacture a Product, or (c) is intended to treat any indication for which such Product is being Exploited.  

 

	 	1.25	 “IND” means: (a) an investigational new drug application filed with the FDA for
authorization for the investigation of a Product, and (b) any of its foreign equivalents as filed with the applicable Regulatory Authorities in other countries or regulatory jurisdictions in the Territory, as applicable. 

 

	 	1.26	 “Intellectual Property Rights” means all trade secrets, copyrights, patents and other
patent rights, trademarks, service marks, moral rights, rights in data and any and all other intellectual property or proprietary rights (including, without limitation, applications relating thereto) in any inventions, compounds, techniques, Know-How or discoveries, whether or not patentable now known or hereafter recognized in any jurisdiction. 

  

	 	1.27	 “Know-How” means any and all tangible and
intangible information and materials, including research and development data, regulatory submissions and correspondence, manufacturing information and processes, formulations, assays, cell lines, sequences, composition of matter, constructs,
discoveries, improvements, modifications, processes, methods, protocols, formulas, utility, data (including physical, chemical, biological, toxicological, pharmacological, preclinical, clinical, and veterinary data), results, inventions, techniques,
discoveries, know-how and 

  
 4 

	 	
trade secrets, patentable or otherwise, and all other scientific, marketing, financial and commercial information or data. 

 

	 	1.28	 “Licensor Know-How” means Know-How which is owned or Controlled by LICENSOR or Oncternal or any of LICENSOR’s or Oncternal’s other Affiliates as of the Effective Date, including producer cell lines, master cells banks and
Regulatory Filings, necessary or useful for the Exploitation of Products; provided that Licensor Know-How expressly excludes any Know-How (i) licensed to LICENSOR
under the UCSD License Agreement or the Selexis Agreement or (ii) included within Product IP. 

  

	 	1.29	 “Licensor Patents” means the patents and patent applications which are owned or
Controlled by LICENSOR or Oncternal or any of LICENSOR’s or Oncternal’s other Affiliates, in each case, having claims Covering, but not exclusively Covering, the (i) Products but only to the extent such Products were existing as of
the Effective Date or (ii) any inventions within the Licensor Know-How but only to the extent such inventions were existing as of the Effective Date, (b) all regular, divisional, continuation,
substitution, continuation-in-part, and continued prosecution applications that claim priority to those patents or patent applications described in subsection (a); (c)
all patents that have issued or in the future issue from any of the foregoing patent applications in subsections (a) or (b), including utility, model and design patents, certificates of invention and applications for certificates of invention;
(d) any reissues, renewal, extensions (including patent term extensions and supplemental certificates and the like), adjustments, reexaminations, revalidations, registrations and pediatric exclusivity periods of any of the foregoing; and
(e) any foreign equivalents of any of the foregoing; provided that the Licensor Patents shall expressly exclude the Platform Patents and the Product IP and any patents licensed under the Selexis Agreement. For clarity, LICENSOR represents and
warrants that, as of the Effective Date, there are no Licensor Patents. 

  

	 	1.30	 “Licensed Technology” means the Licensor Patents and the Licensor Know-How. 

  

	 	1.31	 “LICENSOR’s Equity” means (i) LICENSOR’s ownership
percentage of LICENSEE’s total outstanding equity plus (ii) the ownership percentage of LICENSEE’s total outstanding equity by any Persons that have purchased equity of LICENSEE from LICENSOR (whether purchased directly or indirectly
through subsequent resale), in each case, on a Fully Diluted Basis; provided, that LICENSOR’s Equity shall remain fixed at the percentage existing at the time an agreement is executed for a Change in Control of LICENSEE. For clarity, when
determining LICENSOR’s Equity liquidation preferences shall not be considered. 

  

	 	1.32	 “Major European Market Country” means France, Germany, Great Britain, Spain and Italy.

  

	 	1.33	 “Net Sales” means the total of the gross invoice prices of Products sold or leased by
LICENSEE, its Affiliates and sublicensees, or any combination thereof, less the sum of the following actual and customary deductions where applicable and separately listed: cash, trade, or quantity discounts or rebates (as allowed under applicable
law); sales tax, use tax, tariff, import/export duties or other excise taxes imposed on particular sales (except for value-added and income taxes imposed on the sales of Product in foreign countries); transportation charges; or credits to

  
 5 

	 	
customers because of rejections, returns or recalls of Products or because of rebates or charge-backs. For purposes of calculating Net Sales, transfers to a sublicensee or an Affiliate of Product
under this Agreement for (i) end use (but not resale) by the sublicensee or Affiliate shall be treated as sales by LICENSEE at list price of LICENSEE, or (ii) resale by a sublicensee or an Affiliate shall be treated as sales at the list
price of the Sublicensee or Affiliate. 

  

	 	1.34	 “NDA” means: (a) a new drug application filed with the FDA for authorization for
marketing a Product, and (b) any of its foreign equivalents as filed with the applicable Regulatory Authorities in other countries or regulatory jurisdictions in the Territory, as applicable. 

 

	 	1.35	 “Person” means an individual, corporation, partnership, limited liability company,
trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. 

 

	 	1.36	 “Platform Patents” means the Patent Rights as that term is defined in the UCSD
License Agreement as of the Effective Date, including the patents and patent applications set forth in Schedule A. 

  

	 	1.37	 “Proceeding” means any action, arbitration, audit, hearing, investigation, litigation
or suit (whether civil, criminal, administrative, investigative or informal) commenced, brought, conducted or heard by or before, or otherwise involving any governmental entity or arbitrator. 

 

	 	1.38	 “Products” means any product (i) that is an ADC Product or (ii) that is a
Bispecific Product. For clarity, Products may contain a toxic payload and also be reactive with other targets in addition to ROR1. For further clarity, subject to the final sentence of Section 2.1.1, Products does not include CAR-T Products or ROR1 Antibody Products. 

  

	 	1.39	 “Product IP” means (i) the patents and patents applications set forth on
Schedule B (including all related file histories) and (ii) all Know–How, trademarks, service marks, good will, moral rights, and any and all other Intellectual Property Rights (including, without limitation, the right to sue for
infringement, including past infringement), whether or not patentable now known or hereafter recognized in any jurisdiction owned or controlled by LICENSOR, Oncternal or any of its or their Affiliates as of the Effective Date, in each case, that is
exclusively related to a Product, including the Know-How set forth on Schedule B. 

  

	 	1.40	 “Registration Study” means a clinical study that would satisfy the requirements of 21
C.F.R. § 312.21(c) (or analogous statutory requirements outside of the United States). 

  

	 	1.41	 “Regulatory Approval” means, with respect to a Product in any country or jurisdiction,
any approval (including where required or reasonably prudent to obtain, pricing and reimbursement approvals), registration, license or authorization that is required by the applicable Regulatory Authority to market and sell such Product in such
country or jurisdiction. 

  

	 	1.42	 “Regulatory Authority(ies)” means, collectively, the entities in each
country in 

  
 6 

	 	
the Territory responsible for: (i) granting Regulatory Approvals for a Product in the Territory; or (ii) the establishment, maintenance and/or protection of rights related to the
Licensor Patents or Platform Patents, or any other successor entities thereto. 

  

	 	1.43	 “Regulatory Filings” means, with respect to a Product, any submission to a Regulatory
Authority of any appropriate regulatory application, including, without limitation, any IND, NDA, any submission to a regulatory advisory board, any marketing authorization application, and any supplement or amendment thereto. 

 

	 	1.44	 “ROR1 Antibody Product” means any product containing or comprising a ROR1 reactive
Antibody, including, without limitation, cirmtuzumab, that is not an ADC Product or a Bispecific Product. 

  

	 	1.45	 “Subcontractors” is defined in Section 2.2.3. 

 

	 	1.46	 “Term” is defined in Section 12.1. 

 

	 	1.47	 “Territory” means worldwide. 

 

	 	1.48	 “Third Party” means any Person other than a Party or an Affiliate of a Party.

  

	 	1.49	 “UCSD License Agreement” means that certain License Agreement, dated March 31,
2016, by and between Oncternal and The Regents of the University of California. 

  

	 	1.50	 “Valid Claim” means a claim of (a) an issued and unexpired patent included within
the Platform Patents, the Licensor Patents or the Product IP that (i) has not been revoked, declared unenforceable or unpatentable, or held invalid by a court or other governmental agency of competent jurisdiction that is unappealable or
unappealed within the time allowed for appeal, (ii) has not been admitted to be rendered invalid or unenforceable through reissue, disclaimer or otherwise, and (iii) has not been finally cancelled, withdrawn, abandoned, allowed to lapse,
or rejected by any governmental agency of competent jurisdiction or (b) a pending application within the Platform Patents, the Licensor Patents or the Product IP that has been pending for no more than seven (7) years from the first
priority date. 

  

	2.	 LICENSE GRANT; EXCLUSIVITY; ASSIGNMENT OF CERTAIN RIGHTS 

 

	 	2.1	 License Grant. 

 

	 	2.1.1	 Licensed Technology. Subject to the terms and conditions of this Agreement, LICENSOR hereby grants to
LICENSEE an exclusive and sublicensable (through multiple tiers and subject to Section 2.2) right and license under the Licensed Technology to Exploit Products within the Field and within the Territory (the “License”). For
clarity, the Parties acknowledge and agree that the License includes the right, under the Licensed Technology, to manufacture and Develop the naked ROR1 reactive Antibody solely to the extent necessary to Exploit a Product. 

 

	 	2.2	 Sublicense Rights. 

 

	 	2.2.1	 LICENSEE shall have the right to sublicense the rights granted under the

  
 7 

	 	
License in Section 2.1 to one or more of its Affiliates or Third Parties, provided that LICENSEE shall cause its Affiliates, and shall use Commercially Reasonable Efforts to cause any such
Third Parties, to comply with and be bound by those terms and conditions under this Agreement that by their terms are intended to obligate a sublicensee. Notwithstanding the foregoing, LICENSEE shall remain responsible for complying with such
applicable terms and conditions. A breach by any such Affiliate or Third Party sublicensee of LICENSEE of any such obligation of LICENSEE shall constitute a breach by LICENSEE of this Agreement and shall entitle LICENSOR to exercise its rights
hereunder against LICENSEE, in addition to any other rights and remedies to which LICENSOR may be entitled. 

  

	 	2.2.2	 The terms of this Section 2.2 shall apply to each subsequent sublicensee or sub-sublicensee, as if same
were LICENSEE’s original sublicensee. 

	 	

	 	2.2.3	 LICENSEE and its sublicensees shall have the right to utilize subcontractors, including service providers,
manufacturers, clinical research organizations and distributors who are performing services on LICENSEE’s and/or its sublicensee’s behalf (“Subcontractors”). Any use of such Subcontractors shall not require the consent of
LICENSOR nor shall such Subcontractors be deemed sublicensees for purposes of this Agreement, including this Section 2.2; provided, that, for clarity, LICENSEE and/or its sublicensees shall have the right to grant a sublicense under the License
to any such Subcontractors. 

  

	 	2.3	 UCSD License Agreement. 

 

	 	2.3.1	 Simultaneous with the execution of this Agreement, LICENSOR and LICENSEE agree to enter into a partial
assignment and assumption of the UCSD License Agreement in the form set forth in Schedule C attached hereto (the “Assignment”). Thereafter, LICENSOR, or Oncternal, in conjunction with LICENSEE, will use good faith efforts to
negotiate an amendment to the UCSD License Agreement (as necessary and appropriate) to address certain matters to be agreed by Oncternal and LICENSOR, collectively, and LICENSEE and UCSD including (i) that if the UCSD License Agreement is
terminated for reasons other than LICENSEE’s, its Affiliates’ or sublicensees’ fault, then LICENSEE shall retain its rights under the UCSD License Agreement and (ii) that milestones payments will be clarified such that if a
Product would trigger two different sets of milestones (i.e., milestones associated with an “ADC Licensed Product” and an “Antibody Fragment or Synthetic Antibody Licensed Product” (as such terms are used in the UCSD License
Agreement)) then only the higher of such milestones will be due and payable to UCSD and (iii) that LICENSEE’s status as an Affiliate assignee is permitted by the UCSD License Agreement (and LICENSEE is not considered a “Third Party
Sublicensee” as such term is defined in the UCSD License Agreement) and such status (for purposes of UCSD) shall be retained regardless of any changes in LICENSEE’s ownership, (iv) an appropriate process to enable Oncternal and
LICENSOR, collectively, and LICENSEE and UCSD to discuss and appropriately address patenting matters related to the Platform Patents, (v) the provisions set forth in Section 2.3.4 below, and (vi) that each

  
 8 

	 	
Party shall be released by UCSD from any breaches by the other Party of its assigned or retained portion of the UCSD License Agreement, and (v) the right to sublicense to an Affiliate
without the consent of UCSD. Alternatively to negotiating such an amendment, LICENSOR or LICENSEE may request that UCSD split the UCSD License Agreement into two separate license agreements and in such case LICENSEE would handle its own independent
negotiations with UCSD; provided, that Oncternal shall agree to any reasonable complementary amendment that is necessary to the UCSD License Agreement retained by Oncternal in light of such separate negotiations (e.g., a termination of the UCSD
License Agreement with respect to Products, so that the Products can be directly licensed by UCSD to LICENSEE). Each Party shall have the right to provide input to the other and Oncternal with respect to any such amendments and/or splitting of the
UCSD License Agreement and may join any discussions with UCSD concerning such amendments and/or splitting of the UCSD License Agreement; provided, that, such right to provide input shall terminate with respect to any Party or Oncternal, as
applicable, that receives notice from UCSD that such Party or Oncternal is in breach of the UCSD License Agreement and has not cured such breach during the applicable cure period; provided, further that, in any event, LICENSOR and Oncternal, on the
one hand, or LICENSEE, on the other hand, will not directly communicate with UCSD in the event that UCSD objects to such direct participation in regards to the other such entity(ies) agreement with UCSD (e.g., if UCSD objects to Oncternal
participating in direct discussions regarding LICENSEE’s direct license then Oncternal will not participate). 

  

	 	2.3.2	 Subject to Section 2.3.1, LICENSOR and Oncternal shall maintain their respective rights under the UCSD
License Agreement in full force and effect, without amendment, and perform their respective obligations thereunder in all material respects, except to the extent any failure to do so would not cause an adverse effect on LICENSEE’s rights under
this Agreement. LICENSOR shall keep LICENSEE promptly informed of any development pertaining to the UCSD License Agreement that would reasonably be expected to have an adverse effect on LICENSEE’s rights under this Agreement or the UCSD License
Agreement and in the event that such adverse effect could constitute a breach of the UCSD License Agreement that is uncured by Oncternal, LICENSEE shall have the right to cure such breach. In the event that LICENSEE establishes an independent
agreement with UCSD or UCSD agrees or consents in writing to the Assignment contemplated hereunder then this Section 2.3.2 shall be of no further force or effect. 

 

	 	2.3.3	 Subject to Section 2.3.1, LICENSEE shall maintain its rights under the UCSD License Agreement in full
force and effect and perform its obligations thereunder in all material respects, without amendment, except to the extent any failure to do so would not cause an adverse effect on LICENSOR’s rights under this Agreement or Oncternal’s
rights under the UCSD License Agreement. LICENSEE shall keep LICENSOR promptly informed of any development pertaining to the UCSD License Agreement that would reasonably be expected to have an adverse effect on LICENSOR’s rights under this
Agreement or Oncternal’s rights under the 

  
 9 

	 	
UCSD License Agreement and in the event that such adverse effect could constitute a breach of the UCSD License Agreement that is uncured by LICENSEE, LICENSOR and/or Oncternal shall have the
right to cure such breach. In the event that LICENSEE establishes an independent agreement with UCSD or UCSD agrees or consents in writing to the Assignment contemplated hereunder then this Section 2.3.3 shall be of no further force or effect.

  

	 	2.3.4	 The Parties will use their respective commercially reasonable efforts to cause any amendment to the UCSD
License Agreement, whether a single agreement or a split agreement, to have the following terms related to patents and patent applications and which terms will control, in any event, as between the Parties and their Affiliates:

  

	 	(a)	 Platform Patents. Except as set forth in subsection (b) below, Oncternal has the first right but
not the obligation to conduct, control and pay for the prosecution, maintenance, challenges against validity and unenforceability or patentability with respect to the Platform Patents in the Territory. At Oncternal’s request, LICENSEE shall
reasonably cooperate with and assist Oncternal in connection with such activities. As between the Parties, Oncternal and LICENSEE shall each bear fifty percent (50%) of the reasonable out of pockets costs of the prosecution and maintenance of the
Platform Patents and LICENSEE shall within forty five (45) days reimburse Oncternal for its portion of the costs upon receipt of an undisputed and appropriately documented invoice therefor; provided, that, upon written notice from LICENSEE to
Oncternal, LICENSEE may elect to stop sharing in the costs of any given Platform Patent and, if such notice is provided, then the subject Platform Patent(s) shall no longer be Platform Patents hereunder and shall be excluded from the definition of
Platform Patents. 

  

	 	(b)	 Information Rights. Oncternal shall (i) keep LICENSEE reasonably informed as to the status of each
Platform Patent in the Territory, (ii) provide LICENSEE with copies of correspondence and materials relating to the prosecution, maintenance and defense of each Platform Patent in the Territory, and consider in good faith the reasonable
requests, suggestions and advice of LICENSEE with respect thereto to pass along to UCSD, including, in any event, passing along to UCSD LICENSEE’s reasonable requests for any particular or additional such correspondence or materials and
(iii) promptly provide LICENSEE with copies of correspondence and materials received from or filed with any Regulatory Authority within the Territory related to the Platform Patents which have been received from UCSD. The foregoing activities
shall be undertaken on timing that is reasonably appropriate in light of any timing requirements that Oncternal is subject to so that LICENSEE has a meaningful opportunity to provide input and for Oncternal to consider and act on such input.

  

	 	(c)	 Patent Term Extension. If election with respect to obtaining patent term extension or supplemental
protection certificates or their 

  
 10 

	 	
equivalents in any country with respect to a Product becomes available, upon Regulatory Approval or otherwise, the Parties will discuss in good faith which of the Platform Patents, if any, will
be extended. Oncternal will have final decision making authority for which of the Platform Patents, if any, to extend. 

  

	 	(d)	 Enforcement of Platform Patents. LICENSEE shall have the first right, but not the obligation, using
counsel of its choice, to enforce the Platform Patents against any actual or suspected infringement of the Platform Patents with respect to the Exploitation of an Infringing Product in the Field and Territory by a Third Party or defend any
declaratory action with respect thereto brought by such Third Party (a “Platform Patent Action”), at its expense, and Oncternal shall provide all reasonable assistance to LICENSEE in such Platform Patent Action, including joining,
at LICENSEE’s reasonable expense, such Platform Patent Action if necessary to maintain the Platform Patent Action, or to seek additional or alternative damages or injunctive relief under such Platform Patent Action. Notwithstanding anything to
the contrary herein, neither LICENSEE nor any of its sublicensees shall, without the prior written consent of Oncternal (which shall not be unreasonably withheld, conditioned or delayed), enter into any settlement that would: (i) adversely
affect the validity, enforceability or scope of any of the Platform Patents anywhere in the world, or (ii) give rise to liability of Oncternal or its Affiliates. 

 

	 	(e)	 Recoveries. Any recovery received as a result of any Platform Patent Action shall be used first to
reimburse the Parties for their costs and expenses (including attorneys’ and professional fees) incurred in connection with such action (and not previously reimbursed), and any remaining amounts of such recovery shall be awarded to the Party
that brought the suit; provided that if both Parties jointly bring a Platform Patent Action any amount recovered will be applied pro-rata (based on the agreed allocation of costs and expenses to be borne by
each Party in such action or suit) for the costs and expenses with respect to such action or suit (including reasonable attorneys’ fees and costs). 

  

	 	2.4	 Retained Rights. Each Party reserves all rights with respect to all Intellectual Property Rights that
are not specifically granted herein. Nothing in this Agreement shall be construed to confer any rights upon LICENSEE or LICENSOR by implication, estoppel, or otherwise as to any technology or Intellectual Property Rights of the other Party or its
Affiliates other than as expressly set forth herein. 

  

	 	2.5	 Exclusivity. 

 

	 	2.5.1	 After the Effective Date and during the Term, neither LICENSOR nor any of its Affiliates (including Oncternal)
shall Develop or Commercialize, directly or indirectly, or grant any Third Party any rights to Exploit any Product; provided, however, that the foregoing shall in no way preclude or otherwise limit LICENSOR’s or any of its Affiliate’s
rights to perform or complete any obligations under this Agreement or any other Agreement 

  
 11 

	 	
which may be entered into from time to time by and between LICENSOR and/or any of its Affiliates on the one hand and LICENSEE and/or its Affiliates or sublicensees on the other. The restrictions
set forth in this Section 2.5.1 shall apply to an acquirer of LICENSOR pursuant to a Change in Control (and any of such acquirer’s Affiliates existing prior to the date of such Change in Control), subject to Section 2.5.3.

  

	 	2.5.2	 After the Effective Date and during the Term, neither LICENSEE nor any of its Affiliates shall Develop or
Commercialize, directly or indirectly, or grant any Third Party any rights to Exploit any ROR1 reactive Antibody which is not conjugated, fused, or operatively linked with another chemical or biological entity; provided, however, that the foregoing
shall in no way preclude or otherwise limit LICENSEE’s or any of its Affiliate’s ability to exercise its rights and perform or complete any obligations under this Agreement, including without limitation, Sections 3.1 and 3.3 and any other
activities in the Exploitation of Products that use a naked ROR1 reactive Antibody. The restrictions set forth in this Section 2.5.2 (i) shall apply to an acquirer of LICENSEE pursuant to a Change in Control (and any of such acquirer’s
Affiliates existing prior to the date of such Change in Control), subject to Section 2.5.3 and (ii) shall not restrict LICENSEE or any of its Affiliates or sublicensees from, directly or indirectly, using a ROR1 reactive Antibody which is
not conjugated, fused, or operatively linked with another chemical or biological entity in experiments or studies to elucidate or document the difference obtained between any such Antibody and a Product or in the context of a companion diagnostic;
provided neither LICENSEE nor any of its Affiliates or sublicensees shall, directly or indirectly, use a ROR1 reactive Antibody which is not conjugated, fused, or operatively linked with another chemical or biological entity in any clinical trial or
other human dosing study except in the context of a companion diagnostic. 

  

	 	2.5.3	 Notwithstanding Section 2.5.1 or 2.5.2(i) above, if the acquirer of a Party or any of such acquirer’s
Affiliates (collectively, but excluding such Party and its Affiliates existing immediately prior to the closing of such acquisition, the “Acquirer”) is engaged, directly or indirectly, in any activities that, if carried out by such
Party, would cause such Party to breach its exclusivity obligations set forth in Section 2.5.1 or 2.5.2(i) above (such activities, a “Competing Program”), then the Acquirer shall have six (6) months from the closing date
of such acquisition to notify the other Party in writing that it will either (a) continue such Competing Program, provided that such Competing Program was not and is not conducted through use of any Product IP or Platform Patents or any of such
other Party’s Confidential Information, or (b) complete the Divesture (as defined below) of such Competing Program. The Acquirer’s conduct of such Competing Program during such six (6) month period and thereafter, if applicable,
shall not be deemed a breach of the acquired Party’s exclusivity obligations set forth in Section 2.5.1 or 2.5.2(i), as applicable, provided that the requirements of subclause (a) above are met. The acquired Party shall provide the
other Party with written notice of any such acquisition no later than thirty (30) days after the date thereof. “Divesture”, as used in this Section 2.5.3, means the sale or transfer of rights to the Competing Program by
the Acquirer to a Third Party, which may include the receipt of fees, milestones and royalties on sales of products arising from the divested Competing 

  
 12 

	 	
Program, provided that neither the Acquirer nor any of its Affiliates engage in any management, governance or decision-making activities in connection with such Competing Program.

  

	 	2.6	 Oncternal License and Assignment Agreement. LICENSOR and Oncternal shall not amend
or terminate the Oncternal License and Assignment Agreement without first obtaining the prior written consent of LICENSEE’s chief executive officer, provided that no consent shall be required if such amendment does not directly or indirectly
adversely affect LICENSEE’s rights under this Agreement. 

  

	 	2.7	 Selexis Sublicense. The Parties acknowledge and agree that Oncternal and Licensor do not
have the right to sublicense the Selexis Patents and the Selexis Know-How licensed to Oncternal under that certain Commercial License Agreement between Selexis SA (“Selexis”) and Oncternal (as
successor in interest to Roar Therapeutics) dated May 19, 2014 (the “Selexis Agreement” and as such terms are defined therein) and the Selexis Patents and the Selexis Know-How are
not “Controlled” by LICENSOR and not sublicensed under this Agreement. Notwithstanding the foregoing, LICENSOR and Oncternal agree to use reasonable efforts to assist LICENSEE in obtaining a license directly from Selexis to manufacture and
use the Cell Line (as defined under the Selexis Agreement) in connection with the Products. Notwithstanding the foregoing, pursuant to the Transition Services Agreement, Oncternal has agreed to supply the
UC-961 Antibody to LICENSEE for the period set forth in the Transition Services Agreement and in accordance with the terms therein. If either Oncternal or LICENSEE determines that a sublicense under the
Selexis Agreement is also necessary for Oncternal to supply just the UC-961 Antibody to LICENSEE for incorporation in the Products, the Parties shall promptly negotiate and enter into a separate simple form
sublicense (and consistent with the relevant terms of the Transition Services Agreement) which shall remain in place until such time as LICENSEE has its own agreement with Selexis for use of the Cell Line in connection with the Products.

  

	3.	 DEVELOPMENT AND COMMERCIALIZATION; REGULATORY 

 

	 	3.1	 Product Development. LICENSEE shall itself, or through its sublicensees, use Commercially
Reasonable Efforts to Develop the Product, including each of the Products which are in development as of the Effective Date. In connection with its efforts to Develop Products, as between the Parties and subject to the performance of LICENSOR’s
obligations under this Agreement and the performance of Oncternal’s obligations under the Asset Purchase Agreement and Transition Services Agreement, each between Oncternal and LICENSEE of even date herewith (the “Asset Purchase
Agreement”, the “Transition Services Agreement”, and each a “Transaction Agreement”, respectively), LICENSEE shall, as between the Parties, bear all responsibility and expense for filing Regulatory Filings
and obtaining Regulatory Approval for such Products. 

  

	 	3.2	 Product Commercialization. LICENSEE shall itself, or through its sublicensees, use Commercially
Reasonable Efforts to obtain Regulatory Approval to Commercialize the Products and where Regulatory Approval to Commercialize Product is obtained by LICENSEE or its sublicensees use Commercially Reasonable Efforts to Commercialize the Products.

  
 13 

	 	3.3	 Companion Diagnostics. The Parties shall use Commercially Reasonable Efforts to
collaborate in the development of a companion diagnostic to identify patient cancers expressing ROR1, and the Parties shall discuss in good faith how best to share any costs associated therewith (if sharing at all); provided, that, if a mutual path
forward cannot be established after such good faith discussions, then each Party shall have the right to unilaterally develop a companion diagnostic; provided, that, if a Party unilaterally develops a companion diagnostic, and the other Party or any
of its Affiliates subsequently desires access to such companion diagnostic, then such Party shall reimburse the developing Party for sixty percent (60%) of the documented costs that the developing Party incurred in developing such companion
diagnostic (and thereafter each Party will be responsible for its own costs with respect to the use of such companion diagnostic in conjunction with its products). Notwithstanding the foregoing, Antibodies, Products or fragments thereof that are
being developed by a Party as potential therapeutic agents shall not be utilized as companion diagnostics. 

  

	 	3.4	 Right of Reference. 

 

	 	3.4.1	 LICENSOR hereby grants LICENSEE and its sublicensees a non-exclusive
right of reference with respect to any Regulatory Filings owned or Controlled by LICENSOR or Oncternal or any of their Affiliates (excluding any Affiliates which become Affiliates subsequent to a Change in Control of LICENSOR or Oncternal) during
the Term for any ROR1 Antibody Product that is necessary or reasonably useful to Exploit any Product in the Field. For clarity, this right of reference includes LICENSEE’s right to cross reference U.S. IND #133131. 

  

	 	3.4.2	 LICENSEE hereby grants LICENSOR and Oncternal and their licensees a
non-exclusive right of reference with respect to any Regulatory Filings owned or Controlled by LICENSEE or any of its Affiliates during the Term (excluding any Affiliates which become Affiliates subsequent to
a Change in Control of LICENSEE) during the Term for any ROR1 Antibody Product that is necessary or reasonably useful to Exploit such ROR1 Antibody Product. 

  

	4.	 PAYMENT TERMS 

 

	 	4.1	 Payment Terms. 

 

	 	4.1.1	 Milestone Payments. LICENSEE shall notify LICENSOR as soon as practicable upon achievement of each
milestone set forth in the applicable table below (each, a “Milestone”). In further consideration of the licenses and rights granted to LICENSEE, within sixty (60) days of achievement of each Milestone set forth in the
applicable table below, LICENSEE shall pay to LICENSOR the corresponding non-creditable and non-refundable milestone payment (each, a “Milestone
Payment”). 

  

	 	(a)	 If LICENSOR’s Equity is less than [***] at the time LICENSEE achieves any of the following Milestones:

  
 14 

 
			
	 	 
	MILESTONE*	  	MILESTONE
PAYMENT
	 	 
	[***]	  	[***]
	 	 
	[***]	  	[***]
	 	 
	[***]	  	[***]
	 	 
	[***]	  	[***]
	 	 
	
[***]
	  	[***]

 *each Milestone shall only be payable once, regardless of the number of Products achieving such
Milestone. 
  

	 	(b)	 If LICENSOR’s Equity is [***] at the time LICENSEE achieves any of the following Milestones:

  

			
	 	 
	MILESTONE*	  	MILESTONE
PAYMENT
	 	 
	[***]	  	[***]
	 	 
	[***]	  	[***]
	 	 
	
[***]
	  	[***]

 *each Milestone shall only be payable once, regardless of the number of Products achieving such
Milestone. 
  

	 	(c)	 IF LICENSOR’s Equity is [***] at the time LICENSEE achieves any specific Milestone, no payments will be
due resulting from such Milestone. For clarity, (i) should LICENSOR’s Equity subsequently change LICENSOR shall not be entitled to the retroactive payment or retroactive increased payment of any Milestone and (ii) Milestones (1), (2)
and (3) under Sections 4.1.1 (a) and (b) may only be paid under either Section 4.1.1(a) or (b), but not both. 

  

	 	(d)	 For the avoidance of doubt and notwithstanding anything to the contrary herein payment of a Milestone to
LICENSOR by a sublicensee, assignee or other transferee of, or Third Party retained by, LICENSEE shall be deemed to have been satisfied by LICENSEE for purposes of this Section 4.1.1. 

 

	 	4.1.2	 Royalty Payments. 

  
 15 

	 	(a)	 Royalties. In consideration of the licenses and rights granted to LICENSEE hereunder, LICENSEE shall pay
to LICENSOR a royalty on a Product-by-Product basis equal to the Royalty Percentage set forth below of annual Net Sales of such Product in the Territory during the
Royalty Term applicable to such Product (collectively, “Royalties”). As used herein, “Royalty Percentage” means a percentage, as determined by LICENSOR’s Equity at the time of First Commercial Sale of the relevant
Product, as set forth below. 

  

							
	 	 	 	 
	LICENSOR’s Equity	  	[***]	  	[***]	  	[***]
	 	 	 	 
	
Royalty Percentage
	  	[***]	  	[***]	  	[***]

  

	 	(b)	 Royalty Term. The Royalties payable under this Section 4.1.2 shall be payable, subject to
Section 4.1.2(f), on a Product-by-Product and country-by-country basis from the
First Commercial Sale of such Product in such country until the latest of: (i) the tenth (10th) anniversary of the date of such First Commercial Sale of such Product in such country or
(ii) the expiration of the last Valid Claim in such country that Covers such Product (the “Royalty Term”). 

  

	 	(c)	 Quarterly Payments. LICENSEE shall pay to LICENSOR the applicable Royalties within sixty (60) days
following the expiration of each Calendar Quarter after the date of the First Commercial Sale. Royalties will be payable on a country-by-country, Product-by-Product, basis commencing as of the First Commercial Sale of a Product in each country until the expiration of the Royalty Term for such Product in each country.

  

	 	(d)	 Reports. All payments shall be accompanied by a report that sets forth in reasonable detail (i) the
Net Sales of Licensed Products for the previous Calendar Quarter, broken down by country (where available) and Product, (ii) the royalty payment that is due and payable, and (iii) the basis for calculating such royalty payment including
the gross sales (where available) of Licensed Products by country (where available) and Product, the rate of currency conversion and date such conversion was calculated. 

 

	 	(e)	 Combination Products. In the event that a Product is Commercialized in combination (whether co-formulated, co-packaged, or administered contemporaneously or in close proximity) with one or more products which are themselves not Products under this Agreement for a
single price, the Net Sales for such Product shall be calculated by multiplying the sales price of such combination sale by the fraction A/(A+B) where A is the fair market value of the Product and B is the fair market value of the other product(s)
in the combination sale. If the fair market value for any product sold in combination with a Product cannot be reasonably determined, the price attributed to such product will be 

  
 16 

	 	
based on the relative cost of goods for such product, as determined in accordance with GAAP. 

  

	 	(f)	 Royalty Buy-Out. Notwithstanding this Section 4.1.2,
LICENSEE shall have the right and option to buy-out LICENSOR’s right to receive Royalties by way of providing written notice to LICENSOR of LICENSEE’s intent to exercise such buy-out right no later than six (6) months following either (A) LICENSEE’s first receipt of Regulatory Approval to Commercialize a Product or (B) a Change in Control of LICENSEE (and, for
clarity, either event shall trigger such option). If LICENSEE delivers such a notice: (i) the Royalty Term with respect to all Products will be deemed to have expired, and (ii) LICENSEE will pay LICENSOR a lump sum payment equal to (A)
[***] if LICENSOR’s Equity is [***] or (B) [***] if LICENSOR’s Equity is [***] at the time that such buy-out is exercised. 

 

	 	4.1.3	 Other Payments. LICENSEE shall pay to LICENSOR any other amounts due under this Agreement within sixty
(60) days following receipt of an undisputed invoice. 

  

	 	4.1.4	 Late Payments. In the event that any undisputed payments due hereunder are not made when due, then such
payment shall accrue interest commencing on such due date until paid at the Prime Rate of Interest, as reported in the Wall Street Journal on such due date, plus [***]. The payment of such interest shall not limit or otherwise be deemed to be
in satisfaction of LICENSOR exercising any other rights it may have under this Agreement arising from LICENSEE’s failure to make such payment when due. 

  

	 	4.1.5	 After Royalty Term. After the expiration of the Royalty Term in any relevant country for a Product,
LICENSEE shall not have any further obligation under this Agreement to pay royalties to LICENSOR in such country for such Product and LICENSEE’s License with respect to such Product and such country shall become perpetual, irrevocable and fully
paid-up. 

  

	4.2	 Payment Method. 

 

	 	4.2.1	 Any payments that are recorded in currencies other than the US Dollar shall be converted into US Dollars
at the thirty (30) day average of the daily foreign exchange rates published in the Wall Street Journal, Western Edition (or any other qualified source that is acceptable to both Parties) for the Calendar Quarter in which such payments or
expenses occurred, or for periods less than a Calendar Quarter, the average of the daily rates published in the Wall Street Journal, Western Edition for such period. 

 

	 	4.2.2	 All payments from LICENSEE to LICENSOR shall be made by wire transfer in US Dollars to the credit of such bank
account as may be designated by LICENSOR in writing to LICENSEE; provided that, if any such payment or wire transfer is rendered impossible or illegal by reason of Applicable Laws in a given country, then LICENSEE shall promptly notify

  
 17 

	 	
LICENSOR of the conditions preventing such payment or wire transfer and the amount of such payment shall be deposited in local currency in a recognized banking institution in the relevant country
in the name or to the credit of LICENSOR. Any payment which falls due on a date which is not a Business Day may be made on the next succeeding Business Day. 

  

	 	4.3	 Taxes. 

  

	 	4.3.1	 It is understood and agreed between the Parties that any amounts payable by LICENSEE to LICENSOR hereunder are
exclusive of any and all applicable sales, use, VAT, GST, excise, property, and other taxes, levies, duties or fees (collectively, “Taxes”), which shall be added thereon as applicable. LICENSEE shall be responsible for billing and
collection from its customers and remitting to the appropriate taxing authority any and all Taxes which it is required to collect or remit. Each Party will be responsible for their own income and property taxes. If LICENSEE is required to make a
payment to LICENSOR subject to a deduction of tax or withholding tax, (i) if such withholding or deduction obligation arises as a direct result of any failure on the part of LICENSEE to comply with applicable tax laws or filing or record
retention requirements, that has the effect of modifying the tax treatment of the Parties hereto (a “LICENSEE Withholding Tax Action”), then the sum payable by LICENSEE (in respect of which such deduction or withholding is required
to be made) shall be increased to the extent necessary to ensure that LICENSOR receives a sum equal to the sum which it would have received had no such LICENSEE Withholding Tax Action occurred, or (ii) otherwise, the sum payable by LICENSEE (in
respect of which such deduction or withholding is required to be made) shall be made to LICENSOR after deduction of the amount required to be so deducted or withheld, which deducted or withheld amount shall be remitted in accordance with applicable
law. 

  

	 	4.3.2	 To the extent LICENSEE is required to deduct and withhold taxes on any payments to LICENSOR, LICENSEE shall pay
the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to LICENSOR an official tax certificate or other evidence of such withholding sufficient to enable LICENSOR to claim such payments of taxes.
LICENSOR shall provide to LICENSEE any tax forms that may be reasonably necessary in order for LICENSEE not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Each Party shall provide the other with
reasonable assistance to enable the recovery, as permitted by law, of withholding taxes, VAT, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or
VAT. 

  

	 	4.3.3	 The Parties agree to cooperate and produce on a timely basis any tax forms or reports, including an IRS Form W-8BEN, reasonably requested by the other Party in connection with any payment made by LICENSEE to LICENSOR under this Agreement. 

 

	 	4.3.4	 In the event that a Party undertakes any corporate action that affects the tax treatment of payments under this
Agreement (e.g., reincorporation outside 

  
 18 

	 	
of the United States, or assignment of this Agreement to an Affiliate outside of the United States), then the Party undertaking such action shall be solely responsible for the taxes accruing in
connection with (including any incremental taxes that come to apply as a result of) such action. 

  

	5.	 RECORDS; AUDIT RIGHTS 

 

	 	5.1	 Relevant Records. 

 

	 	5.1.1	 Relevant Records. LICENSEE shall maintain accurate financial books and records pertaining to the
sublicensing of the Licensed Technology pursuant to Section 2.2 and LICENSEE’s sale of each Product (collectively, “Relevant Records”). LICENSEE shall maintain the Relevant Records for the longer of: (a) the period of
time required by Applicable Law, or (b) two (2) years following expiration or termination of this Agreement. 

  

	 	5.1.2	 Audit Request. LICENSOR shall have the right during the term and for twelve (12) months thereafter
to engage, at its own expense, an independent auditor reasonably acceptable to LICENSEE (and which auditor has entered a confidentiality agreement with LICENSEE) to examine the Relevant Records from time-to-time, but no more frequently than once every twelve (12) months, and no more than once with respect to the same records, as may be necessary to verify the payments made by LICENSEE under this
Agreement. Such audit shall be requested in writing at least seven (7) days in advance, and shall be conducted during LICENSEE’s normal business hours and otherwise in manner that minimizes any interference to LICENSEE’s business
operations. 

  

	 	5.1.3	 Audit Fees and Expenses. LICENSOR shall bear any and all fees and expenses it may incur in connection
with any such audit of the Relevant Records; provided, however, in the event an audit reveals an underpayment by LICENSEE of more than ten percent (10%) as to the period subject to the audit, LICENSEE shall reimburse LICENSOR for any reasonable and
documented out-of-pocket costs and expenses of the audit within sixty (60) days after receiving invoices thereof. 

 

	 	5.1.4	 Payment of Deficiency. If any audit establishes that LICENSEE underpaid any amounts due to LICENSOR
under this Agreement, then LICENSEE shall pay LICENSOR any such deficiency within sixty (60) days after receipt of written notice thereof unless it disputes the results of such audit in accordance with Section 14 (Dispute Resolution) of
this Agreement. If any audit establishes that LICENSEE overpaid any amounts due to LICENSOR under this Agreement, then LICENSEE shall be credited any such overpayment against future Royalties and if no further Royalties are due then such amount
shall be refunded to LICENSEE within sixty (60) days. For the avoidance of doubt, such payment will be considered a late payment, subject to Section 4.1.4. 

 

	6.	 INTELLECTUAL PROPERTY RIGHTS 

 

	 	6.1	 Pre-existing IP. Each Party shall retain all rights, title and
interests in and to any Intellectual Property Rights that are owned, licensed or sublicensed by such Party 

  
 19 

	 	
prior to or independent of this Agreement. 

  

	 	6.2	 Patent Prosecution. For clarity, the following Section 6.2 is only applicable to the extent
there are any Licensor Patents. 

  

	 	(a)	 Licensor Patents. Except as set forth in subsection (b) below, LICENSOR and/or Oncternal has the
first right but not the obligation to conduct, control and pay for the prosecution, maintenance, challenges against validity and unenforceability or patentability with respect to the Licensor Patents in the Territory. At LICENSOR’s request,
LICENSEE shall reasonably cooperate with and assist LICENSOR and/or Oncternal in connection with such activities. As between the Parties, LICENSOR and LICENSEE shall each bear fifty percent (50%) of the reasonable out of pockets costs of the
prosecution and maintenance of the Licensor Patents and LICENSEE shall within forty five (45) days reimburse LICENSOR for its portion of the costs upon receipt of an undisputed and appropriately documented invoice therefor; provided, that, upon
written notice from LICENSEE to LICENSOR, LICENSEE may elect to stop sharing in the costs of any given Licensor Patent and, if such notice is provided, then the subject Licensor Patent(s) shall no longer be Licensor Patents hereunder and shall be
excluded from the definition of Licensor Patents. 

  

	 	(b)	 Failure to Prosecute or Maintain Licensor Patents. In the event that Oncternal and LICENSOR elect to
forgo the prosecution or maintenance of any of the Licensor Patents, LICENSOR shall notify LICENSEE of such election at least forty-five (45) days prior to any filing or payment due date, or any other due date that requires action
(“Licensor Patent Abandonment Notice”). Upon receipt of a Licensor Patent Abandonment Notice, LICENSEE shall have the right, but not the obligation, upon written notice to LICENSOR, at its sole discretion and expense, to have any
such Licensor Patent in such country assigned to LICENSEE and LICENSOR shall, and hereby does, assign any such patents to LICENSEE (each such patent, an “Abandoned Patent”), and the Abandoned Patent(s) shall no longer be Licensor
Patents hereunder and shall be excluded from the definition of Licensor Patents. LICENSOR hereby agrees to sign all necessary papers and do all lawful acts reasonably requisite in connection with the prosecution, assignment and enforcement of any
such Abandoned Patent. Upon any such assignment of an Abandoned Patent, LICENSEE shall grant and hereby does grant to LICENSOR and its Affiliates a non-exclusive, perpetual, irrevocable, fully paid-up, royalty free, worldwide right and license under such Abandoned Patent (and any patent claiming priority to or from such patent) to practice the inventions under such Abandoned Patent and to Develop and
Commercialize any products claimed by such Abandoned Patent (excluding the Products); provided, that, the foregoing license is sublicenseable solely in conjunction with LICENSOR or its Affiliates granting or assigning a Third Party rights with
respect to both (i) one or more products, and (ii) intellectual property rights, in each case that are controlled 

  
 20 

	 	
by LICENSOR or its Affiliates. 

  

	 	(c)	 Information Rights. LICENSOR shall (i) keep LICENSEE reasonably informed as to the status of each
Licensor Patent in the Territory, (ii) provide LICENSEE with copies of correspondence and materials relating to the prosecution, maintenance and defense of each Licensor Patent in the Territory, and consider in good faith the reasonable
requests, suggestions and advice of LICENSEE with respect thereto, and (iii) promptly provide LICENSEE with copies of correspondence and materials received from or filed with any Regulatory Authority within the Territory related to the Licensor
Patents. The foregoing activities shall be undertaken on timing that is reasonably appropriate in light of any timing requirements that LICENSOR is subject to so that LICENSEE has a meaningful opportunity to provide input and for LICENSOR to
consider and act on such input. 

  

	 	(d)	 Patent Term Extension. If election with respect to obtaining patent term extension or supplemental
protection certificates or their equivalents in any country with respect to a Product becomes available, upon Regulatory Approval or otherwise, the Parties will discuss in good faith which of the Licensor Patents, if any, will be extended. LICENSEE
will have final decision making authority for which of the Licensor Patents, if any, to extend, provided that LICENSEE shall not extend any such patent term without the prior written consent of LICENSOR (which shall not be unreasonably withheld,
conditioned or delayed). Without limiting the foregoing, consent shall be deemed reasonably withheld if LICENSOR intends to apply for patent term extension with respect to such Licensor Patent for one of its or its Affiliate’s or
sublicensee’s products. 

  

	7.	 INFRINGEMENT; MISAPPROPRIATION 

 

	 	7.1	 Notification. Each Party will promptly notify the other Party in writing of any actual, suspected or
threatened infringement, misappropriation or other violation by a Third Party of any Licensed Technology in the Field and in the Territory of which it becomes aware. The Parties and Oncternal shall enter into a joint interest/common defense
agreement at the request of either Party (or Oncternal) prior to, or at any time following, the sharing of any such information. 

  

	 	7.2	 Enforcement Action. For clarity, the following Section 7.2 is only applicable to the extent
there are any Licensor Patents. 

  

	 	7.2.1	 Enforcement of Licensor Patents. LICENSEE shall have the first right, but not the obligation, using
counsel of its choice, to enforce the Licensor Patents against any actual or suspected infringement of the Licensor Patents with respect to the Exploitation of an Infringing Product in the Field and Territory by a Third Party or defend any
declaratory action with respect thereto brought by such Third Party (a “Licensor Patent Action”), at its expense, and LICENSOR shall provide all reasonable assistance to LICENSEE in such Licensor Patent Action, including joining, at
LICENSEE’s reasonable expense, such Licensor Patent Action if necessary 

  
 21 

	 	
to maintain the Licensor Patent Action, or to seek additional or alternative damages or injunctive relief under such Licensor Patent Action. Notwithstanding anything to the contrary herein,
neither LICENSEE nor any of its sublicensees shall, without the prior written consent of LICENSOR (which shall not be unreasonably withheld, conditioned or delayed), enter into any settlement that would: (i) adversely affect the validity,
enforceability or scope of any of the Licensor Patents anywhere in the world, or (ii) give rise to liability of LICENSOR or its Affiliates.  

  

	 	7.2.2	 Recoveries. Any recovery received as a result of any Licensor Patent Action shall be used first to
reimburse the Parties for their costs and expenses (including attorneys’ and professional fees) incurred in connection with such action (and not previously reimbursed), and any remaining amount of such recovery shall be awarded to the Party
that brought the suit; provided that if both Parties jointly bring a Licensor Patent Action any amount recovered will be applied pro-rata (based on the agreed allocation of costs and expenses to be borne by
each Party in such action or suit) for the costs and expenses with respect to such action or suit (including reasonable attorneys’ fees and costs) and the remaining amounts shall be awarded to LICENSEE as Net Sales and subject to the payment of
Royalties (to the extent applicable) thereon. 

  

	8.	 CONFIDENTIALITY 

 

	 	8.1	 Definition. “Confidential Information” means all types of financial, business,
scientific, technical (including but not limited to information concerning ROR1 Antibody Products, the Products, biological materials, gene or protein sequences, Antibodies, antigens, cell lines, compounds, assays or test results), economic or
engineering information, including without limitation, business strategies, business forecasts, product development plans, promotional and marketing objectives, results of operations, customer lists, supplier lists, patent disclosures, unpublished
patent applications, know-how, trade secrets, compilations, ideas, inventions, discoveries, techniques, methods, processes, procedures, formulae, designs, patterns, drawings, schematics, plans, configurations,
specifications, data sheets, mock-ups, models, compounds, compositions, structures, prototypes, clinical trial protocols, clinical data and analysis, formulae, software programs, source documents, programs,
code, materials, equipment, samples, test results, opinions, data, analysis and other proprietary information, whether tangible or intangible, and whether or how stored, compiled, or memorialized physically, electronically, graphically,
photographically, or in writing, which is disclosed by one Party to the other Party hereunder or obtained by a Party through observation or examination of the other Party’s facilities, information and/or materials (such observation or
examination hereinafter also referred to as “disclosure” for purposes of this Agreement). Notwithstanding the foregoing, all Confidential Information related exclusively to a Product shall be deemed to be LICENSEE’s Confidential
Information (and, for clarity, (i) Confidential Information existing as of the Effective Date exclusively relating to a Product is being assigned to LICENSEE under this Agreement and LICENSEE shall be deemed the disclosing Party and LICENSOR
shall be deemed to be the receiving Party with respect thereto, and (ii) Section 8.3.1(b) shall not apply to such Confidential Information), and LICENSEE the disclosing Party, and LICENSOR the receiving Party, thereof regardless of the
Party initially disclosing the same. For clarity, notwithstanding the foregoing, all 

  
 22 

	 	
Confidential Information related exclusively to a naked ROR1 reactive Antibody disclosed by LICENSOR shall be LICENSOR’s Confidential Information, and LICENSOR the disclosing Party, and
LICENSEE the receiving Party, thereof. 

  

	 	8.2	 Obligations. The receiving Party shall protect all the disclosing Party’s Confidential Information
against unauthorized disclosure to Third Parties with the same degree of care as the receiving Party uses for its own similar information, but in no event less than a reasonable degree of care. The receiving Party may disclose the disclosing
Party’s Confidential Information to its Affiliates, and their respective directors, shareholders, officers, employees, Subcontractors, sublicensees, consultants, attorneys, accountants, acquirers, merger partners, banks and investors and other
potential sources of funding or evaluating an actual or potential investment or acquisition or business opportunity (collectively, “Recipients”) who have a
need-to-know such information for purposes related to this Agreement or for due diligence purposes, but only to the extent necessary to fulfill such purpose, provided
that the receiving Party shall hold such Recipients to written obligations of confidentiality with terms and conditions at least as restrictive as those set forth in this Agreement. Notwithstanding the foregoing, each Party shall have the right to
disclose the other Party’s Confidential Information to the extent reasonably necessary under Applicable Laws in addition, LICENSEE shall have the right to disclose LICENSOR’s Confidential Information as part of any Regulatory Filing for
the Products and LICENSOR shall have the right to disclose LICENSEE’s Confidential Information as part of any Regulatory Filing for a ROR1 Antibody Product. 

 

	 	8.3	 Exceptions. 

  

	 	8.3.1	 The obligations under Section 8.2 shall not apply to any information to the extent the receiving Party can
demonstrate by competent evidence that such information: 

  

	 	(a)	 is (at the time of disclosure) or becomes (after the time of disclosure) known to the public or part of the
public domain through no breach of this Agreement by the receiving Party or any Recipients to whom it disclosed such information; 

  

	 	(b)	 was known to, or was otherwise in the possession of, the receiving Party prior to the Term of this Agreement
and was not subject to an obligation of confidentiality; 

  

	 	(c)	 is disclosed to the receiving Party on a non-confidential basis by a
Third Party who is entitled to disclose it without breaching any confidentiality obligation to the disclosing Party; or 

  

	 	(d)	 is independently developed by or on behalf of the receiving Party or any of its Affiliates outside of this
Agreement, as evidenced by its written records, without use of the Confidential Information. 

  

	 	8.3.2	 The receiving Party may disclose the disclosing Party’s Confidential Information if required to do so
under Applicable Laws or a court order or other governmental order, provided that the receiving Party (to the extent allowed by the Applicable Law): (a) provides the disclosing Party with

  
 23 

	 	
prompt notice of such disclosure requirement if legally permitted, (b) affords the disclosing Party an opportunity to oppose or limit, or secure confidential treatment for such required
disclosure and (c) if the disclosing Party is unsuccessful in its efforts pursuant to subsection (b), discloses only that portion of the Confidential Information that the receiving Party is legally required to disclose as advised by the
receiving Party’s legal counsel. In the event of a limited disclosure of the disclosing Party’s Confidential Information that is required by law or regulation, the receiving Party shall continue to treat such disclosed information as the
disclosing Party’s Confidential Information for all other purposes and subject to the other terms and conditions of this Agreement. 

  

	 	8.4	 Right to Injunctive Relief. Each Party agrees that breaches of this Article 8 may cause irreparable
harm to the other Party and shall entitle such other Party, in addition to any other remedies available to it (subject to the terms of this Agreement), the right to seek injunctive relief enjoining such action without the need to post any bond.

  

	 	8.5	 Ongoing Obligation for Confidentiality. Upon termination of this Agreement, the receiving Party shall,
and shall cause its Recipients to, destroy or return (as requested by the disclosing Party) any Confidential Information of the disclosing Party, except for one (1) copy which may be retained in its confidential files for archive purposes.

  

	 	8.6	 Publicity Review. Subject to this Section 8.6, the Parties shall jointly discuss and must
mutually agree, based on the principles of this Section 8.6, on any statement to the public regarding this Agreement (which, for clarity, means the terms and conditions of this Agreement and not the Products themselves), subject in each case to
disclosure otherwise required by Applicable Laws or the rules of any applicable securities exchange. When a Party elects to make any such statement or disclosure required under Applicable Law, it will give the other Party at least five
(5) Business Days’ notice to review and approve such statement, unless the applicable Regulatory Authority requires disclosure such that a Party is prohibited by Applicable Law to provide such advance review by the other Party (in which
case it shall be disclosed according to such requirement and notice will be provided as soon as possible). Notwithstanding anything in this Section 8.6 to the contrary, the terms of this Agreement may be disclosed to (i) Regulatory
Authorities, including the United States Securities and Exchange Commission or any other exchange or securities commission having authority over a Party, where required by and in accordance with Applicable Law with redaction of financial information
not otherwise required to be disclosed under Applicable Laws, in the reasonable judgment of the Party subject to such disclosure requirement, in which event the disclosing Party shall provide in advance of submission to the other Party for review
and comment a copy of such redactions made to this Agreement or (ii) bona fide potential or actual investors, advisors, collaborators, or the like, that are subject to appropriate obligations of confidentiality.

 

	9.	 REPRESENTATIONS, WARRANTIES AND COVENANTS 

 

	 	9.1	 Representations, Warranties and Covenants by Each Party. Each Party represents, warrants and
covenants to the other Party as of the Effective Date that: 

  

  
 24 

	 	(a)	 it is a company duly organized, validly existing, and in good standing under the laws of its jurisdiction of
formation; 

  

	 	(b)	 it has full power and authority to execute, deliver, and perform under this Agreement, and has taken all
corporate action required by Applicable Law and its organizational documents to authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated by this Agreement; 

 

	 	(c)	 this Agreement constitutes a valid and binding agreement enforceable against it in accordance with its terms;
and 

  

	 	(d)	 all consents, approvals and authorizations from all governmental authorities or other Third Parties required to
be obtained by such Party in connection with this Agreement have been obtained. 

  

	 	9.2	 Additional Representations, Warranties and Covenants by LICENSEE. 

 

	 	9.2.1	 the execution and delivery of this Agreement and all other instruments and documents required to be executed
pursuant to this Agreement, and the consummation of the transactions contemplated hereby do not and shall not: (i) conflict with or result in a breach of any provision of its organizational documents, (ii) result in a breach of any
agreement to which LICENSEE or any of its Affiliates is a party that would impair the performance of its obligations hereunder; or (iii) violate any Applicable Law. 

 

	 	9.2.2	 LICENSEE represents and warrants to LICENSOR that it shall comply with all Applicable Law with respect to the
performance of rights and its obligations hereunder. 

  

	 	9.3	 Additional Representations, Warranties and Covenants by LICENSOR. LICENSOR, hereby represents,
warrants and covenants to LICENSEE that except as set forth in the Disclosure Schedule attached hereto as Schedule E: 

  

	 	9.3.1	 the execution and delivery of this Agreement and all other instruments and documents required to be executed
pursuant to this Agreement, and the consummation of the transactions contemplated hereby do not and shall not: (i) conflict with or result in a breach of any provision of its organizational documents, (ii) result in a breach of any
agreement to which LICENSOR or any of its Affiliates is a party that would impair the performance of its obligations hereunder; (iii) violate any Applicable Law; or (iv) result in the imposition of any mortgage, security interest, pledge,
conditional sale or other title retention agreement, lien, charge or encumbrance on or with respect to any of the Product IP. 

  

	 	9.3.2	 It shall comply with all Applicable Law with respect to the performance of rights and its obligations
hereunder; 

  

	 	9.3.3	 All licenses to Third Parties granted by LICENSOR or any of its Affiliates under the Licensed Technology will
be consistent with LICENSEE’s rights under Article 2; 

  
 25 

	 	9.3.4	 It has the full right, power and authority to grant all of the licenses granted to LICENSEE under this
Agreement; 

  

	 	9.3.5	 It or Oncternal is the sole and exclusive owner of all right, title and interest in and to the Licensed
Technology existing as of the Effective Date and LICENSOR is the sole and exclusive owner of all right, title and interest in and to the Product IP existing as of the Effective Date and has not received any written notice of any ownership or
inventorship challenge, interference, invalidity or unenforceability with respect to any patents or patent applications concerning the Product IP, Licensed Technology or Platform Patents; 

 

	 	9.3.6	 Except for any license granted to a Third Party under the rights reserved for LICENSOR pursuant to
Section 2.4, as of the Effective Date, LICENSOR has not granted to any Third Party any rights to any of the Licensed Technology, Platform Patents or Product IP in the Field with respect to which LICENSEE has been granted a license or
assignment, respectively, hereunder; 

  

	 	9.3.7	 As of the Effective Date, there is no pending Proceeding that has been commenced by or against LICENSOR or any
of its Affiliates regarding the Licensed Technology, Platform Patents or Product IP. To the actual knowledge of LICENSOR following reasonable investigation no such Proceeding has been threatened; 

 

	 	9.3.8	 As of the Effective Date, the Licensed Technology and Product IP are not subject to any liens or encumbrances;

  

	 	9.3.9	 To the actual knowledge of LICENSOR, the Licensed Technology and the Product IP, in conjunction with rights in
the Platform Patents assigned to LICENSEE pursuant to the Asset Purchase Agreement, include all intellectual property and Know-How relating to a naked ROR1 reactive Antibody used by or on behalf of LICENSOR or
its Affiliates as of the Effective Date which is necessary or useful for the Exploitation of one or more Products in the Field; 

  

	 	9.3.10	 As of the Effective Date, neither LICENSOR nor any of its Affiliates has received any written communication
and, to the actual knowledge of LICENSOR following reasonable investigation, there is no claim or action alleging that LICENSOR or its Affiliate’s use of any of the Licensed Technology or Product IP or a naked ROR1 reactive Antibody infringes,
or constitutes contributory infringement, inducement to infringe, misappropriation or unlawful use of, the intellectual property rights of any Person; 

  

	 	9.3.11	 As of the Effective Date, except under the UCSD License Agreement (including the agreements with Biosite and
Xoma Technology referenced therein) and except under the Commercial License Agreement between Selexis SA and Oncternal (as successor in interest to Roar Therapeutics), dated May 19, 2014, with respect to the ROR1 reactive Antibody, no royalties
or milestones are due under any agreement to which LICENSOR or any of its Affiliates (including Oncternal) is a party in connection with 

  
 26 

	 	
the Exploitation of any Product; 

  

	 	9.3.12	 The Product IP in conjunction with the Purchased Assets (as defined under the Asset Purchase Agreement)
constitute all of the assets, rights or properties (tangible and intangible) owned by LICENSOR, or its Affiliates (including Oncternal) that are exclusively related to the Exploitation of Products in the Field; 

 

	 	9.3.13	 As of the Effective Date, there are no patents or patent applications owned or Controlled by LICENSOR or
Oncternal or any of their respective Affiliates that Cover any Product other than the patents and patent applications set forth in Schedule B; and 

  

	 	9.3.14	 As of the Effective Date, (i) the UCSD License Agreement is in effect and is valid and binding on LICENSOR
and its Affiliates and enforceable in accordance with its terms, and (ii) neither LICENSOR nor any of its Affiliates is in material breach of, or material default under, the UCSD License Agreement, and no event has occurred that, with the
giving of notice or lapse of time or both, would constitute a material breach or material default by LICENSOR or any of its Affiliates thereunder. 

  

	 	9.4	 No Other Warranties. EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 9, (A) NEITHER PARTY MAKES ANY
REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO WARRANTIES OF TITLE, NON-INFRINGEMENT, VALIDITY, ENFORCEABILITY,
MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; AND (B) ANY INFORMATION PROVIDED BY A PARTY OR ITS AFFILIATES IS MADE AVAILABLE ON AN “AS IS” BASIS WITHOUT WARRANTY WITH RESPECT TO COMPLETENESS, OR FITNESS FOR A PARTICULAR
PURPOSE OR ANY OTHER KIND OF WARRANTY WHETHER EXPRESS OR IMPLIED. Each Party acknowledges and agrees that any Products are experimental in nature and may have unknown characteristics. 

 

	10.	 INDEMNIFICATION 

 

	 	10.1	 Indemnification by LICENSEE. LICENSEE agrees to indemnify, hold harmless and defend LICENSOR and
its Affiliates, licensees and distributors and their respective officers, directors, employees, contractors, agents and permitted assigns, from and against any and all Claims arising or resulting from: (a) the Exploitation of a Product or
Platform Patents by LICENSEE, its Subcontractors or sublicensees, (b) the negligence, recklessness or wrongful intentional acts or omissions or violations of Applicable Law by LICENSEE, its Affiliates, Subcontractors or sublicensees in
exercising its rights or carrying out its obligations hereunder, (c) breach by LICENSEE of any representation, warranty or covenant as set forth in this Agreement, or (d) breach by LICENSEE or its assigns of any representation, warranty or
covenant as set forth in the Assignment or failure to timely pay, perform or discharge any obligations under the UCSD License Agreement assumed by LICENSEE or its assigns thereunder. As used herein, “Claims” means collectively, any
and all Third Party demands, claims and Proceedings (whether criminal or civil, in contract, tort or otherwise) for losses, damages, liabilities, costs 

  
 27 

	 	
and expenses (including reasonable attorneys’ fees). 

  

	 	10.2	 Indemnification by LICENSOR. LICENSOR hereby agrees to indemnify, defend and hold harmless
LICENSEE, Sublicensees, its Affiliates and its and their directors, officers, agents and employees from and against any and all Claims arising or resulting from: (a) the Exploitation of any ROR 1 Antibody Product or Platform Patents by or on
behalf of LICENSOR, (b) the negligence, recklessness or wrongful intentional acts or omissions or violations of Applicable Law by or on behalf of LICENSOR, (c) breach by LICENSOR of any representation, warranty or covenant as set forth in
this Agreement, or (d) breach by LICENSOR or its Affiliates or its or their assigns of any representation, warranty or covenant as set forth in the Assignment or failure to timely pay, perform or discharge any obligations under the UCSD License
Agreement retained by Oncternal. 

  

	 	10.3	 Indemnification Procedure. Promptly after receipt by a Party seeking indemnification under this
Section 10 (an “Indemnitee”) of notice of any pending or threatened Claim against it, such Indemnitee shall give written notice to the Party from whom the Indemnitee is entitled to seek indemnification pursuant to this Article
10 (the “Indemnifying Party”) of the commencement thereof; provided that the failure so to notify the Indemnifying Party shall not relieve it of any liability that it may have to any Indemnitee hereunder, except to the extent the
Indemnifying Party demonstrates that it is materially prejudiced thereby. The Indemnifying Party shall be entitled to participate in the defense of such Claim and, to the extent that it elects within ten (10) Business Days of its receipt of
notice of the Claim from the Indemnitee, to assume control of the defense and settlement of such Claim (unless the Indemnifying Party is also a party to such proceeding and the Indemnifying Party has asserted a cross claim against the Indemnified
Party or a court has otherwise determined that such joint representation would be inappropriate) with counsel reasonably satisfactory to the Indemnitee and, after notice from the Indemnifying Party to the Indemnitee of its election to assume the
defense of such Claim, the Indemnifying Party shall not, as long as it diligently conducts such defense, be liable to the Indemnitee for any Litigation Costs subsequently incurred by the Indemnitee. No compromise or settlement of any Claim may be
effected by the Indemnifying Party without the Indemnitee’s written consent, which consent shall not be unreasonably withheld or delayed, provided no consent shall be required if (A) there is no finding or admission of any violation of
Applicable Laws or any violation of the rights of any person and no effect on any other claims that may be made against the Indemnitee, (B) the sole relief provided is monetary damages that are paid in full by the Indemnifying Party, and
(C) the Indemnitee’s rights under this Agreement are not restricted by such compromise or settlement. Notwithstanding the foregoing, the Indemnitee shall be entitled to conduct its own defense at the cost and expense of the Indemnifying
Party if the Indemnitee establishes that the conduct of its defense by the Indemnifying Party would reasonably be likely to prejudice materially the Indemnitee due to a conflict of interest between the Indemnitee and the Indemnifying Party; and
provided further that in any event the Indemnitee may participate in such defense at its own expense. 

  

	11.	 LIMITATION OF LIABILITY 

 

	 	11.1	 Consequential Damages Waiver. EXCEPT FOR (i) GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, (ii) A
BREACH OF ARTICLE 8 (CONFIDENTIALITY), (iii) IN CONNECTION WITH A PARTY’S 

  
 28 

	 	
INDEMNIFICATION OBLIGATIONS UNDER SECTION 10.1 OR 10.2, OR (iv) A PARTY’S BREACH OF ITS OBLIGATIONS UNDER SECTION 2.5, AS APPLICABLE, NEITHER PARTY SHALL BE LIABLE FOR ANY INDIRECT,
CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES, INCLUDING DAMAGES FOR LOST PROFITS OR LOST REVENUES REGARDLESS OF WHETHER IT HAS BEEN INFORMED OF THE POSSIBILITY OR LIKELIHOOD OF SUCH DAMAGES OR THE TYPE OF CLAIM, CONTRACT OR TORT (INCLUDING
NEGLIGENCE). 

  

	 	11.2	 Liability Cap. EXCEPT FOR (A) GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, (B) IN CONNECTION WITH A
PARTY’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 10.1 OR 10.2, (C) LICENSEE’S PAYMENT OBLIGATIONS UNDER THIS AGREEMENT, OR (D) A PARTY’S BREACH OF ITS OBLIGATIONS UNDER SECTION 2.5 OR ARTICLE 8, EACH PARTY’S TOTAL LIABILITY
FOR DAMAGES IN CONNECTION WITH THIS AGREEMENT SHALL NOT EXCEED US$12,000,000, REGARDLESS OF WHETHER SUCH PARTY HAS BEEN INFORMED OF THE POSSIBILITY OR LIKELIHOOD OF SUCH DAMAGES OR THE TYPE OF CLAIM, CONTRACT OR TORT (INCLUDING NEGLIGENCE). The
Parties intend that no double remedies or recoveries are intended or permitted under this Agreement and that claims asserted under one Section or subsection of this Agreement may not also be asserted under another such subsection of this Agreement
or under any other Transaction Agreement if such assertion would result in double recovery. 

  

	12.	 TERM; TERMINATION 

 

	 	12.1	 Term. The term of this Agreement shall commence as of the Effective Date and shall expire on a Product-by-Product and country-by-country basis, upon the date of expiration of the Royalty
Term with respect to such Product and country, unless earlier terminated as set forth below (collectively, the “Term”). 

  

	 	12.2	 Termination for Convenience. LICENSEE shall have the right, without penalty, to terminate this Agreement
in its entirety or on a Product-by-Product basis for convenience upon providing at least ninety (90) days advance written notice thereof in the event such Product
has not been Commercialized (or no Product has been Commercialized in the case of termination of this Agreement in its entirety) or one hundred eighty (180) days advance written notice thereof in the event such Product has been Commercialized
(or any Product has been Commercialized in the case of termination of this Agreement in its entirety). 

  

	 	12.3	 Termination for Cause. Each Party shall have the right, without prejudice to any other remedies
available to it at law or in equity, to terminate this Agreement in its entirety or on a Product-by-Product basis in the event the other Party has materially breached
this Agreement and fails to cure such breach within ninety (90) days of receiving written notice thereof; provided, however, (a) if such breach relates to less than all Products, then the other Party’s termination right shall only be
on a Product-by-Product basis with respect to the Product(s) to which the breach relates, and (b) if such breach is capable of being cured, but cannot be cured
within such ninety (90) day period, and the breaching Party initiates actions to cure such breach within such period and thereafter diligently pursues such actions, the breaching Party shall have such additional period as is reasonable to cure
such breach, but in 

  
 29 

	 	
no event will such additional period exceed an additional ninety (90) days. In the event that a Party challenges the existence of a purported material breach, and avails itself of the
dispute resolution procedures set forth in Article 14, the notice period shall be tolled while such dispute resolution procedures are proceeding and this Agreement shall continue in accordance with its terms during such a period. For purposes of
this Section 12.3, a “material breach” means a breach that would result in a material failure of fundamental obligations under this Agreement and for which monetary damages are an insufficient remedy. 

 

	 	12.4	 Termination for Patent Challenge. LICENSOR shall have the right, on sixty (60) days’
written notice to LICENSEE, to terminate this Agreement if LICENSEE or its Affiliates or sublicensees, individually or in association with any other person or entity (a “Challenging Party”), commences a legal action (except to the
extent required by Applicable Law) challenging the validity or enforceability of any Licensor Patents in any court or before any governmental authority with authority to determine the validity or enforceability of a Licensor Patent (“Patent
Challenge”). Such termination shall be effective sixty (60) days after written notice by LICENSOR to LICENSEE referencing this Section 12.4, unless the Challenging Party, within such sixty (60) days, withdraws such Patent
Challenge. Notwithstanding anything to the contrary herein, Patent Challenge does not include, and termination by LICENSOR under this Section 12.4, is not permitted for any counterclaim made, filed or maintained by LICENSEE or its Affiliates or
sublicensees as defendants in any patent infringement claim, demand, lawsuit, cause of action or other action made, filed or maintained by LICENSOR or Oncternal or their Affiliates and/or licensors, including where such counterclaim challenges the
scope of any Licensor Patents, including without limitation any counterclaim by LICENSEE that the making, using, selling, offering for sale and importation of any Product is not within the scope of the Licensor Patents. 

 

	 	12.5	 Termination for a Bankruptcy Event. Each Party shall have the right to terminate this Agreement
in the event of a Bankruptcy Event with respect to the other Party. “Bankruptcy Event” means the occurrence of any of the following: (a) the institution of any bankruptcy, receivership, insolvency, reorganization or other
similar proceedings by or against a Party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any section or chapter of the United States Bankruptcy Code, as amended or under any similar laws or statutes of
the United States or any state thereof (the “Bankruptcy Code”), where in the case of involuntary proceedings such proceedings have not been dismissed or discharged within ninety (90) days after they are instituted, (b) the
insolvency or making of an assignment for the benefit of creditors or the admittance by a Party of any involuntary debts as they mature, (c) the institution of any reorganization, arrangement or other readjustment of debt plan of a Party not
involving the Bankruptcy Code, (d) appointment of a receiver for all or substantially all of a Party’s assets, or (e) any corporate action taken by the board of directors of a Party in furtherance of any of the foregoing actions.

  

	 	12.6	 Effect of Termination or Expiration. 

 

	 	12.6.1	 Upon the natural expiration of this Agreement, LICENSOR hereby grants to LICENSEE a royalty-free, fully paid-up right, perpetual, irrevocable and exclusive license, with the right to sublicense through multiple tiers, to use the Licensor Know-How for the purpose of the
Exploitation of the Products 

  
 30 

	 	
in the Field within the Territory. 

  

	 	12.6.2	 Upon termination of this Agreement (provided if termination is solely with respect to a Product, the following
shall be read to be solely with respect to such Product): 

  

	 	(a)	 LICENSEE shall have the right to sell its remaining inventory of Product for a period of one hundred eighty
(180) days following the termination of this Agreement so long as LICENSEE is able to do so in compliance with Applicable Laws, and LICENSEE otherwise is not in material breach of this Agreement. 

 

	 	(b)	 Subject to Section 12.6.2(a), all licenses granted hereunder shall terminate, provided that, any
sublicenses granted by LICENSEE to a Third Party (including further sublicenses such direct sublicensees may have granted) shall survive at the request of the direct sublicensee; provided further that each direct sublicensee is then in material
compliance with its sublicense agreement and promptly agrees in writing to be bound by the applicable terms of this Agreement (including, to the extent applicable, agreeing to pay amounts due hereunder). 

 

	 	12.7	 Remedies. All of the non-breaching/terminating Party’s
remedies shall be cumulative, and the exercise of one remedy hereunder by the non-defaulting/terminating Party shall not be deemed to be an election of remedies. These remedies shall include the non-breaching/terminating Party’s other rights of recovery for such breach with or without terminating this Agreement. 

 

	 	12.8	 Survival. Expiration or termination of this Agreement shall not relieve the Parties of any obligation
accruing hereunder prior to such expiration or termination. Without limiting the foregoing, the provisions of Articles 1 (to the extent necessary to give effect to other surviving provision), 4 and 5 (with respect to amounts due prior to such
expiration or termination), 8, 10, 11, 14, 15, and 16, and Sections 6.1, 12.6 (as applicable), 12.7, this 12.8, and 13.1 (for the period set forth therein) shall survive expiration or termination of this Agreement. 

 

	13.	 LICENSEE INSURANCE 

 

	 	13.1	 Insurance Requirements. Prior to the Commencement of any Phase I Clinical Trial for a Product or
otherwise Commercializing the Product, LICENSEE shall, at its sole cost and expense, obtain and keep in force during the Term and for a period of not less than (a) three (3) years after termination or expiration of this Agreement, or
(b) the date that all statutes of limitation covering claims or suits that may be instituted for personal injury based on the sale or use of the Products have expired, commercial general liability insurance from a minimum “A-” AM Bests rated insurance company, including contractual liability and product liability or clinical trials, if applicable, with coverage limits of not less than five million dollars (US $5,000,000)
per occurrence and five million dollars (US $5,000,000) in the aggregate. LICENSEE has the right to provide the total limits required by any combination of primary and umbrella/excess coverage. The minimum level of insurance set forth herein shall
not be construed to create a limit on LICENSEE’s liability hereunder. Such policies shall name LICENSOR and its Affiliates as 

  
 31 

	 	
additional insured. 

  

	 	13.2	 Policy Notification. LICENSEE shall provide LICENSOR with a certificate of insurance signed by an
authorized representative of LICENSEE’s insurance underwriter evidencing the insurance coverage required by this Agreement: (a) prior to Commencement of the first Phase I Clinical Trial for a Product, (b) thirty (30) days prior to
expiration, termination, or reduction of such insurance coverage, and (C) upon LICENSOR’s request not more than once annually. 

  

	 	13.3	 Third Parties. LICENSEE shall use Commercially Reasonable Efforts to cause Third Parties engaged
by LICENSEE to perform LICENSEE’s obligations under this Agreement to maintain such types of insurance coverages and for such period of time as are customary for such Third Parties given the nature of the services to be provided.

  

	14.	 DISPUTE RESOLUTION 

 

	 	14.1	 General. Except for disputes for which injunctive or other equitable relief is sought to prevent the
unauthorized use or disclosure of proprietary materials or information, prevent the infringement or misappropriation of a Party’s Intellectual Property Rights or prevent a breach of Section 2.5, the following procedures shall be used to
resolve any dispute arising out of or in connection with this Agreement. 

  

	 	14.2	 Meeting. Promptly after the written request of either Party, each of the Parties shall appoint a
designated representative to meet in person or by telephone to attempt in good faith to resolve any dispute arising out of or resulting from this Agreement (“Dispute”). If such designated representatives do not resolve such Dispute
within sixty (60) Business Days of such written request, then the Executive Officer of each Party shall meet in person or by telephone to review and attempt to resolve such Dispute in good faith. The Executive Officers shall have sixty
(60) Business Days to attempt to resolve the dispute (such total one hundred and twenty (120) Business Days the “Dispute Resolution Period”). If the Parties are unable to resolve a Dispute within a Dispute Resolution
Period, then such Dispute shall be resolved in accordance with Section 14.3. 

  

	 	14.3	 Arbitration. 

 

	 	14.3.1	 Any Disputes that are not resolved by the Parties in accordance with Section 14.2 shall be submitted to
binding arbitration with the office of the American Arbitration Association (“AAA”) in San Diego County, California in accordance with the then-prevailing commercial arbitration rules of the American Arbitration Association. Such
Dispute shall be heard by a panel of three (3) arbitrators appointed in accordance with such rules. 

  

	 	14.3.2	 All such arbitration proceedings shall be held in English and a transcribed record shall be prepared in
English. The Party submitting the Dispute to arbitration shall select the first of the three (3) arbitrators and shall provide notice of the same at the time it submits the Dispute to arbitration. The
non-initiating Party shall then have thirty (30) days to select the second arbitrator. Thereafter, the first and second arbitrators shall have thirty (30) days to choose the third arbitrator. If no
arbitrator is appointed within the times herein provided or any extension of time which is mutually agreed 

  
 32 

	 	
upon, the AAA shall make such appointment of the first two (2) arbitrators within thirty (30) days of such failure who shall thereafter pick the third as set forth herein. Each Party in
any arbitration proceeding commenced hereunder shall initially bear such Party’s own costs and expenses (including expert witness and attorneys’ fees) of investigating, preparing and pursuing such arbitration claim. The fees and expenses
of the arbitrators, will be shared equally by the Parties. Nothing in this Agreement shall be deemed as preventing either Party from seeking injunctive relief (or any other provisional remedy) from any court having jurisdiction over the Parties and
the subject matter of the Dispute as necessary to protect either Party’s name, Confidential Information, Intellectual Property or any other proprietary rights or to prevent a breach of Section 2.5. If the Dispute involves scientific or
technical matters, each arbitrator chosen hereunder shall have educational training and experience relevant to the field of biotechnology. The award rendered by the arbitrators shall be written, final and
non-appealable, and judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The prevailing Party shall be entitled to recover from the losing Party the
prevailing Party’s attorneys’ fees and costs. The arbitrator shall have the right to apportion liability between the Parties, but will not have the authority to award any damages or remedies not available under the express terms of this
Agreement. The arbitration award will be presented to the Parties in writing, and upon the request of either Party, will include findings of fact and conclusions of law. The award may be confirmed and enforced in any court of competent jurisdiction.

  

	15.	 PRODUCT IP ASSIGNMENT 

 

	 	15.1	 Transfer of Product IP. LICENSOR hereby sells, assigns, transfers and conveys to LICENSEE, and LICENSEE
hereby purchases, all of LICENSOR’s right, title and interest in and to the Product IP, free and clear of any Liens. Simultaneous with the execution of this Agreement, the Parties shall execute the bill of sale and assignment and assumption
attached hereto as Schedule D in connection with the transfer and assignment of the Product IP. 

  

	16.	 GENERAL PROVISIONS 

 

	 	16.1	 Assignment. Neither Party may assign its rights and obligations under this Agreement without the other
Party’s prior written consent, except that: (a) each Party may assign its rights and obligations under this Agreement or any part hereof to one or more of its Affiliates without the consent of the other Party; and (b) either Party may
assign this Agreement in the event of a Change in Control. The assigning Party shall provide the other Party with prompt written notice of any such assignment. Any permitted assignee pursuant to clauses (a) and (b) above shall assume all
obligations of its assignor under this Agreement, and no permitted assignment shall relieve the assignor of liability for its obligations hereunder. In addition, each of LICENSOR and Oncternal covenants and agrees that it shall not assign any of the
Licensed Technology to any Affiliate or Third Party unless the obligations under this Agreement (and the Oncternal License and Assignment Agreement) are also assigned, pursuant to this Section 16.1, to and explicitly assumed by such Affiliate
or Third Party in writing. Any attempted assignment in contravention of the foregoing shall be null and void. Absent a novation executed 

  
 33 

	 	by the Parties, the assigning Party shall continue to be liable to the non-assigning Party for any breaches of this Agreement by the Affiliate, successor in interest or acquirer.

  

	 	16.2	 Severability. Should one or more of the provisions of this Agreement become void or unenforceable as a
matter of law, then such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement, and the Parties agree to substitute a valid and enforceable provision therefor which,
as nearly as possible, achieves the desired economic effect and mutual understanding of the Parties under this Agreement. 

  

	 	16.3	 Governing Law. This Agreement shall be governed by and construed under the laws in effect in the State
of California, without giving effect to any conflicts of laws provision thereof or of any other jurisdiction that would produce a contrary result, except that issues subject to the arbitration clause and any arbitration hereunder shall be governed
by the applicable commercial arbitration rules and regulations. 

  

	 	16.4	 Force Majeure. Except with respect to delays or nonperformance by a Party caused by the negligent or
intentional act or omission of such Party, any delay or nonperformance by such Party will not be considered a breach of this Agreement to the extent such delay or nonperformance is caused by acts of God, natural disasters, acts or failures to act of
the government (including any Regulatory Authority) or civil or military authority, fire, floods, epidemics, quarantine, energy crises, war or riots or other similar cause outside of the reasonable control of such Party (each, a “Force
Majeure Event”), provided that the Party affected by such Force Majeure Event will promptly begin or resume performance as soon as reasonably practicable after the event has abated. If the Force Majeure Event prevents a Party from
performing any of its obligations under this Agreement for one hundred eighty (180) days or more, then the other Party may terminate this Agreement immediately upon written notice to the non-performing
Party. 

  

	 	16.5	 Waivers and Amendments. The failure of any Party to assert a right hereunder or to insist upon
compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other Party. No waiver shall be effective unless it has been
given in writing and signed by the Party giving such waiver. No provision of this Agreement may be amended or modified other than by a written document signed by authorized representatives of each Party. 

 

	 	16.6	 Relationship of the Parties. Nothing contained in this Agreement shall be deemed to constitute a
partnership, joint venture, or legal entity of any type between LICENSOR and LICENSEE, or to constitute one Party as the agent of the other. Moreover, each Party agrees not to construe this Agreement, or any of the transactions contemplated hereby,
as a partnership for any tax purposes. Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give any Party the power or authority to act for, bind, or commit the other Party.

  

	 	16.7	 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties
hereto and their respective successors and permitted assigns. 

  
 34 

	 	16.8	 Notices. Any notice, request, demand or other communication required or permitted hereunder shall be in
writing and shall be deemed to have been given (i) if delivered or sent by facsimile transmission, upon receipt, (ii) if sent by reputable courier service guaranteeing overnight delivery, on the next Business Day, (iii) if sent by
registered or certified mail, upon the sooner of the date on which receipt is acknowledged or the expiration of three (3) Business Days after deposit in United States post office facilities properly addressed with postage prepaid, or
(iv) if sent by electronic mail, upon confirmed receipt. All notices to a party will be sent to the addresses set forth below or to such other address or person as such party may designate by notice to each other Party hereunder:

  

			
	If to LICENSOR:	 	 Velos Biopharma Holdings, LLC
 3525 Del Mar
Heights Road #821
 San Diego, CA 92130-2122
 Attn: Cam
Gallagher, CEO

		
	with a copy to:	 	 Latham & Watkins LLP
 12670 High
Bluff Drive
 San Diego, CA 92130
 Attn: Cheston Larson,
Esq./Steven T. Chinowsky, Esq.
 Fax: (858) 523-5450

		
	If to LICENSEE:	 	 VelosBio Inc.
 3210 Merryfield Row

San Diego, CA 92121 Attn: Chief Executive Officer

		
	with a copy to:	 	 Morgan, Lewis & Bockius LLP
 One
Market, Spear Street Tower
 San Francisco, CA 94105
 Attn:
Benjamin Pensak

		
	If to Oncternal:	 	 Oncternal Therapeutics, Inc.
 3525 Del Mar
Heights Road #821
 San Diego, CA 92130-2122
 Attn: James
Breitmeyer, President & CEO
 Fax: (858) 408-3010

		
	with a copy to:	 	 Latham & Watkins LLP
 12670 High
Bluff Drive
 San Diego, CA 92130
 Attn: Cheston J. Larson,
Esq./Steven T. Chinowsky, Esq.
 Fax: (858) 523-5450

	
	 or to such other place and with such other copies as either party may designate as to itself by written notice to the
other.

  

	 	16.9	 Further Assurances. Each Party hereby covenants and agrees without the necessity of any further
consideration, to execute, acknowledge and deliver any and all such other documents and take any such other action as may be reasonably necessary or appropriate, at the cost of the requesting Party (unless otherwise set forth herein), to carry out
the intent and purposes of this Agreement. 

  
 35 

	 	16.10	 No Third Party Beneficiary Rights. Except with respect to Oncternal which shall be
deemed to be an intended third party beneficiary of LICENSOR’s rights under this Agreement and except as otherwise expressly stated herein, this Agreement is not intended to and shall not be construed to give any Third Party any interest or
rights (including, without limitation, any third party beneficiary rights) with respect to or in connection with any agreement or provision contained herein or contemplated hereby.  

 

	 	16.11	 Entire Agreement. This Agreement, together with its Schedules and the Assignment and the Transition
Services Agreement and Asset Purchase Agreement, sets forth the entire agreement and understanding of the Parties and their Affiliates as to the subject matter hereof and supersedes all proposals, oral or written, and all other prior communications,
understandings, discussions, negotiations or agreements between the Parties and their Affiliates with respect to such subject matter. In the event of any inconsistency between this Agreement, and the Transition Services Agreement or Asset Purchase
Agreement, this Agreement shall control. 

  

	 	16.12	 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. 

  

	 	16.13	 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall
be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. 

  

	 	16.14	 Interpretation; Waiver of Rule of Construction. 

 

	 	16.14.1	 Except where the context expressly requires otherwise, (a) the use of any gender herein shall be deemed to
encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b) the words “include”, “includes” and “including” shall be deemed to be followed
by the phrase “without limitation” (and, for clarity, where words such as “without limitation” follow “including” in this Agreement no alternative or additional meaning is intended), (c) the word “shall”
shall be construed to have the same meaning and effect as the word “will”, (d) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other
document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any Person shall be construed to include the
Person’s successors and permitted assigns, (f) the words “herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular
provision hereof, (g) all references herein to Sections or Schedules shall be construed to refer to Sections or Schedules of this Agreement, and references to this Agreement include all Schedules hereto, (h) the word “notice”
means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement, (i) the term “or” shall be interpreted in the inclusive
sense commonly associated with the term “and/or”, (j) the phrase “non-creditable and non-refundable” shall

  
 36 

	 	
not forestall a Party’s right to claim or receive damages in connection with a breach of this Agreement (including damages that are equal to or less than any payment described as “non-creditable and non-refundable”), and (k) the phrases “relating exclusively” or “relate exclusively” or the like shall be understood to
mean that the object of such phrase may be the entirety of something or may be a portion of a greater whole. 

  

	 	16.14.2	 Each Party has had the opportunity to consult with counsel in connection with the review, drafting and
negotiation of this Agreement. Accordingly, any rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

 

	 	16.15	 Guaranty. In consideration of the rights granted to LICENSOR under this Agreement, and to induce
LICENSEE to enter into this Agreement, Oncternal, hereby irrevocably and unconditionally guarantees, in favor of LICENSEE and its Affiliates, the performance of all of LICENSOR’s obligations under Sections 2.1 (License Grant), 2.2 (Sublicense
Rights), 2.3 (UCSD License Agreement), 2.5.1 and 2.5.3 (Exclusivity), 2.6 (Oncternal License and Assignment Agreement), 3.4 (Right of Reference), 6.2 (Patent Prosecution), 9.1 (Representations, Warranties and Covenants), 9.3 (Additional
Representations, Warranties and Covenants by LICENSOR), 10.2 (Indemnification by LICENSOR), 16.1 (Assignment) and 16.9 (Further Assurances); Articles 6 (Intellectual Property Rights), 7 (Infringement; Misappropriation), 8 (Confidentiality) and 15
(Product IP Assignment); and Schedules C and D; in each case subject to any defenses, counter-claims and limitations of liabilities which are available to LICENSOR; provided that if at the time of such
non-performance by LICENSOR, LICENSOR is not an Affiliate of Oncternal, then the foregoing guaranty shall apply solely to the extent the breach or failure in performance by LICENSOR of its obligation arises
out of or results from the negligence or willful misconduct of Oncternal or the breach by Oncternal of obligations under the Oncternal License and Assignment Agreement. Oncternal agrees to take such action as may be necessary to keep itself informed
as to the scope and performance of such obligations and of the affairs of LICENSOR and agrees that LICENSEE has no obligation to notify Oncternal of any matter which may increase or change its obligations hereunder as a guarantor or to assist
Oncternal in managing or supervising LICENSOR. No failure or delay or lack of demand, notice or diligence in exercising any right under this Section 16.15 shall operate as a waiver thereof, nor shall any single or partial exercise of any such
right preclude any other or further exercise thereof or the exercise of any other right under this Section 16.15. This guarantee is an absolute, unconditional and continuing guarantee of performance. Any provision of this Section 16.15
that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or
unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. Oncternal represents, warrants and covenants to LICENSEE that it has the corporate power and authority to enter into this
guarantee, that all corporate and governmental approvals needed by it to enter into and to perform 

  
 37 

	 	
hereunder have been secured or obtained, and that the provisions of this Section 16.15 are a legal and valid obligation binding upon it and is enforceable in accordance with its terms, and
that the execution hereof does not conflict with any agreement, undertaking, or instrument to which it is a party. Oncternal hereby expressly waives any requirement that LICENSEE exhaust any right, power or remedy against LICENSOR hereunder prior to
proceeding directly against Oncternal under this Section 16.15. 

 [Signatures on next page] 

  
 38 

 IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first set
forth above. 
  
  

									
	LICENSOR:	  		 	LICENSEE:
			
	Velos Biopharma Holdings, LLC	  		 	VelosBio Inc.
					
	By:	 	 /s/ Cam Gallagher
	  		 	By:	 	 /s/ David Johnson

	Name:	 	Cam Gallagher	  		 	Name:	 	David Johnson
	Its:	 	Chief Executive Officer	  		 	Its:	 	President and Chief Executive Officer
				
	With respect to relevant Sections and Articles of this Agreement only:	  		 		 	
				
	Oncternal Therapeutics, Inc.	  		 		 	
					
	By:	 	 /s/ James Breitmeyer
	  		 		 	
	Name:	 	James Breitmeyer	  		 		 	
	Its:	 	President and Chief Executive Officer	  		 		 	

 Signature Page to License and Assignment Agreement 

  

 SCHEDULE A: PLATFORM PATENTS 

Patent families 701, 702, 703, 704 and 708 as detailed further below: 
  

 
 [***] 

 SCHEDULE B: PRODUCT IP 

Patents and patent applications: 
  

	 	•	 	 Patent families 710, 711 and 712, as detailed further below: 

 
 

 
 Know-How (in each case, to the extent exclusively related to a Product):

  

	 	•	 	 Know-How owned or controlled by LICENSOR or Oncternal (prior to or on the
Effective Date) or LICENSEE (after the Effective Date) under any of the Assigned Contracts (as defined in the Asset Purchase Agreement) 

	 	•	 	 Images and structures, and any related descriptions, reflected in LICENSOR’s or Oncternal’s board
meeting minutes or materials 

	 	•	 	 Know-How owned or controlled by LICENSOR or Oncternal and arising out of
any of the following activities under agreements between Oncternal and the indicated counterparty: 

	 	•	 	 Know-How owned or controlled by LICENSOR or Oncternal and arising out of
any of the following activities: 

  
 

 

 SCHEDULE C: FORM OF ASSIGNMENT-IN-PART OF UCSD LICENSE AGREEMENT 

PARTIAL ASSIGNMENT AND ASSUMPTION OF LICENSE AGREEMENT 

This PARTIAL ASSIGNMENT AND ASSUMPTION OF LICENSE AGREEMENT, dated as of February 6, 2018 (this “Assignment”), by
and between VELOS BIOPHARMA HOLDINGS, LLC, a Delaware limited liability company (“Assignor”), and, VelosBio Inc. a Delaware corporation (“Assignee”).
Assignor and Assignee are referred to herein individually as a “Party” and collectively as the “Parties.” Oncternal Therapeutics, Inc. is a party to this Agreement solely for purposes of Section 4
and Annex 2, part 3. 
 WHEREAS, Assignor and Assignee have entered into a License and Assignment Agreement, dated as of February 6,
2018 (the “License and Assignment Agreement”), pursuant to which Assignor has agreed to license certain intellectual property relating to the Products (as hereinafter defined), including a partial assignment and assumption of
that certain License Agreement, dated March 31, 2016, by and between Oncternal Therapeutics, Inc., a Delaware corporation (together with its successors and permitted assigns (other than Assignor), “Oncternal”) and The
Regents of the University of California, as amended (the “UCSD License Agreement”), attached hereto as Annex 1, but only insofar as it relates to the Products. 

WHEREAS, Section 10.3 of the UCSD License Agreement provides that the UCSD License Agreement may be assigned by Assignor in whole or in
part to an affiliate which agrees to be bound by the terms of the UCSD License Agreement upon written notice to The Regents of the University of California. 

WHEREAS, as of the date hereof, Oncternal, Assignor and Assignee are all affiliates of each other. 

WHEREAS, on the date hereof, pursuant to that certain License and Assignment Agreement between Oncternal and Assignor, Oncternal assigned and
transferred to Assignor, and Assignor agreed to accept and assume, all rights and obligations of Oncternal under the UCSD License Agreement with respect only to the Products. 

WHEREAS, pursuant to Section 2.3 of the License and Assignment Agreement, Assignor has agreed to assign and transfer to Assignee, and
Assignee has agreed to accept and assume, all rights and obligations of Assignor under the UCSD License Agreement with respect only to the Products, as hereinafter set forth. 

NOW, THEREFORE, in consideration of the premises and the mutual representations, warranties, covenants, conditions and agreements set forth
herein and in the License and Assignment Agreement and for other valuable consideration, receipt of which is hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows: 

 1.    Defined Terms. As used herein, the following terms have the
following meanings: 
 “ADC Product” means any product containing or comprising a ROR1 reactive Antibody conjugated
or fused directly or indirectly with a cytotoxic or cytostatic compound or radionuclide (or any other method of delivering a toxic moiety to a cell using an Antibody). For clarity, “ADC Product” includes, but is not limited to, any
Bispecific Product conjugated, fused, or operatively linked directly or indirectly with a cytotoxic or cytostatic compound or radionuclide (or any other method of delivering a toxic moiety to a cell using an Antibody), but excludes a CAR-T Product. 
 “Antibody” means all forms of antibodies, including, but not
limited to: murine, chimeric, primatized, humanized, de-immunized, and human; as well as all intact antibodies and fragments (including, but not limited to, Fab, scFv formats (including diabodies and tandem
scFvs), single domain antibodies (such as nanobodies), and small modular immunopharmaceuticals (SMIPs)). For clarity, an Antibody includes any Antibody whose carbohydrates or Fc region have been chemically or genetically modified, for example, to
alter its pharmacokinetics, or its interactions with immune effector cells or complement components. 
 “Bispecific
Product” means any product containing or comprising a ROR1 reactive Antibody conjugated, fused, or operatively linked to any other moiety such that such product can bind simultaneously one or more epitopes on ROR1 and one or more
different targets (e.g., polypeptide, carbohydrate, or lipid). For clarity, Bispecific Product does not include a CAR-T Product, but does include “multispecific” Antibodies. 

“CAR-T Product” means any product that is a genetically engineered immune
effector cell expressing a ROR1 reactive Antibody or the genetic techniques to produce them, or other genetically engineered cellular therapies having an affinity for ROR1. For clarity, a CAR-T Product can
also include additional Antibodies recognizing other cellular targets, or the genetic techniques to produce them, but does not include any Bispecific Product. 

“Field” means therapeutic, diagnostic and preventive applications in all indications. 

“Licensed Method” has the meaning set forth in the UCSD License Agreement. 

“Licensed Product” has the meaning set forth in the UCSD License Agreement. 

“Platform Patents” has the meaning set forth in the License and Assignment Agreement. 

“Products” means any product (i) that is an ADC Product or a Bispecific Product and (ii) would constitute a
Licensed Product under the UCSD License Agreement. For clarity, Products may contain a toxic payload and also be reactive with other targets in addition to ROR1. For further clarity, subject to the final sentence of Section 2.1.1 the License
and Assignment Agreement, Products does not include CAR-T Products or ROR1 Antibody Products. 

 “ROR1 Antibody Product” means any product containing or comprising a
ROR1 reactive Antibody, including, without limitation, cirmtuzumab, that is not an ADC Product or a Bispecific Product. 

“Technology” has the meaning set forth in the UCSD License Agreement. 

“Territory” has the meaning set forth in the UCSD License Agreement. 

“Term” has the meaning set forth in the UCSD License Agreement. 

2.    Assignment in Part. Subject to the terms set forth herein, Assignor does hereby assign, transfer and deliver
to Assignee, and Assignee hereby accepts and assumes and agrees to timely perform, pay and discharge, all rights, duties and obligations of Assignor under the UCSD License Agreement with respect to, and only to the extent that, such rights, duties
and obligations relate to the Products, which assignment in part includes an assignment of the license under Section 2.1 of the UCSD License Agreement under the Platform Patents to make and have made, to use and have used, to sell and have
sold, to offer for sale, and to import and have imported Products (but no other Licensed Products) and to practice Licensed Methods with respect to Products (but no other Licensed Products) and to use Technology in the Field with respect to Products
(but no other Licensed Products) within the Territory and during the Term, in all cases on and subject to the terms and conditions of the UCSD License Agreement. Nothing herein shall be deemed or construed to constitute an assignment of any rights
under the UCSD License Agreement relating to any Licensed Products other than the Products. Assignee hereby agrees to be bound by and comply with the terms of the UCSD License Agreement (including, without limitation, Section 3.1(c)B,
Section 3.1(c)D, Section 3.3(a)(i)-(v), Section 3.3(a)B, Section 3.3(a)D, Section 3.4, Article 4, Article 5, Article 6 and Section 8.2 thereof) and to perform, discharge and be responsible for all liabilities arising
thereunder to the extent relating solely to the Products. Without limiting the foregoing, the Parties hereby acknowledge and agree that the fees, milestones and other payments set forth on, or allocated to Assignee in, Annex 2 hereto relate to the
Products (or, with respect to general payments, represent the portion of such payments attributable to the Products), and such fees, milestones and other payments are assigned and delegated to, and assumed by, Assignee hereunder. 

3.    No Merger. Nothing contained in this Assignment shall in any way supersede, modify, replace, amend, change,
rescind, waive, exceed, expand, enlarge or otherwise affect the provisions of the License and Assignment Agreement, including the warranties, covenants, agreements, conditions and representations contained in the License and Assignment Agreement
and, in general, any of the rights and remedies, and any of the obligations and indemnifications, of Assignor or Assignee set forth in the License and Assignment Agreement. Except as expressly provided in the License and Assignment Agreement, this
Assignment is made without warranty of any kind, express or implied at common law, by statute or otherwise. 

4.    Further Assurances. Assignor and Assignee each covenant and agree, in connection with the License and
Assignment Agreement and this Assignment, promptly to execute and deliver any additional documents and instruments and perform any additional acts that may be reasonably necessary or desirable to effectuate and perform more fully the provisions of
this Assignment and the assignment and assumption in part made pursuant to Section 2 hereof. 

 5.    Miscellaneous. This Assignment: (a) is executed
pursuant to the License and Assignment Agreement, (b) shall be governed by and construed in accordance with the internal laws of the State of California, without regard to the principles of conflicts of law thereof, (c) shall be binding
upon and inure to the benefit of the Parties and their respective successors and permitted assigns and (d) may be executed and delivered either originally or by facsimile transmission or electronic transmission in PDF format, and in one or more
counterparts, each of which shall be considered an original document, but all of which together shall be considered one and the same document. This Assignment may not be amended, modified, supplemented or waived except in a writing signed by each of
Assignor and Assignee. The section headings contained in this Assignment are for reference purposes only and shall not affect in any way the meaning or interpretation of this Assignment. Capitalized terms used herein and not otherwise defined have
the meanings set forth in the License and Assignment Agreement. 
 [Signature pages follow] 

 This Partial Assignment and Assumption of License Agreement is being executed and delivered
by Assignor and Assignee and shall be effective as of the date first above written. 
  

									
	ASSIGNOR:	  		 	ASSIGNEE:
			
	Velos Biopharma Holdings, LLC	  		 	VelosBio Inc.
					
	By:	 	 /s/ Cam Gallagher
	  		 	By:	 	 /s/ David Johnson

	Name:	 	Cam Gallagher	  		 	Name:	 	David Johnson
	Its:	 	Chief Executive Officer	  		 	Its:	 	President and Chief Executive Officer
				
	With respect to relevant Sections of this Partial Assignment and Assumption of License Agreement only:	  		 		 	
				
	Oncternal Therapeutics, Inc.	  		 		 	
					
	By:	 	 /s/ James Breitmeyer
	  		 		 	
	Name:	 	James Breitmeyer	  		 		 	
	Its:	 	President and Chief Executive Officer	  		 		 	

 Annex 1 

UCSD License Agreement 

 Annex 2 

Fees, Milestones and Payments Assumed by Assignee 

The Parties hereby acknowledge and agree that the fees, royalties and other payments set forth below relate or are attributable to the Products, and
accordingly Assignee hereby assumes and agrees to timely pay and discharge the fees, royalties and other payments set forth below. The Parties further acknowledge and agree that the following payment terms are subject to Section 2.3.1 and any
amended or alternate agreement that one or both Parties (and/or their Affiliates) and UCSD may enter. 
  

	 	1.	 License Maintenance Fees 

Fifty percent (50%) of the annual license maintenance fee payable under Section 3.1(b) of the UCSD License Agreement from and after
January 1, 2018 shall be assigned to and assumed, paid and discharged by Assignee. For clarity, Assignee’s responsibilities for License Maintenance Fees shall commence as of January 1, 2018 and does not include any such fees due prior
to such date. 
  

	 	2.	 Milestone Payments 

All of the milestone payments payable under Section 3.1(c) of the UCSD License Agreement under subclause B (“For the first ADC
Licensed Product”) and subclause D (“For the first Antibody Fragment or Synthetic Antibody Licensed Product”) of such Section shall be assigned to and assumed, paid and discharged by Assignee. 

 

	 	3.	 Sales Milestones 

All of the milestone payments payable under Section 3.1(c) of the UCSD License Agreement under subclause E thereof relating to Net Sales
(as defined in the UCSD License Agreement) of Products shall be assigned to and assumed, paid and discharged by Assignee. In the event that any such milestone payment is triggered by cumulative Net Sales of Products and Net Sales by Oncternal of
other Licensed Products, the portion of such milestone payment so assumed and payable by Assignee shall equal the percentage of the aggregate Net Sales of Licensed Products constituting Net Sales of Products. 

Each of Assignor (and Oncternal) and Assignee would have the right to audit the other party’s applicable books and records with respect
to Net Sales of Licensed Products in accordance with Section 5.1.2 applied mutatis mutandis. 
  

	 	4.	 Royalty Payments 

The royalty payments payable under Section 3.1(d) of the UCSD License Agreement relating to Net Sales (as defined in the UCSD License
Agreement) of “ADC Licensed Products” and “Antibody Fragment or Synthetic Antibody Licensed Products” shall be assigned to and assumed, paid and discharged by Assignee. 

	 	5.	 Sublicense Fees 

Any and all Sublicense Fees or Sublicense royalty payments (as such terms are defined or used in the UCSD License Agreement) payable under
Section 3.1(g)-(h) relating to any sublicense by or through Assignee related to the Products shall be assigned to and assumed, paid and discharged by Assignee. 
  

	 	6.	 Minimum Payment Obligation 

In the event that any minimum annual royalty payment is triggered under Section 3.1(i) of the UCSD License Agreement from and after the
first calendar year of commercial sales of Products by Assignee (or its Affiliates or sublicensees), a percentage of such minimum annual royalty payment shall be assigned to and assumed, paid and discharged by Assignee, which percentage shall
represent the percentage of total earned royalties contributed by Oncternal (or its affiliates of sublicensees). By way of illustration, if the minimum annual royalty for a calendar year is $500,000, and Assignee pays total earned royalties of
$100,000 and Oncternal pays total earned royalties of $25,000 in such calendar year, Oncternal has contributed 20% of the total earned royalties and thus Licensee is only responsible for 20% of the residual minimum annual royalty of $375,000, or
$75,000 and Oncternal is responsible for 80% of the of the residual minimum annual royalty of $375,000, or $300,000. 
  

	 	7.	 Patent Costs 

All of the reimbursements or advance payments payable under Section 3.2 of the UCSD License Agreement for Patent Costs (as defined in the
UCSD License Agreement) that relate exclusively to Products shall be assigned to and assumed, paid and discharged by Assignee. In the event that any such Patent Costs relate to Platform Patents that relate to both Products and other Licensed
Products, Assignee shall assume and be responsible for 50% of such Patent Cost. 
 As of the Effective Date, such amounts equal $165,400.

  

	 	8.	 Biosite and Xoma Payments 

All payments due to or in respect of either Biosite Incorporated or Xoma Technology Ltd. under the UCSD License Agreement (and the agreements
with Biosite and Xoma Technology referenced therein) shall be assigned to and assumed, paid and discharged by the Party that is developing or marketing the applicable product. 

 

	 	9.	 Annual Spend 

Fifty percent (50%) of all payments due under Section 3.3(a)(ii) of the UCSD License Agreement shall be assigned to and assumed, paid and
discharged by Assignee. 
  

	 	10.	 Research & Development 

 Fifty percent (50%) of all payments due under Section 3.4 of the UCSD License Agreement
shall be assigned to and assumed, paid and discharged by Assignee from and after January 1, 2018. For clarity, Assignee’s responsibilities for such payments shall commence as of January 1, 2018 and do not include any such fees due
prior to such date. 
  

	 	11.	 Selexis Royalties 

As set forth in the Transition Services Agreement. 

 SCHEDULE D 

BILL OF SALE AND ASSIGNMENT AND ASSUMPTION 

This Bill of Sale and Assignment and Assumption (“Bill of Sale”) dated as of February 6, 2018 is executed and delivered by Velos Biopharma
Holdings LLC (the “Assignor”) and VelosBio Inc. (the “Assignee”). 
 WHEREAS, pursuant to that certain License and
Assignment Agreement, dated February 6, 2018, by and between the Assignor and the Assignee (the “Agreement”), the Assignor has agreed to sell, assign, transfer and deliver to the Assignee the Product IP, and the Assignee has agreed
to accept and assume the Product IP. 
 NOW, THEREFORE, in consideration of the mutual promises set forth in the Agreement and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby agrees as follows: 
  

	 	1.	 The Assignor hereby sells, assigns, transfers and delivers to the Assignee, its successors and assigns, to have
and to hold forever, all right, title and interest in, to and under all of the Product IP. For purposes of convenience, “Product IP” is defined to mean (i) the patents and patents applications set forth on Annex 1 (to this Bill
of Sale) (including all related family members) and (ii) all Know–How, patent rights, trademarks, service marks, good will, moral rights, and any and all other intellectual property or proprietary rights (including, without limitation,
applications relating thereto and the right to sue for infringement, including past infringement), whether or not patentable now known or hereafter recognized in any jurisdiction owned or controlled by Assignor, Oncternal Therapeutics, Inc. or any
of its or their Affiliates as of January 5, 2018 that is exclusively related to a Product, including the Know-How set forth on Annex 1 (to this Bill of Sale). 

 

	 	2.	 This Bill of Sale and all of its terms shall inure to the benefit of the parties hereto and their respective
successors and assigns and shall bind the parties and their respective successors and assigns. 

  

	 	3.	 Each party hereto agrees that it will, from time to time after the date hereof, without further consideration,
execute, acknowledge and deliver all such further acts, assignments, transfers, conveyances, evidences of title, assumptions and assurances as may be required to carry out the intent of this Bill of Sale, including preparing a notarized version of
this Bill of Sale upon the request of a party. Each party hereby appoints the other party as its attorney-in-fact to do, at the other party’s option, all acts
necessary or appropriate to effectuate the assignments pursuant to Section 1 above, including executing and recording all instruments appropriate to effect and confirm any such assignment, and the subsequent prosecution, maintenance, and
enforcement of any Product IP. These powers of attorney are coupled with an interest and are irrevocable. 

  

	 	4.	 With respect to the patents and patent applications included within the Product IP: 

	 	a.	 Assignor has assigned and/or by these presents does hereby sell, assign, transfer and convey unto Assignee, the
whole and entire right, title and interest (i) in and to the patents identified in Annex 1 (to this Bill of Sale) (“Patents”), for the territory of the United States and its possessions and territories and all foreign
countries; (ii) in and to any and all United States and foreign patent applications claiming priority to the Patents including, without limitation, applications for patents including provisionals, non-provisionals, divisions, continuations, continuations-in-part, requests for continued examinations, utility models, PCT applications and designs and any other related United States and foreign applications and
equivalents thereof (the “Applications”), along with the right to claim priority to the Applications under any treaty relating thereto; (iii) in and to all United States and foreign patents, utility models, inventor’s
certificates and designs and all equivalents thereof which may be granted for the Patents or the Applications, including extensions, renewals, reissues and reexamination certificates thereof (the “Future Patents”); and (iv) in
and to all rights to sue or claim for damages, injunctive reliefs and administrative reliefs and collect damages resulting from past, present and future infringement of any and all of the Patents and the Future Patents. 

 

	 	b.	 The Patents, the Applications and the Future Patents shall be held and enjoyed by Assignee, for Assignee’s
own use and benefit, and for Assignee’s legal representatives and assigns, to the full end of the term or terms of the Patents and the Future Patents, as fully and entirely as the same would have been held by Assignor had this assignment and
sale not been made; and for the aforesaid consideration, Assignor hereby covenants, agrees and undertakes to execute promptly or cause to be executed promptly, whenever requested by Assignee, all patent applications, assignments, lawful oaths and
any other papers which Assignee may deem necessary or desirable for securing to Assignee or for maintaining for Assignee all of the Patents, the Applications and the Future Patents hereby assigned or agreed to be assigned, all without further
compensation to Assignor, but at the reasonable and pre-approved cost and expense of the Assignee, its successors, legal representatives, and assigns. It is agreed that Assignor shall be legally bound, upon
request of Assignee or its successors or assigns or a legal representative thereof, to supply all information and evidence of which the undersigned has knowledge or possession, relating to the making and practicing of the Patents and to testify in
any legal proceeding relating thereto without further compensation to Assignor, but at the reasonable and pre-approved cost and expense of the Assignee, its successors, legal representatives, and assign.

  

	 	5.	 This Bill of Sale shall be governed by, and construed and enforced in accordance with, the laws of the State of
California other than conflict of laws principles thereof directing the application of any law other than that of California. Courts within the 

  
 53 

	 	
State of California will have jurisdiction over all disputes between the parties hereto arising out of or relating to this Bill of Sale and the agreements, instruments and documents contemplated
hereby. The parties hereby consent to and agree to submit to the jurisdiction of such courts. Each of the parties hereto waives, and agrees not to assert in any such dispute, to the fullest extent permitted by applicable law, any claim that:
(i) such party is not personally subject to the jurisdiction of such courts, (ii) such party and such party’s property is immune from any legal process issued by such courts or (iii) any litigation commenced in such courts is
brought in an inconvenient forum. 

  

	 	6.	 All capitalized terms not defined herein shall have the meaning set forth in the Agreement.

 [Signatures appear on next page] 

 IN WITNESS WHEREOF, intending to be legally bound hereby, the parties hereto has
caused this instrument to be signed in its name by its duly authorized representatives as of the date first above written. 
  

			
	VELOS BIOPHARMA HOLDINGS, LLC
		
	By:	 	/s/Cam Gallagher
	Name:	 	Cam Gallagher
	Title:	 	Chief Executive Officer
	
	VELOSBIO INC.
		
	By:	 	/s/David Johnson
	Name:	 	David Johnson
	Title:	 	President and Chief Executive Officer

 Annex 1 

Product IP 
 Patents and patent applications:

  

	 	•	 	 Patent families 710, 711 and 712, as detailed further below: 

 
 

 
 Know-How (in each case, to the extent exclusively related to a Product):

  

	 	•	 	 Know-How owned or controlled by Assignor or Oncternal Therapeutics, Inc.
(“Oncternal”) (prior to or on the Effective Date) or Assignee (after the Effective Date) under any of the Assigned Contracts (as defined in the Asset Purchase Agreement) 

	 	•	 	 Images and structures, and any related descriptions, reflected in Assignor’s or Oncternal’s board
meeting minutes or materials 

	 	•	 	 Know-How owned or controlled by Assignor or Oncternal and arising out of
any of the following activities under agreements between Oncternal and the indicated counterparty 

	 	•	 	 Know-How owned or controlled by Seller and arising out of any of the
following activities: 

  

 

 

  

 SCHEDULE E 

DISCLOSURE SCHEDULE 
 to
the 
 LICENSE AND ASSIGNMENT AGREEMENT 

among 
 Velos Biopharma
Holdings, LLC 
 and 

VelosBio Inc. 
 and

 Oncternal Therapeutics, Inc. 

Section 9.3.4: Oncternal has rights and obligations regarding (i) the use of the producer cell line used to generate a master
cell bank for the manufacture of the cirmtuzumab antibody and (ii) use and distribution of cirmtuzumab in finished products. Those rights cannot be sublicensed without the consent of Selexis SA. 

Section 9.3.5, 9.3.7 and 9.3.8 
 The Exploitation of
one or more Products in the Field may require rights under certain intellectual property related to antibody drug conjugation. 

Section 9.1(d), 9.3.4 and 9.3.11: LICENSOR is aware that the development of the cirmtuzumab antibody was sponsored in part by The
California Institute for Regenerative Medicine (“CIRM”), CLL Global Research Foundation, and Blood Cancer Research Fund and as a consequence the UCSD License Agreement is subject to overriding obligations to the same under the sponsorship
agreements. UCSD will not share these agreements with Oncternal or LICENSOR, but LICENSOR is not aware of any obligations under those agreements that would have an adverse impact on the license granted hereto to LICENSEE. 

Section 9.3.9: LICENSEE has submitted a pre-IND Briefing package to the US FDA containing
extensive information concerning the ADC Product and its characterization, including information that has not been shared with Oncternal management. 

Section 9.3.14: Under the UCSD License Agreement, certain periodic written progress reports are outstanding and past due (although
extensive updates have been provided during multiple joint development meetings). For a variety of business reasons, IND-enabling toxicology studies for the ADC and Genetically Engineered Cellular Therapy
Licensed Products were not initiated within one year from the Effective Date of the UCSD License Agreement. Although UCSD is aware of such matters, Oncternal has not been notified of any material breach or material default under the UCSD License
Agreement.EX-10.55

 Exhibit 10.55 

***CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND
(2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 
 AMENDED AND RESTATED LICENSE AGREEMENT 

BETWEEN 
 ONCTERNAL
THERAPEUTICS, INC. 
 AND 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 

FOR 
 CASE NO. SD2005-212 
 CASE NO. SD2010-306 

CASE NO. SD2011-178 

CASE NO. SD2012-143 

CASE NO. SD2012-403 

CASE NO. SD2015-027 

CASE NO. SD2015-200 

 TABLE OF CONTENTS 

 

					
		
	 Article 1. DEFINITIONS
	  	 	2	 
		
	 Article 2. GRANT
	  	 	5	 
		
	 Article 3. CONSIDERATION
	  	 	7	 
		
	 Article 4. REPORTS, RECORDS AND PAYMENTS
	  	 	13	 
		
	 Article 5. PATENT MATTERS
	  	 	17	 
		
	 Article 6. GOVERNMENTAL MATTERS
	  	 	20	 
		
	 Article 7. TERMINATION OR EXPIRATION OF THE AGREEMENT
	  	 	20	 
		
	 Article 8. LIMITED WARRANTY AND INDEMNIFICATION
	  	 	22	 
		
	 Article 9. USE OF NAMES AND TRADEMARKS
	  	 	24	 
		
	 Article 10. MISCELLANEOUS PROVISIONS
	  	 	24	 

 AMENDED AND RESTATED LICENSE AGREEMENT 

This Amended and Restated License Agreement (“Agreement”) is made by and between Oncternal Therapeutics, Inc., a Delaware corporation having an
address at 3525 Del Mar Heights Road, #821, San Diego, California 92130 (“LICENSEE”) and The Regents of the University of California, a California public corporation having its statewide administrative offices at 1111 Franklin Street,
Oakland, California 94607-5200 (“UNIVERSITY”), represented by its San Diego campus having an address at University of California San Diego, Office of Innovation and Commercialization, Mail Code 0910, 9500 Gilman Drive, La Jolla, California
92093-0910 (“UCSD”). 
 This Agreement is effective on the date of the last signature (“Effective Date”). 

RECITALS 
 WHEREAS, the inventions
disclosed in UCSD Disclosure Docket No. SD SD2005-212, SD2010- 306, SD2011-178, SD2012-143,
SD2012-403, SD2015-027 and SD2015-200 and titled, respectively, “Method for determining leukemic cells apart from normal
cells,” “Receptor tyrosine kinase-like orphan receptor (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof,” “Antitumor properties of particular monoclonal antibodies specific for ROR1,”
“Antihuman ROR1-specific monoclonal antibodies,” “ROR1 peptide-based vaccine for ROR1+ cancers,” “Cancer treatment using a new combination of antitumor compound and antitumor antibody” and
“UC-961 blocks Wnt5a-induced non-canonical Wnt-signaling” (collectively, “Inventions”), were made in the course of research at UCSD by
Dr. Thomas Kipps and his associates (hereinafter and collectively, the “Inventors”) and are covered by Patent Rights as defined below; 

WHEREAS, the research was sponsored in part by the Government of the United States of America and as a consequence this license is subject to
overriding obligations to the Federal Government under 35 U.S.C. §§ 200-212 and applicable regulations; 

WHEREAS, the development of the Inventions was sponsored in part by The California Institute for Regenerative Medicine (“CIRM”), CLL Global
Research Foundation, and Blood Cancer Research Fund (“Sponsors”) and as a consequence this license is subject to overriding obligations to the same under the sponsorship agreements; 

WHEREAS, LICENSEE obligations to CIRM under Title 17, California Code of Regulations are appended in Exhibit A; 

WHEREAS, the Inventors are employees of UCSD, and they are obligated to assign all of their right, title and interest in the Inventions to UNIVERSITY;

 WHEREAS, LICENSEE, through Hale BioPharma Ventures LLC, entered into a secrecy agreement (UC Control No. 2015-20-0548) with UNIVERSITY, effective May 18, 2015, for the purpose of evaluating the Inventions; 

WHEREAS, LICENSEE entered into a Letter of Intent (UC Control
No. 2016-30-0316) with UNIVERSITY, effective December 21, 2015, for the purpose of negotiating this Agreement; 

  
 1 

 WHEREAS, LICENSEE entered into a License Agreement (UC Control No. 2016-03-0432) with UNIVERSITY, effective March 31, 2016 (the “Original Agreement”); and Amendment No. 1 (UC Control
No. 2016-03-0432 R(501); 
 WHEREAS, UNIVERSITY is desirous that
the Inventions be developed and utilized to the fullest possible extent so that its benefits can be enjoyed by the general public; 
 WHEREAS,
LICENSEE is desirous of obtaining certain rights from UNIVERSITY for commercial development, use, and sale of the Inventions, and the UNIVERSITY is willing to grant such rights; 

WHEREAS, LICENSEE understands that UNIVERSITY may publish or otherwise disseminate information concerning the Inventions at any time and that LICENSEE
is paying consideration thereunder for its early access to the Inventions, not continued secrecy therein; 
 WHEREAS, LICENSE AND UNIVERSITY desire
to amend and restate the Original Agreement as set forth below. 
 NOW, THEREFORE, the parties agree: 

ARTICLE 1. DEFINITIONS 
 The terms, as
defined herein, shall have the same meanings in both their singular and plural forms. 
  

	1.1	 “ADC Product” means any product containing or comprising a ROR1 reactive Antibody (or antibody
fragment) conjugated or fused directly or indirectly with a cytotoxic or cytostatic compound or radionuclide (or any other method of delivering a toxic moiety to a cell using an Antibody). For clarity, “ADC Product” includes, but is not
limited to, any Bispecific Product conjugated, fused, or operatively linked directly or indirectly with a cytotoxic or cytostatic compound or radionuclide (or any other method of delivering a toxic moiety to a cell using an Antibody), but excludes a
Genetically Engineered Cellular Therapy or CAR-T Licensed Product (defined below). 

  

	1.2	 “Affiliate” means any corporation or other business entity which is bound in writing by LICENSEE to
the terms set forth in this Agreement and in which LICENSEE owns or controls, directly or indirectly, at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors, or in which LICENSEE is owned or
controlled directly or indirectly by at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors; but in any country where the local law does not permit foreign equity participation of at least fifty
percent (50%), then an “Affiliate” includes any company in which LICENSEE owns or controls or is owned or controlled by, directly or indirectly, the maximum percentage of outstanding stock or voting rights permitted by local law.

  

	1.3	 “Antibody” means all forms of antibodies, including, but not limited to: murine, chimeric,
primatized, humanized, de-immunized and human; as well as all intact antibodies and fragment. 

  
 2 

			
	Eff. 4/18/12	  	OAL FINAL

	1.4	 “Antibody Licensed Product” means any product containing or comprising a ROR1 reactive Antibody,
including, without limitation, cirmtuzumab, that is not an ADC Product or a Bispecific Product. 

  

	1.5	 “Biosite Agreement” means the Service Agreement by and between Biosite Incorporated and University,
dated June 14, 2010. 

  

	1.6	 “Bispecific Product” means any product containing or comprising a ROR1 reactive Antibody (or antibody
fragment) conjugated, fused, or operatively linked to any other moiety such that such product can bind simultaneously one or more epitopes on ROR1 and one or more different targets (e.g., polypeptide, carbohydrate, or lipid) and covered under Patent
Rights. For clarity, Bispecific Product does not include a Genetically Engineered Cellular Therapy or CAR-T Licensed Product, but does include “multispecific” Antibodies. 

 

	1.7	 “Combination Product” means any product which is a Licensed Product (as defined below) and contains,
other product(s) that is not an excipient, diluent, adjuvant, buffer and the like and (i) does not use Inventions, Technology or Patent Rights (as defined below); (ii) the sale, use or import by itself does not contribute to or induce the
infringement of Patent Rights; (iii) is sold separately by LICENSEE, its Sublicensee (as defined below) or an Affiliate; and (iv) enhances the market price of the final product(s) sold, used or imported by LICENSEE, its Sublicensee, or an
Affiliate. 

  

	1.8	 “Field” means human therapeutic, diagnostic and preventive applications in all indications; provided
that the “Field” does not include (i) the development or commercialization of an “ADC Product” (defined above), or (ii) a “Bispecific Product” (defined above). 

 

	1.9	 “Genetically Engineered Cellular Therapy or CAR-T Licensed
Product” means any product that is a genetically engineered immune effector cell expressing a ROR1 reactive Antibody or the genetic techniques to produce it, or other genetically engineered cellular therapies having an affinity for ROR1. For
clarity, a Genetically Engineered Cellular Therapy or CAR-T Product can also include additional Antibodies recognizing other cellular targets, or the genetic techniques to produce them, but does not include
any Bispecific Product. 

  

	1.10	 “Licensed Method” means any method that is claimed in Patent Rights (as defined below), the use of
which in or for the Field would constitute, but for the license granted to LICENSEE under this Agreement, an infringement, an inducement to infringe or contributory infringement, of any Valid Claim within Patent Rights. 

 

	1.11	 “Licensed Product” means any service, material, composition or product, or any product that uses
Technology, or that is claimed in Patent Rights, or that is produced by the Licensed Method, or the manufacture, use, sale, offer for sale, or importation of which in each case of the foregoing, in or for the Field, would constitute, but for the
license granted to LICENSEE under this Agreement, an infringement, an inducement to infringe 

  
 3 

			
	Eff. 4/18/12	  	OAL FINAL

	 	 
or contributory infringement, of any Valid Claim within the Patent Rights, provided that Licensed Product shall not include an ADC Product or a Bispecific Product. 

 

	1.12	 “Naked Antibody” means an Antibody that is used in unmodified form and is not conjugated or fused
with another chemical or biological entity covered by the Patent Rights. 

  

	1.13	 “Net Sales” means the total of the gross invoice prices of Licensed Products sold or leased by
LICENSEE, Sublicensee, Affiliate, or any combination thereof, less the sum of the following actual and customary deductions where applicable and separately listed: cash, trade, or quantity discounts or rebates (as allowed under applicable law);
sales tax, use tax, tariff, import/export duties or other excise taxes imposed on particular sales (except for value-added and income taxes imposed on the sales of Licensed Product in foreign countries); transportation charges; or credits to
customers because of rejections, returns or recalls of Licensed Products or because of rebates or charge-backs. For purposes of calculating Net Sales, transfers to a Sublicensee or an Affiliate of Licensed Product under this Agreement for
(i) end use (but not resale) by the Sublicensee or Affiliate shall be treated as sales by LICENSEE at list price of LICENSEE, or (ii) resale by a Sublicensee or an Affiliate shall be treated as sales at the list price of the Sublicensee or
Affiliate. 

  

	1.14	 “Patent Costs” means all
out-of-pocket expenses for the preparation, filing, prosecution, and maintenance of all United States and foreign patents included in Patent Rights. Patent Costs shall
also include out-of-pocket expenses for patentability opinions, inventorship determination, preparation and prosecution of patent application, re-examination, re-issue, interference, and opposition activities related to patents or applications in Patent Rights. 

  

	1.15	 “Patent Rights” means UNIVERSITY’s rights in any of the following: (i) the patents and
patent applications listed in Exhibit C attached hereto, (ii) all continuing applications of any of the foregoing, including divisions, substitutions, and
continuations-in-part (but only to the extent the claims thereof are entirely supported in the specification and entitled to the priority date of the parent
application), (iii) all patents issuing on any of the foregoing applications including reissues, reexaminations and extensions, and (iv) all corresponding foreign applications or patents of any of the foregoing. 

 

	1.16	 “Sponsor’s Rights” means all the applicable provisions of any license to the United States
Government executed by UNIVERSITY and the overriding obligations to the US Government under 35 U.S.C. §§ 200-212 and the overriding obligations to Sponsors under the sponsorship agreements with the
same. 

  

	1.17	 “Sublicense” means an agreement into which LICENSEE enters with a third party that is not an
Affiliate for the purpose of (i) granting certain rights; (ii) granting an option to certain rights; or (iii) forbearing the exercise of any rights, granted to LICENSEE under this Agreement. “Sublicensee” means a third party
with whom LICENSEE enters into a Sublicense. 

  
 4 

			
	Eff. 4/18/12	  	OAL FINAL

	1.18	 “Technology” means all relevant written technical information relating to the Inventions, which the
Inventors may provide to LICENSEE prior to the Effective Date, and (b) all technical information, regulatory filings related to the Inventions developed prior to the Effective Date. 

 

	1.19	 “Term” means the period of time beginning on the Effective Date and ending on the later of
(i) the expiration date of the longest-lived Patent Rights; or (ii) the fifteenth anniversary of the first commercial sale of Licensed Product. 

  

	1.20	 “Territory” means world-wide where Patent Rights exist to the extent this license may legally be
granted. 

  

	1.21	 “Upstream University Agreements” means any agreement entered into by and between UNIVERSITY and one
or more third parties under which UNIVERSITY has agreed, either on behalf of itself or any licensee or sublicensee of UNIVERSITY, to pay, or to cause its licensee or sublicensee to pay, any upfront payments, royalties, maintenance fees, milestone
payments or other consideration in connection with the practice or use of the Licensed Patents or the Technology or the research, development, manufacture or commercialization of any Licensed Products, including without limitation, the Biosite
Agreement as well as any agreement entered into by UNIVERSITY or LICENSEE with Xoma Technology Ltd., or any successor-in-interest thereto, as contemplated in the Biosite
Agreement. 

  

	1.22	 “Valid Claim” means any claim (a) issued in an unexpired patent which has not been held
unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction in the Territory following exhaustion of all possible appeal processes, and which has not been admitted to be invalid or
unenforceable through reissue, re-examination or disclaimer or (b) of a patent application pending, so long as at least one claim covering a Licensed Product in such patent application is being diligently
prosecuted in the Territory. 

 ARTICLE 2. GRANT 

 

	2.1	 License. Subject to the limitations set forth in this Agreement and Sponsor’s Rights,
UNIVERSITY hereby grants to LICENSEE, and LICENSEE hereby accepts, a license under Patent Rights to make and have made, to use and have used, to sell and have sold, to offer for sale, and to import and have imported Licensed Products and to practice
Licensed Methods and to use Technology in the Field within the Territory and during the Term. 

  

	The	 license granted herein is (a) non-exclusive for US Patent
No. 8,212,009 in the field of flow cytometry and imaging-based reagent sales; (b) co-exclusive (with other licensees of the Patent Rights) for the use of the Naked Antibody in a diagnostic
application, the use of a Naked Antibody as an experimental control with respect to Licensed Products, and the use of a Naked Antibody as a framework for the Field; and (c) exclusive for all therapeutic uses and other remaining Patent Rights in
the Field. 

  
 5 

			
	Eff. 4/18/12	  	OAL FINAL

	2.2	 Sublicense. 

(a)        The license granted in Paragraph 2.1 includes the right of LICENSEE to grant
Sublicenses to Affiliates or third parties during the Term but only for as long as the license is exclusive (except in the case of US Patent No. 8,212,009 where the Agreement is nonexclusive). If at any time an Affiliate no longer qualifies as
an Affiliate under this Agreement, then any sublicense to the former Affiliate has to satisfy the requirements of paragraph 2.2(b). 

(b)        With respect to Sublicense granted to third parties pursuant to Paragraph 2.2(a),
LICENSEE shall: 
 (i)        not receive, or agree to receive, anything of value in lieu of cash
as consideration from a third party under a Sublicense granted pursuant to Paragraph 2.2(a) without the express written consent of UNIVERSITY; 

(ii)        to the extent applicable, include all of the rights of and obligations due to UNIVERSITY
(and, if applicable, the Sponsor’s Rights) and contained in this Agreement; 

(iii)        promptly provide UNIVERSITY with a copy of each Sublicense issued; and 

(iv)        collect and guarantee payment of all payments due, directly or indirectly, to UNIVERSITY
from Sublicensees and summarize and deliver all reports due, directly or indirectly, to UNIVERSITY from Sublicensees. 

(c)        Upon termination of this Agreement for any reason, UNIVERSITY, at its sole discretion,
shall determine whether LICENSEE shall cancel or assign to UNIVERSITY any and all Sublicenses. 
  

	2.3	 Reservation of Rights. UNIVERSITY reserves the right to: 

(a)        use the Inventions, Technology and Patent Rights for educational and research purposes;

 (b)        publish or otherwise disseminate any information about the Inventions and Technology
at any time; and 
 (c)        allow other nonprofit institutions to use and publish or otherwise
disseminate any information about Inventions, Technology and Patent Rights for educational and research purposes. 
  

	2.4	 Upstream University Agreements. To the extent of the actual knowledge of the licensing professional
managing the Inventions, the Upstream University Agreements are in full force and effect. LICENSEE agrees to abide by the obligations set forth in EXHIBIT D which have been excerpted from the Biosite Agreement. 

  
 6 

			
	Eff. 4/18/12	  	OAL FINAL

 ARTICLE 3. CONSIDERATION 

 

	3.1	 Fees and Royalties. The parties hereto understand that the fees and royalties payable by LICENSEE to
UNIVERSITY under this Agreement are partial consideration for the license granted herein to LICENSEE under Technology and Patent Rights. LICENSEE shall pay UNIVERSITY: 

(a)         University acknowledges and agrees that a license issue fee of five hundred thousand
dollars (US$500,000) was timely paid by LICENSEE; and additional consideration in the form of 1,250,000 shares (5%) of the LICENSEE’s common stock authorized in the Articles/ Certificate of Incorporation of the LICENSEE dated December 21,
2015, a copy of which is attached to this Agreement as Exhibit B, was delivered to UNIVERSITY. 

(b)         license maintenance fees of twenty-five thousand dollars (US$25,000) per year and payable
on the first anniversary of the Effective Date and annually thereafter on each anniversary; provided however, that LICENSEE’s obligation to pay this fee shall end on the date when LICENSEE is commercially selling a Licensed Product; 

(c)        a license restatement fee of twenty-five thousand dollars (US$25,000) payable within thirty
(30) days after the Effective Date; 
 (d)        milestone payments in the amounts noted below
and payable within thirty (30) days of the occurrence, according to the following schedule or events: 
  

	 	A.	 For the first Antibody Licensed Product: 

 

			
	
Event
  
	  	Amount
     

	 [***]

 
	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  

	 	B.	 For the first Genetically Engineered Cellular Therapy or CAR-T
Licensed Product: 

  

			
	
Event
  
	  	
Amount     

	[***]	  	[***]
	[***]	  	[***]
	[***]    	  	[***]

  
 7 

			
	Eff. 4/18/12	  	OAL FINAL

			
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  

	 	C.	 Sales Milestones for all Licensed Products: 

LICENSEE shall pay UNIVERSITY sales milestones upon the cumulative Net Sales of all Licensed Products according to the following schedule: 

 

					
	(i)	  	Of at least [***]	  	        [***]
	(ii)	  	Of at least [***]	  	        [***]
	(iii)	  	Of at least [***]	  	        [***]
	(iv)	  	Of at least [***]	  	        [***]
	(v)	  	Of at least [***]	  	        [***]

 provided, however, that in no event will any milestone set forth in this Agreement be due more than once. 

(e)        an earned royalty of [***] on Net Sales of Antibody Licensed Products by LICENSEE and/or
its Affiliate(s); an earned royalty of [***] on Net Sales of Genetically Engineered Cellular Therapy or CAR-T Licensed Products by LICENSEE and/or its Affiliate(s); 

provided, however, that no more than one earned royalty shall be due under this Agreement with respect to the sale of any Licensed Product;
and 
 provided, further, that the earned royalty due on Net Sales of Combination Product by LICENSEE and/or its Affiliate(s) shall be
calculated as below: 
 Earned Royalties due UNIVERSITY = [A/(A+B)] x royalty rate on Net Sales of the Licensed Products x Net Sales of
Combination Product, where: 
 A is the separately listed sale price of the Licensed Product; and 

B is the separately listed sale prices of the individual products that satisfy the requirements outlined in Paragraph 1.8
(“Combination Products”). In no event shall the amount payable to UNIVERSITY be less than [***] of the amount otherwise due. 

For any products in B for which LICENSEE has reduced its earned royalties payable to UNIVERSITY under Paragraph 3.l(f) or (g), this
provision shall not apply. 
 (f)        In the event of (i) expiration of applicable Patent
Rights to a Licensed Product while use of Technology still applies, and/or (ii) a Licensed Product is indicated for use 

  
 8 

			
	Eff. 4/18/12	  	OAL FINAL

 
in combination with another pharmaceutical product, the earned royalty shall be reduced by [***]. If LICENSEE has reduced its earned royalties payable to UNIVERSITY under Paragraph 3.1(e) or
(g), this provision shall not apply. 
 (g)        In the event LICENSEE is required to pay
royalties or milestones to one or more third parties for patent or technology rights necessary to make, use or sell Licensed Products, LICENSEE may deduct [***] from the earned royalties payable to UNIVERSITY for every [***] LICENSEE actually pays
to said third parties provided, however, except as otherwise set forth herein, in no event shall the amount payable to UNIVERSITY be less than [***] of the amount otherwise due. If LICENSEE has reduced its earned royalties payable to UNIVERSITY
under Paragraph 3.1(e) or (f), this provision shall not apply. 
 (h)        Sublicense Fees
(defined below) received by LICENSEE from its Sublicensees that are not earned royalties according to the following schedule: 
  

			
	Development stage of Licensed Product	  	            Percent of Sublicense Fee
		
	Prior to the initiation of the first Phase II clinical trial for the Antibody Licensed Product	  	            [***]
		
	Prior to the initiation of the first Phase II clinical trial with respect to any Licensed Product (with the exception to the Antibody Licensed Product)	  	            [***]
		
	After initiation of the first Phase II clinical trial but prior to regulatory approval for any Licensed Product	  	            [***]
		
	After regulatory approval for any Licensed Product	  	            [***]

 “Sublicense Fees” means all upfront fees, milestone payments and similar license fees received by
LICENSEE from its Sublicensees in consideration for the grant of a Sublicense for Patent Rights and Technology, but excluding: 

(i)        any royalty payments or other share of net sales (including revenue sharing, profit
payments that would otherwise be reflected in Net Sales) on the sale or distribution of Licensed Products or services using Licensed Products; 

(ii)         payments for equity or debt securities of LICENSEE (except to the extent such payments
exceed the fair market value of such securities upon date of receipt, in which case such premiums over fair market value shall be deemed to be “Sublicense Revenue”); 

  
 9 

			
	Eff. 4/18/12	  	OAL FINAL

 (iii)        research or development funding
explicitly earmarked to be applied directly to the future research and/or development of Licensed Products and/or Licensed Services; 

(iv)        amounts payed by a Sublicensee for supply of goods from LICENSEE related to the Licensed
Products; and 
 (v)        payments and reimbursement of Patent Costs previously paid to
UNIVERSITY by LICENSEE with respect to the filing, preparation, prosecution or maintenance of the Patent Rights. 

(i)        on each and every Sublicense royalty payment received by LICENSEE from its Sublicensees on
sales of Licensed Product by Sublicensee royalties based on the royalty rate in Paragraphs 3.1(e) through (g) as applied to Net Sales; 

(j)        beginning the calendar year of commercial sales of the first Licensed Product by LICENSEE,
its Sublicensee, or an Affiliate and if the total earned royalties paid by LICENSEE under Paragraphs 3.1(e) through (g) to UNIVERSITY in any such year cumulatively amounts to less than the amounts in the schedule below: 

Year 1: [***] 
 Year 2: [***]

 Year 3: [***] 
 Year 4-5: [***] 
 Year 6 and beyond: [***] 

(“minimum annual royalty”), LICENSEE shall pay to UNIVERSITY a minimum annual royalty on or before February 28 following the
last quarter of such year the difference between amount noted above and the total earned royalty paid by LICENSEE for such year under Paragraphs 3.1(e) through (g); provided, however, that for the year of commercial sales of the first Licensed
Product, the amount of minimum annual royalty payable shall be pro-rated for the number of months remaining in that calendar year. 

All fees and royalty payments specified in Paragraphs 3.1(a) through 3.1(j) above shall be paid by LICENSEE pursuant to Paragraph 4.3 and
shall be delivered by LICENSEE to UNIVERSITY as noted in Paragraph 10.1. 
  

	3.2	 Patent Costs. LICENSEE shall reimburse UNIVERSITY all past (prior to the Effective Date) and future (on
or after the Effective Date) Patent Costs within thirty (30) days following the date an itemized invoice is sent from UNIVERSITY to LICENSEE. In UNIVERSITY’s discretion, for Patent Costs anticipated to exceed [***] (“Anticipated
Costs”), UNIVERSITY will inform LICENSEE no less than sixty (60) days prior to the date when Anticipated Costs are incurred. UNIVERSITY may, at its discretion and in accordance with Paragraph 5.l(c), require full advance payment of
Anticipated Costs at least fifteen (15) business days before required filing dates (“Advance Payment Deadline”). In the event UNIVERSITY has provided LICENSEE with a sixty (60) days’ notice of Anticipated Costs, and LICENSEE
does not pay the Anticipated Costs on or 

  
 10 

			
	Eff. 4/18/12	  	OAL FINAL

	 	 
before the Advance Payment Deadline, UNIVERSITY will act at its sole discretion with regard to filing, prosecution and maintenance of those Patent Rights associated with the sixty
(60) days’ notice. In the event that the Anticipated Costs paid by LICENSEE is greater than the actual cost, the excess amount is creditable against future Patent Costs. In the event that the actual costs exceed the Anticipated Costs paid
in advance by LICENSEE, LICENSEE shall pay such excess costs within thirty (30) days following the date an itemized invoice is sent as set forth in Paragraph 4.3. 

 

	    	 In the event that UNIVERSITY licenses Patent Rights to a third party (“Additional Licensee”),
UNIVERSITY shall cause any Additional Licensee to pay a pro-rata share of future Patent Costs after the execution date of the Additional Licensee’s license. For purposes if this Paragraph 3.2, “pro-rata” shall mean a fractional share of the total Patent Costs multiplied by a fraction, the numerator of which is one and the denominator of which is the Additional Licensee plus one.

  

	3.3	 Due Diligence. 

 

	 	(a)        LICENSEE	 shall, either directly or through its Affiliate(s) or Sublicensee(s): 

(i)        diligently proceed with the development, manufacture and sale of Licensed Products; 

(ii)        annually spend not less than [***] for the development of Licensed Products during the
first five (5) years of this Agreement. LICENSEE recognizes the expertise of the Inventors in Inventions and, pursuant to Paragraph 3.4 below, is committed to contract the Inventors to further develop Inventions at UCSD of at least [***]
per year for a total of five years. LICENSEE may credit the amount actually paid to UCSD under such contract against its obligation under this paragraph; 

(iii)        market Licensed Products in the United States within nine (9) months of receiving
regulatory approval to market such Licensed Products; 
 (iv)        fill the market demand for
Licensed Products following commencement of marketing at any time during the term of this Agreement; and 

(v)        obtain all necessary governmental approvals for the manufacture, use and sale of Licensed
Products. 
  

	 	A.	 First Antibody Licensed Product - UC99961/UC-961/ Cirmtuzumab

 (i)        open IND and initiate Phase I clinical trial for Licensed
Product within one (1) year from the Effective Date; 
 (ii)        dose the first patient in
the first Phase II clinical trial for Licensed Product within three (3) years from the Effective Date; 

  
 11 

			
	Eff. 4/18/12	  	OAL FINAL

 (iii)        dose the first patient in the first
Phase I/Phase II clinical trial in ovarian and/or breast cancer with Licensed Product within three (3) years from the Effective Date; 

(iv)        complete first end of Phase II meeting with FDA for Licensed Product within three and one
half (3.5) years from the Effective Date; 
 (v)        dose first patient in the first Phase II
clinical trial in ovarian or breast cancer for Licensed Product within four (4) years from the Effective Date; 

(vi)        dose first patient in the first Phase III clinical trial for Licensed Product within five
and one half (5.5) years from the Effective Date; 
 (vii)        complete enrollment of the first
Phase III clinical trial for Licensed Product within seven (7) years from the Effective Date; 

(viii)        submit the first NDA for the Licensed Product to the United States FDA within eight
(8) years from the Effective Date; 
 (ix)        dose first patient in each Phase III
clinical trial for Licensed Product in ovarian or breast cancer within six (6) years form the Effective Date; and 

(x)        LICENSEE will provide additional diligence for the development of Licensed Products within
three (3) years from the Effective Date. 
  

	 	B.	 First Genetically Engineered Cellular Therapy or CAR-T Licensed
Product 

 (i)        Initiate
IND-enabling toxicology studies for Licensed Product within three (3) years from the Effective Date; 

(ii)        File the first IND for Licensed Product within four (4) years from the Effective
Date; 
 (iii)        Initiate the first Phase I clinical trial for Licensed Product within four
and one half (4.5) years from the Effective Date; 
 (iv)        Dose first patient in first Phase
II clinical trial for Licensed Product within six (6) years from the Effective Date; 

(v)        Conduct end of Phase II meeting with the FDA for Licensed Product within seven
(7) years from the Effective Date; and 
 (vi)        LICENSEE will provide additional
diligence for the development of Genetically Engineered Cellular Therapy or CAR-T Licensed Products within four (4) years from the Effective Date; 

  
 12 

			
	Eff. 4/18/12	  	OAL FINAL

 (b) If LICENSEE fails to perform any of its obligations specified in Paragraph 3.3(a)
in any Licensed Product category (e.g. Antibody Licensed Product or Genetically Engineered Cellular Therapy or CAR-T Licensed Product), then UNIVERSITY shall have the right and option, if LICENSEE fails to
cure such breach or provide an acceptable plan of action to cure such breach, to either terminate this Agreement or change LICENSEE’s exclusive license to a nonexclusive license with respect to such Licensed Product category. This right, if
exercised by UNIVERSITY, supersedes the rights granted in Article 2. 
 The deadlines for the diligence milestones set forth in
Paragraph 3.3(a) above shall be extended by the length of any delay caused by a regulatory authority where such delay by the regulatory authority was not the result of the LICENSEE’s actions or inactions and was not the result of the
LICENSEE’s failure to abide by the regulatory authority’s instructions or LICENSEE’s failure to provide data to the regulatory authority in the form and manner required by such regulatory authority. 

In the event of delays due to efficacy and/or safety of Licensed Products and beyond the control of LICENSEE, LICENSEE and UNIVERSITY shall
discuss in good faith extensions of the time-lines presented in Paragraph 3.3(a) above. 
  

	3.4	 Research Support. LICENSEE agrees to provide research support to Inventors to further develop the
Inventions at UCSD in the amount of not less than five hundred thousand dollars (US$500,000) in the aggregate per year for five (5) years under sponsored research agreements (“Sponsored Research Agreements”) to be negotiated by
LICENSEE with the UCSD Office of Contract and Grant Administration. In consideration of the foregoing, LICENSEE shall enter into a Sponsored Research Agreement conducted under the direction of Dr. Thomas Kipps, MD within thirty (30) days
of the Effective Date. All amounts paid by LICENSEE to UNIVERSITY under the Sponsored Research Agreement shall cumulatively count towards LICENSEE’s annual spend obligation under Article 3.3(a)(ii). 

In addition, and to the extent such financial support is required by CIRM, LICENSEE agrees to provide support for up to [***] of the costs of
the CIRM-funded clinical trial of UC-961 up to [***] year (prorated for any partial year that the clinical trial grant is in effect), under a Clinical Trials Agreement which will be executed within forty-five
(45) days from the Effective Date. 
 ARTICLE 4. REPORTS, RECORDS AND PAYMENTS 

 

	4.1	 Reports. 

(a)        Progress Reports. 

Beginning six months after the Effective Date and ending on the date of first commercial sale of a Licensed Product in the United States,
LICENSEE shall report to UNIVERSITY progress covering LICENSEE’s (and Affiliate’s and Sublicensee’s) activities for the preceding six months to develop and test all Licensed Products and obtain governmental

  
 13 

			
	Eff. 4/18/12	  	OAL FINAL

 
approvals necessary for marketing the same. Such semiannual reports shall be due within sixty (60) days of the reporting period and include a summary of work completed, summary of work in
progress, current schedule of anticipated events or milestones, market plans for introduction of Licensed Products, and summary of resources (dollar value) spent in the reporting period. The reports referred to in this Paragraph 4.1(a) should
be marked with the following title and case number: “License Agreement between UCSD and Oncternal Therapeutics, Inc. for case SD2012-143.” Reports shall be submitted as attachment to UCSD’s
email address: oic-reports@ucsd.edu. 

(b)        Royalty Reports. 

After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY quarterly royalty reports on
or before each February 28, May 31, August 31 and November 30 of each year. Each royalty report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar quarter and shall
show: 
 (i)        the date of first commercial sale of a Licensed Product in each country; 

(ii)        the gross sales, deductions as provided in Paragraph 1.12 (Net Sales), and Net Sales
during the most recently completed calendar quarter and the royalties, in US dollars, payable with respect thereto; 

(iii)        the number of each type of Licensed Product sold; 

(iv)        Sublicense fees and royalties received during the most recently completed calendar
quarter in US dollars, payable with respect thereto; 
 (v)        the method used to calculate the
royalties; and 
 (vi)        the exchange rates used. 

If no sales of Licensed Products have been made and no Sublicense revenue has been received by LICENSEE during any reporting period, LICENSEE
shall so report. The reports referred to in this Paragraph 4.1(b) should be marked with the following title and case number: “License Agreement between UCSD and Oncternal Therapeutics, Inc. for case
SD2015-143.” Reports shall be submitted as attachment to UCSD’s email address: oic-reports@ucsd.edu. 

(c)        Timely Reports. 

LICENSEE acknowledges the important value that timely reporting provides in the UNIVERSITY’s effective management of its rights under
this Agreement. LICENSEE further acknowledges that failure to render the reports required under this Paragraph 4.1 may harm UNIVERSITY’s ability to manage its rights under this Agreement. As such, reports not submitted by the required due
date under this Paragraph 4.1 will cause to be due by LICENSEE to UNIVERSITY a late reporting fee of five hundred dollars (US$500.00) per month until such report, compliant with the requirements of this

  
 14 

			
	Eff. 4/18/12	  	OAL FINAL

 
Paragraph 4.1, is received by UNIVERSITY. Payment of this fee is subject to Paragraph 4.3 and Paragraph 10.1 herein. 

 

	4.2	 Records & Audits. 

(a)        LICENSEE shall keep, and shall require its Affiliates and Sublicensees to keep, accurate
and correct records of all Licensed Products manufactured, used, and sold, and Sublicense fees received under this Agreement. Such records shall be retained by LICENSEE for at least five (5) years following a given reporting period. 

(b)         All records shall be available during normal business hours for inspection at the expense
of UNIVERSITY by UNIVERSITY’s Internal Audit Department or by a Certified Public Accountant selected by UNIVERSITY and reasonably acceptable to LICENSEE and in compliance with the other terms of this Agreement for the sole purpose of verifying
reports and payments or other compliance issues no more than one time for each annual period. If LICENSEE rejects three choices of CPAs suggested by UNIVERSITY, then UNIVERSITY may choose a CPA without concurrence by LICENSEE. Such inspector shall
not disclose to UNIVERSITY any information other than information relating to the accuracy of reports and payments made under this Agreement or other compliance issues. In the event that any such inspection shows an under reporting and underpayment
in excess of [***] for any twelve-month (12-month) period, then LICENSEE shall pay the cost of the audit as well as any additional sum that would have been payable to UNIVERSITY had the LICENSEE reported
correctly, plus an interest charge at a rate of [***] per year. Such interest shall be calculated from the date the correct payment was due to UNIVERSITY up to the date when such payment is actually made by LICENSEE. For underpayment not in excess
of [***] for any twelve-month (12-month) period, LICENSEE shall pay the difference within thirty (30) days without interest charge or inspection cost. 

 

	4.3	 Payments. 

(a)        All fees, reimbursements and royalties due UNIVERSITY shall be paid in United States
dollars and all checks (should payment by wire not be possible) shall be made payable to “The Regents of the University of California”, referencing UNIVERSITY’s taxpayer identification number,
95-6006144, and sent to UNIVERSITY according to Paragraph 10.l (Correspondence). When Licensed Products are sold in currencies other than United States dollars, LICENSEE shall first determine the earned
royalty in the currency of the country in which Licensed Products were sold and then convert the amount into equivalent United States funds, using the average of the exchange rate quoted in the Wall Street Journal for the thirty (30) days prior
to the end of the applicable reporting period. 
 (b)        Royalty Payments. 

(i)        Royalties shall accrue when Licensed Products are invoiced, or if not invoiced, when
delivered to a third party or Affiliate. 

  
 15 

			
	Eff. 4/18/12	  	OAL FINAL

 (ii)         LICENSEE shall pay earned royalties
quarterly on or before February 28, May 31, August 31 and November 30 of each calendar year. Each such payment shall be for earned royalties accrued within LICENSEE’s most recently completed calendar quarter. 

(iii)         Royalties earned on sales occurring or under Sublicense granted pursuant to this
Agreement in any country outside the United States shall not be reduced by LICENSEE for any taxes, fees, or other charges imposed by the government of such country on the payment of royalty income, except that all payments made by LICENSEE in
fulfillment of University’s tax liability in any particular country may be credited against earned royalties or fees due UNIVERSITY for that country. LICENSEE shall pay all bank charges resulting from the transfer of such royalty payments. 

(iv)        If at any time legal restrictions prevent the prompt remittance of part or all royalties
by LICENSEE with respect to any country where a Licensed Product is sold or a Sublicense is granted pursuant to this Agreement, LICENSEE shall convert the amount owed to UNIVERSITY into US currency and shall pay UNIVERSITY directly from its US
sources of funds for as long as the legal restrictions apply. 
 (v)        LICENSEE shall not
collect royalties from, or cause to be paid on Licensed Products sold to the account of the US Government or any agency thereof as provided for in the license to the US Government. 

(vi)        In the event that any patent or patent claim within Patent Rights is held invalid in a
final decision by a patent office from which no appeal or additional patent prosecution has been or can be taken, or by a court of competent jurisdiction and last resort and from which no appeal has or can be taken, all obligation to pay royalties
based solely on that patent or claim or any claim patentably indistinct therefrom shall cease as of the date of such final decision. LICENSEE shall not, however, be relieved from paying any royalties that accrued before the date of such final
decision, that are based on another patent or claim not involved in such final decision. 

(vii)        Royalty payments under Article 3, recoveries and settlements under Article 5, and
royalty reports under 4.l(b) shall be rendered for any and all Licensed Products even if due after expiration of the Agreement. If no applicable Patent Rights existed in the Territory at the time of any making, use, sale, offer for sale, or import,
then no royalty payments or royalty reports shall be due. 
 (c)        Late Payments.
In the event royalty, reimbursement and/or fee payments are not received by UNIVERSITY when due, LICENSEE shall pay to UNIVERSITY interest charges at a rate of [***] per year. Such interest shall be calculated from the date payment was due until
actually received by UNIVERSITY. 

  
 16 

			
	Eff. 4/18/12	  	OAL FINAL

 ARTICLE 5. PATENT MATTERS 

 

	5.1	 Patent Prosecution and Maintenance. 

(a)         Provided that LICENSEE has reimbursed UNIVERSITY for Patent Costs pursuant to
Paragraph 3.2, UNIVERSITY shall diligently prosecute and maintain the United States and, if available, foreign patents, and applications in Patent Rights using counsel of its choice. UNIVERSITY shall provide LICENSEE with copies of all relevant
documentation relating to such prosecution to allow for review and comment by LICENSEE, including discussion among relevant entities (i.e. entities with interests in the Patent Rights) to the extent appropriate. UNIVERSITY shall reasonably consider
all such comments, provided, however, if the LICENSEE has not commented upon such documentation in a reasonable time for UNIVERSITY to sufficiently consider LICENSEE’s comments prior to a deadline with the relevant government patent office, or
UNIVERSITY must act to preserve the Patent Rights, UNIVERSITY will be free to respond without consideration of LICENSEE’s comments, if any. LICENSEE shall keep this documentation confidential. The counsel shall take instructions only from
UNIVERSITY, and all patents and patent applications in Patent Rights shall be assigned solely to UNIVERSITY. UNIVERSITY shall in any event control all patent filings and all patent prosecution decisions and related filings (e.g. responses to office
actions) shall be at UNIVERSITY’s final discretion (prosecution includes, but is not limited to, interferences, oppositions and any other inter partes matters originating in a patent office). 

(b)        UNIVERSITY shall consider amending any patent application in Patent Rights to include
claims reasonably requested by LICENSEE to protect the products contemplated to be sold by LICENSEE under this Agreement. 

(c)         LICENSEE may elect to terminate its reimbursement obligations with respect to any patent
application or patent in Patent Rights upon three (3) months’ written notice to UNIVERSITY. UNIVERSITY shall use reasonable efforts to curtail further Patent Costs for such application or patent when such notice of termination is received
from LICENSEE. UNIVERSITY, in its sole discretion and at its sole expense, may continue prosecution and maintenance of said application or patent, and LICENSEE shall have no further license with respect thereto.
Non-payment of any portion of Patent Costs or Anticipated Costs with respect to any application or patent may be deemed by UNIVERSITY as an election by LICENSEE to terminate its reimbursement obligations with
respect to such application or patent. UNIVERSITY is not obligated at any time to file, prosecute, or maintain Patent Rights in a country, where, for that country’s patent application LICENSEE is not paying Patent Costs or Anticipated Costs, or
to file, prosecute, or maintain Patent Rights to which LICENSEE has terminated its license hereunder. 

(d)        LICENSEE shall apply for an extension of the term of any patent in Patent Rights if
appropriate under the Drug Price Competition and Patent Term Restoration Act of 1984 and/or European, Japanese and other foreign counterparts of this law. LICENSEE shall prepare all documents for such application, and, if requested by LICENSEE,

  
 17 

			
	Eff. 4/18/12	  	OAL FINAL

 
UNIVERSITY shall execute such documents and take any other additional action as LICENSEE reasonably requests in connection therewith. 

 

	5.2	 Patent Infringement. 

(a)         In the event that UNIVERSITY (to the extent of the actual knowledge of the licensing
professional responsible for the administration of this Invention) or LICENSEE learns of infringement of potential commercial significance of any patent licensed under this Agreement, the knowledgeable party will provide the other (i) with
written notice of such infringement and (ii) with any evidence of such infringement available to it (the “Infringement Notice”). During the period in which, and in the jurisdiction where, LICENSEE has exclusive rights under this
Agreement, neither UNIVERSITY nor LICENSEE will notify a third party (including the infringer) of infringement or put such third party on notice of the existence of any Patent Rights without first obtaining consent of the other. If LICENSEE notifies
a third party of infringement or puts such third party on notice of the existence of any Patent Rights with respect to such infringement without first obtaining the written consent of UNIVERSITY and UNIVERSITY is sued in declaratory judgment,
UNIVERSITY shall have the right to terminate this Agreement immediately without the obligation to provide sixty (60) days’ notice as set forth in Paragraph 7.1. Both UNIVERSITY and LICENSEE will use their diligent efforts to cooperate
with each other to terminate such infringement without litigation. 
 For the avoidance of doubt, this paragraph 5.2(a) does not
prevent LICENSEE or UNIVERSITY from consulting its counsel or insurance providers or prevents LICENSEE from patent marking according to paragraph 5.3. 

(b)         If infringing activity of potential commercial significance with respect to the Field by
the infringer has not been abated within ninety (90) days following the date the Infringement Notice takes effect, LICENSEE may institute suit for patent infringement against the infringer. UNIVERSITY may voluntarily join such suit at its own
expense, but may not thereafter commence suit against the infringer for the acts of infringement that are the subject of LICENSEE’s suit or any judgment rendered in that suit. LICENSEE may not join UNIVERSITY in a suit initiated by LICENSEE
without UNIVERSITY’S prior written consent. If, in a suit initiated by LICENSEE, UNIVERSITY is involuntarily joined other than by LICENSEE, LICENSEE will pay any costs incurred by UNIVERSITY arising out of such suit, including but not limited
to, any legal fees of counsel that UNIVERSITY selects and retains to represent it in the suit. 

(c)         If, within a hundred and twenty (120) days following the date the Infringement Notice
takes effect, infringing activity of potential commercial significance with respect to the Field by the infringer has not been abated and if LICENSEE has not brought suit against the infringer, UNIVERSITY may institute suit for patent infringement
against the infringer. If UNIVERSITY institutes such suit, LICENSEE may not join such suit without UNIVERSITY’S consent and may not thereafter commence suit against the infringer for the acts of infringement that are the subject of
UNIVERSITY’S suit or any judgment rendered in that suit. 

  
 18 

			
	Eff. 4/18/12	  	OAL FINAL

 (d)        Notwithstanding anything to the contrary
in this Agreement, in the event that the infringement or potential infringement pertains to an issued patent included within the Patent Rights and written notice is given under any statute expediting litigation (e.g. the Drug Price Competition and
Patent Term Restoration Act of 1984 and/or foreign counterparts of this Law or the Biologics Price Competition and Innovation Act) (“Act”), then the party in receipt of such notice under the Act (in the case of UNIVERSITY to the extent of
the actual knowledge of the licensing officer responsible for the administration of this Agreement) shall provide the Infringement Notice to the other party promptly. If the time period is such that the LICENSEE will lose the right to pursue legal
remedy for infringement with respect to the Field by not notifying a third party or by not filing suit, the notification period and the time period to file suit will be accelerated to within forty-five (45) days of the date of such notice under
the Act to either party. 
 (e)        Any recovery or settlement received in connection with any
suit will first be shared by UNIVERSITY and LICENSEE equally to cover the litigation costs each incurred, and next shall be paid to UNIVERSITY or LICENSEE to cover any litigation costs it incurred in excess of the litigation costs of the other. In
any suit initiated by LICENSEE, any recovery in excess of litigation costs will be shared between LICENSEE and UNIVERSITY as follows: (i) for any recovery other than amounts paid for willful infringement: (A) UNIVERSITY will receive [***]
of the recovery if UNIVERSITY was not a party in the litigation and did not incur any litigation costs; (B) UNIVERSITY will receive [***] of the recovery if UNIVERSITY was a party in the litigation, but did not incur any litigation costs,
including the provisions of Paragraph 5.2(b) above, or (C) UNIVERSITY will receive [***] of the recovery if UNIVERSITY incurred any unreimbursed litigation costs in connection with the litigation; and (ii) for any recovery for willful
infringement, UNIVERSITY will receive [***] of the recovery. In any suit initiated by UNIVERSITY, any recovery in excess of the litigation costs for UNIVERSITY AND LICENSEE will belong to UNIVERSITY. UNIVERSITY and LICENSEE agree to be bound by all
final and unappealable determinations of patent infringement, validity, and enforceability (but no other issue) resolved by any adjudicated judgment in a suit brought in compliance with this Paragraph 5.2. 

(f)        Any agreement made by LICENSEE for purposes of settling litigation or other dispute shall
comply with the requirements of Paragraph 2.2 (Sublicenses) of this Agreement. 

(g)        Each party will cooperate with the other in litigation proceedings instituted hereunder but
at the expense of the party who initiated the suit (unless such suit is being jointly prosecuted by the parties). 

(h)        Any litigation proceedings will be controlled by the party bringing the suit, except that
UNIVERSITY may be represented by counsel of its choice in any suit brought by LICENSEE. 
  

	5.3	 Patent Marking. LICENSEE shall mark all Licensed Products made, used or sold under the terms of
this Agreement, or their containers, in accordance with the applicable patent marking laws. LICENSEE shall be responsible for all monetary and legal liabilities 

  
 19 

			
	Eff. 4/18/12	  	OAL FINAL

 
arising from or caused by (i) failure to abide by applicable patent marking laws and (ii) any type of incorrect or improper patent marking. 

ARTICLE 6. GOVERNMENTAL MATTERS 
  

	6.1	 Governmental Approval or Registration. If this Agreement or any associated transaction is required by
the law of any nation to be either approved or registered with any governmental agency, LICENSEE shall assume all legal obligations to do so. LICENSEE shall notify UNIVERSITY if it becomes aware that this Agreement is subject to a United States or
foreign government reporting or approval requirement. LICENSEE shall make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket
costs associated with such reporting or approval process. 

  

	6.2	 Export Control Laws. LICENSEE shall observe all applicable United States and foreign laws with respect
to the transfer of Licensed Products and related technical data to foreign countries, including, without limitation, the International Traffic in Arms Regulations and the Export Administration Regulations. 

 

	6.3	 Preference for United States Industry. If LICENSEE sells a Licensed Product or Combination Product in
the US, LICENSEE shall manufacture said product substantially in the US to the extent required by applicable law, unless a waiver is obtained from the appropriate federal agency. 

 

	6.4	 Access Requirements. To the extent required by applicable law, unless a waiver is obtained from the
appropriate agency, LICENSEE shall submit an access plan to CIRM within ten (10) days following final approval of Licensed Product by the FDA. The plan must afford access to Licensed Product to Californians who have no other means to purchase
the Licensed Product (Title 17, California Code of Regulations, section 100607, Exhibit A, “Access Requirements for Products Developed by Grantees”). 

 

	6.5	 March-In Rights. To the extent required by applicable law,
unless a waiver is obtained from the appropriate agency, CIRM may request LICENSEE enter into a license agreement with respect to Licensed Product in any field of use or territory with a responsible applicant or applicants, upon terms that are
reasonable under the circumstances (Title 17, California Code of Regulations, section 100610, Exhibit A, “March-In Rights”). 

ARTICLE 7. TERMINATION OR EXPIRATION OF THE AGREEMENT 
  

	7.1	 Termination by UNIVERSITY. 

(a)         If LICENSEE fails to perform or violates any material term of this Agreement, then
UNIVERSITY may give written notice of default (“Notice of Default”) to LICENSEE. If LICENSEE fails to cure the default or fails to provide UNIVERSITY with a reasonable plan of action to cure such default, UNIVERSITY may terminate this
Agreement and the license granted herein by a second written notice (“Notice of Termination”) to LICENSEE. If a Notice of Termination is sent to LICENSEE, this Agreement shall automatically terminate on the effective date of that notice.
Termination 

  
 20 

			
	Eff. 4/18/12	  	OAL FINAL

 
shall not relieve LICENSEE of its obligation to pay any fees owed at the time of termination and shall not impair any accrued right of UNIVERSITY. During the term of any such Notice of Default or
period to cure, to the extent the default at issue is a failure to pay past or ongoing Patent Costs as provided for under this Agreement, UNIVERSITY shall have no obligation to incur any new Patent Costs under this Agreement and shall have no
obligation to further prosecute Patent Rights or file any new patents under Patent Rights. 

(b)         This Agreement will terminate immediately, without the obligation to provide sixty
(60) days’ notice as set forth in Paragraph 7.l(a), if LICENSEE files a claim asserting that any portion of UNIVERSITY’s Patent Rights is invalid or unenforceable where the filing is by the LICENSEE, a third party on behalf of
the LICENSEE, or a third party at the written urging of the LICENSEE. 
 (c)         This Agreement
shall automatically terminate without the obligation to provide sixty (60) days’ notice as set forth in Paragraph 7.1(a) upon the filing of a petition for relief under the United States Bankruptcy Code by the LICENSEE as a debtor or
alleged debtor. 
  

	7.2	 Termination by LICENSEE. 

(a)         LICENSEE shall have the right at any time and for any reason to terminate this Agreement
upon a ninety (90) day written notice to UNIVERSITY. Said notice shall state LICENSEE’s reason for terminating this Agreement. 

(b)        Any termination under Paragraph 7.2(a) shall not relieve LICENSEE of any obligation or
liability accrued under this Agreement prior to termination or rescind any payment made to UNIVERSITY or action by LICENSEE prior to the time termination becomes effective. Termination shall not affect in any manner any rights of UNIVERSITY arising
under this Agreement prior to termination. 
  

	7.3	 Term. Unless otherwise terminated by operation of law or by acts of the parties in accordance with the
terms of this Agreement, this Agreement will be in force throughout the Term, and will expire upon the completion of the Term. Upon the natural termination of the Term, the licenses granted hereunder shall be deemed to be fully paid up, perpetual
and irrevocable. 

  

	7.4	 Survival on Termination or Expiration. The following paragraphs and articles shall survive the
termination or expiration of this Agreement: 

 (a)        Article 4 (REPORTS,
RECORDS AND PAYMENTS); 
 (b)        Paragraph 7.5 (Disposition of Licensed Products on Hand);

 (c)        Article 8 (LIMITED WARRANTY AND INDEMNIFICATION); 

(d)        Article 9 (USE OF NAMES AND TRADEMARKS); 

  
 21 

			
	Eff. 4/18/12	  	OAL FINAL

 (e)        Paragraph 10.2 (Secrecy); 

(f)        Paragraph 10.5 (Failure to Perform); and 

(g)        Paragraph 10.6 (Governing Laws). 

 

	7.5	 Disposition of Licensed Products on Hand. Upon termination of this Agreement, LICENSEE may dispose of
all previously made or partially made Licensed Product within a period of one hundred and eighty (180) days of the effective date of such termination provided that the sale of such Licensed Product by LICENSEE, its Sublicensees, or Affiliates
shall be subject to the terms of this Agreement, including but not limited to the rendering of reports and payment of royalties required under this Agreement. 

ARTICLE 8. LIMITED WARRANTY AND INDEMNIFICATION 
  

	8.1	 Limited Warranty. 

(a)         UNIVERSITY warrants that it has the lawful right to grant this license. This warranty does
not include Patent Rights to the extent assigned, or otherwise licensed, by UNIVERSITY’s inventors to third parties. 

(b)         The license granted herein is provided “AS IS” and without WARRANTY OF
MERCHANTABILITY or WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE or any other warranty, express or implied. UNIVERSITY makes no representation or warranty that the Licensed Product, Licensed Method or the use of Patent Rights will not infringe any
other patent or other proprietary rights. 
 (c)         UNIVERSITY WILL NOT BE LIABLE FOR ANY LOST
PROFITS, COSTS OF PROCURING SUBSTITUTE GOODS OR SERVICES, LOST BUSINESS, ENHANCED DAMAGES FOR INTELLECTUAL PROPERTY INFRINGEMENT, OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, OR OTHER SPECIAL DAMAGES SUFFERED BY LICENSEE, SUBLICENSEES,
JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO THIS AGREEMENT FOR ALL CAUSES OF ACTION OF ANY KIND (INCLUDING TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF UNIVERSITY HAS BEEN ADVISED OF THE POSSIBILITY OF
SUCH DAMAGES. ALSO, UNIVERSITY WILL NOT BE LIABLE FOR ANY DIRECT DAMAGES SUFFERED BY LICENSEE, SUBLICENSEES, JOINT VENTURES, OR AFFILIATES ARISING OUT OF OR RELATED TO PATENT RIGHTS TO THE EXTENT ASSIGNED, OR OTHERWISE LICENSED, BY UNIVERSITY’S
INVENTORS TO THIRD PARTIES. 
 (d)        Nothing in this Agreement shall be construed as: 

(i)        a warranty or representation by UNIVERSITY as to the validity or scope of any Patent
Rights; 

  
 22 

			
	Eff. 4/18/12	  	OAL FINAL

 (ii)        a warranty or representation that
anything made, used, sold or otherwise disposed of under any license granted in this Agreement is or shall be free from infringement of patents of third parties; 

(iii)        an obligation to bring or prosecute actions or suits against third parties for patent
infringement except as provided in Paragraph 5.2 hereof; 
 (iv)        conferring by
implication, estoppel or otherwise any license or rights under any patents of UNIVERSITY other than Patent Rights as defined in this Agreement, regardless of whether those patents are dominant or subordinate to Patent Rights; or 

(v)        an obligation to furnish any know-how not provided
in Patent Rights. 
  

	8.2	 Indemnification. 

(a)        LICENSEE will, and will require Sublicensees to, indemnify, hold harmless, and defend
UNIVERSITY and its officers, employees, and agents; the sponsors of the research that led to the Inventions; and the inventors of patents or patent applications under Patent Rights, and their employers; against any and all claims, suits, losses,
damages, costs, fees, and expenses resulting from, or arising out of, the exercise of this license or any Sublicense. This indemnification will include, but will not be limited to, any product liability. 

(b)        LICENSEE, at its sole cost and expense, shall insure its activities in connection with the
work under this Agreement and obtain, keep in force and maintain insurance or an equivalent program of self-insurance as follows: 

(i)        comprehensive or commercial general liability insurance (contractual liability included)
with limits of at least: (A) each occurrence, five million dollars (US$5,000,000); (B) products/completed operations aggregate, ten million dollars (US$10,000,000); (C) personal and advertising injury, five million dollars (US$5,000,000); and
(D) general aggregate (commercial form only), ten million dollars (US$ I 0,000,000). If the above insurance is written on a claims-made form, it shall continue for three (3) years following termination or expiration of this Agreement. 

(ii)         Worker’s Compensation as legally required in the jurisdiction in which the LICENSEE
is doing business; and 
 (iii)        the coverage and limits referred to above shall not in any
way limit the liability of LICENSEE. 
 (c)        If requested by UNIVERSITY, LICENSEE shall
furnish UNIVERSITY with certificates of insurance showing compliance with all requirements. Such certificates shall: (i) provide for thirty (30) day advance written notice to UNIVERSITY of any modification; (ii) indicate that
UNIVERSITY has been endorsed as an additionally insured party under the coverage referred to above; and (iii) include a provision that the 

  
 23 

			
	Eff. 4/18/12	  	OAL FINAL

 
coverage shall be primary and shall not participate with nor shall be excess over any valid and collectable insurance or program of self-insurance carried or maintained by UNIVERSITY. 

(d)         UNIVERSITY shall notify LICENSEE in writing of any claim or suit brought against
UNIVERSITY in respect of which UNIVERSITY intends to invoke the provisions of this Article. LICENSEE shall keep UNIVERSITY informed on a current basis of its defense of any claims under this Article. LICENSEE will not settle any claim against
UNIVERSITY without UNIVERSITY’s written consent, where (a) such settlement would include any admission of liability or admission of wrong doing on the part of the indemnified party, (b) such settlement would impose any restriction on
UNIVERSITY /indemnified party’s conduct of any of its activities, or (c) such settlement would not include an unconditional release of UNIVERSITY/indemnified party from all liability for claims that are the subject matter of the settled
claim. 
 ARTICLE 9. USE OF NAMES AND TRADEMARKS 
  

	9.1	 Except as provided in Paragraph 9.3, nothing contained in this Agreement confers any right to use in
advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of either party hereto (including contraction, abbreviation or simulation of any of the foregoing). Unless required by law, the use by
LICENSEE of the name, “The Regents of the University of California” or the name of any campus of the University of California in advertising, publicity, or other promotional activities is prohibited, without the express written consent of
UNIVERSITY. 

  

	9.2	 UNIVERSITY may disclose to the Inventors the terms and conditions of this Agreement upon their request. If such
disclosure is made, UNIVERSITY shall request the Inventors not disclose such terms and conditions to others. 

  

	9.3	 UNIVERSITY may acknowledge the existence of this Agreement and the extent of the grant in Article 2 to third
parties, but UNIVERSITY shall not disclose the financial terms of this Agreement to third parties, except where UNIVERSITY is required by law to do so, such as under the California Public Records Act and in compliance with the terms of the
sponsorship agreement with CIRM. LICENSEE hereby grants permission for UNIVERSITY (including UCSD) to include LICENSEE’s name and a link to LICENSEE’s website in UNIVERSITY’s and UCSD’s annual reports and on UNIVERSITY’s
(including UCSD’s) websites that showcase technology transfer-related stories. 

 ARTICLE 10. MISCELLANEOUS
PROVISIONS 
  

	10.1	 Correspondence. Any notice or payment required to be given to either party under this Agreement shall be
deemed to have been properly given and effective: 

 (a)        on the date of
delivery if delivered in person, 

  
 24 

			
	Eff. 4/18/12	  	OAL FINAL

 (b)        five (5) days after mailing if
mailed by first-class or certified mail, postage paid, to the respective addresses given below, or to such other address as is designated by written notice given to the other party, or 

(c)        upon confirmation by recognized national overnight courier, confirmed facsimile
transmission, or confirmed electronic mail, to the following addresses or facsimile numbers of the parties. 
 If sent to LICENSEE: 

Oncternal Therapeutics, Inc. 

3525 Del Mar Heights Road, Suite 821 

San Diego, California 92130 

Attention: CEO 
 Phone: [***]

 Email: [***] 
 With a copy
to: 
 Hale BioPharma Ventures, LLC 

1042-B N. El Camino Real, Suite 430 

Encinitas, California 92024-1322 

Attention: David F. Hale 

Email: [***] 
 If sent to
UNIVERSITY by mail: 
 University of California, San Diego 

Office of Innovation and Commercialization 

9500 Gilman Drive, Mail Code 0910 

La Jolla, California 92093-0910 

Attention: Director 
 If sent to
UNIVERSITY by overnight delivery: 
 University of California, San Diego 

Office of Innovation and Commercialization 

10300 North Torrey Pines Road 

Torrey Pines Center North, Third Floor 

La Jolla, California 92037 

Attention: Assistant Vice Chancellor 
  

	10.2	 Secrecy. 

(a)         “Confidential Information” shall mean information relating to the Inventions and
disclosed by UNIVERSITY to LICENSEE during the term of this Agreement, which if disclosed in writing shall be marked “Confidential”, or if first disclosed otherwise, shall 

  
 25 

			
	Eff. 4/18/12	  	OAL FINAL

 
within thirty (30) days of such disclosure be reduced to writing by UNIVERSITY and sent to LICENSEE: 

(b)        LICENSEE shall: 

(i)        use the Confidential Information for the sole purpose of performing under the terms of
this Agreement; 
 (ii)        safeguard Confidential Information against disclosure to others with
the same degree of care as it exercises with its own data of a similar nature; 
 (iii)        not
disclose Confidential Information to others (except to its employees, agents or consultants who are bound to LICENSEE by a like obligation of confidentiality) without the express written permission of UNIVERSITY, except that LICENSEE shall not be
prevented from using or disclosing any of the Confidential Information that: 
  

	 	(A)	 LICENSEE can demonstrate by written records was previously known to it; 

 

	 	(B)	 is now, or becomes in the future, public knowledge other than through acts or omissions of LICENSEE;

  

	 	(C)	 is lawfully obtained by LICENSEE from sources independent of UNIVERSITY; or 

 

	 	(D)	 is required to be disclosed by law or a court of competent jurisdiction; and 

(c)        The secrecy obligations of LICENSEE with respect to Confidential Information shall continue
for a period ending five (5) years from the termination date of this Agreement. 

(d)        For the sake of clarity, LICENSEE may disclose the existence of this Agreement (including
the fact that it contains license grants to Patent Rights ) and the terms and conditions contained herein to the extent such disclosure is reasonably necessary for the following purposes: (i) conducting clinical trials; (ii) making
regulatory filings; (iii) complying with applicable governmental regulations; (iv) submitting information to acquirers or Sublicensees of all or a portion of the Patent Rights (potential and actual), consultants and others having a need to
know for the purposes of development, manufacture or marketing of Licensed Product or Licensed Method pursuant to this Agreement, provided that such acquirers, Sublicensees, consultants and others shall also agree to appropriate and comparable
confidentiality and non-use provisions as provided for in this Paragraph 10.2; (v) to the extent required by applicable law (including without limitation any filings by LICENSEE with the Securities and
Exchange Commission or similar authority), orders of courts, regulatory authorities or similar bodies having jurisdiction over LICENSEE; and (vi) fund-raising. 

  
 26 

			
	Eff. 4/18/12	  	OAL FINAL

	10.3	 Assignability. This Agreement may be assigned by UNIVERSITY, but is personal to LICENSEE and assignable
by LICENSEE only with the written consent of UNIVERSITY. Notwithstanding the foregoing, LICENSEE may assign its rights under this Agreement in whole or in part to an Affiliate or to a
successor-in-interest to all or substantially all of the business of LICENSEE to which this Agreement relates upon written notice to UNIVERSITY for the part of its
rights so assigned and only to the extent that assignee Affiliate is responsible for LICENSEE’s duties under this Agreement incurred before the assignment as well as after assignment and payment of an assignment fee equal to [***] of the value
of the transaction. 

  

	10.4	 No Waiver. No waiver by either party of any breach or default of any covenant or agreement set forth in
this Agreement shall be deemed a waiver as to any subsequent and/or similar breach or default. 

  

	10.5	 Failure to Perform. In the event of a failure of performance due under this Agreement and if it becomes
necessary for either party to undertake legal action against the other on account thereof, then the prevailing party shall be entitled to reasonable attorneys’ fees in addition to costs and necessary disbursements. 

 

	10.6	 Governing Laws. THIS AGREEMENT SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE
STATE OF CALIFORNIA, but the scope and validity of any patent or patent application shall be governed by the applicable laws of the country of the patent or patent application. 

 

	10.7	 Force Majeure. A party to this Agreement may be excused from any performance required herein if such
performance is rendered impossible or unfeasible due to any catastrophe or other major event beyond its reasonable control, including, without limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; changes
in regulatory agency policy, practices or demands; strikes, lockouts, or other serious labor disputes; and floods, fires, explosions, or other natural disasters. When such events have abated, the non-performing party’s obligations herein shall
resume. 

  

	10.8	 Headings. The headings of the several articles and paragraphs are inserted for convenience of reference
only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 

  

	10.9	 Entire Agreement. This Agreement embodies the entire understanding of the parties and supersedes all
previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof. 

  

	10.10	 Amendments. No amendment or modification of this Agreement shall be valid or binding on the parties
unless made in writing and signed on behalf of each party. 

  

	10.11	 Severability. In the event that any of the provisions contained in this Agreement is held to be
invalid, illegal, or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this 

  
 27 

			
	Eff. 4/18/12	  	OAL FINAL

	 	 
Agreement shall be construed as if the invalid, illegal, or unenforceable provisions had never been contained in it. 

[Signature page follows] 

  
 28 

			
	Eff. 4/18/12	  	OAL FINAL

 IN WITNESS WHEREOF, both UNIVERSITY and LICENSEE have executed this Agreement, in duplicate
originals, by their respective and duly authorized officers on the day and year written. 
  

			
	ONCTERNAL THERAPEUTICS, INC.:	  	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA:
		
	 By: /s/ James Breitmeyer

            (Signature)
	  	 By: /s/ Ruben Flores, Ph.D.

            (Signature)

		
	 Name: James Breitmeyer
 Title: President and
Chief Executive Officer
	  	 Ruben Flores, Ph.D.
 President and Chief
Executive Officer

		
	Date: 8/31/2018	  	Date: 8/30/2018

  
 29 

 EXHIBIT A 

TITLE 17, CALIFORNIA CODE OF REGULATIONS 

 § 100607. Access Requirements for Products Developed by Grantees. 

(a)        A Grantee, a Collaborator or an Exclusive Licensee that is commercializing a Drug, as
defined in Title 17, California Code of Regulations, section 100601, subdivision (i), that resulted in whole or in part from CIRM-Funded Research must submit a plan to afford access to such a Drug to Californians who have no other means to purchase
the Drug. As used in this section, “no other means” means Californians who are not covered by a prescription drug benefit provided by any third-party payer (private or public) covering the particular Drug, and whose family incomes are
below 300 percent of the federal poverty level. The access plan must be consistent with industry standards at the time of commercialization accounting for the size of the market for the Drug and the resources of the Grantee, the Collaborator or
its Exclusive Licensee. Grantees, Collaborators and/or their Exclusive Licensees shall have the burden of establishing that the proposed access plan satisfies the requirements of this Section. 

(b)        A Grantee, a Collaborator or an Exclusive Licensee that commercializes a Drug must submit
the access plan described in subdivision (a) of this regulation to CIRM within 10 business days following final approval of the Drug by the federal Food and Drug Administration, unless, within that timeframe, the Grantee, Collaborator or
Exclusive Licensee seeks an extension from CIRM. If CIRM grants an extension, the access plan must be submitted no later than 30 business days following final approval of the Drug by the federal Food and Drug Administration. 

(c)        The access plan shall be subject to the approval of CIRM after a public hearing conducted
by CIRM that provides for receipt of public comment. CIRM may adopt appropriate procedures to protect proprietary information submitted by Grantees, Collaborators and Exclusive Licensees in connection with said public hearing. Approval shall not be
unreasonably 

  
 1 

			
	Eff. 4/18/12	  	OAL FINAL

 
withheld. Overall, CIRM shall not require that proposed Access plans exceed industry standards for such plans at the time of commercialization in California. 

(d)        Access plans approved hereunder shall make Grantees, Collaborators and Exclusive Licensees
that commercialize a Drug responsible only for providing the Drug itself. Nothing herein shall require the Grantee, Collaborator or Exclusive Licensee to be responsible for any costs of administering the Drug nor for any associate costs of medical
procedures or protocols for the Drug therapy, nor for any costs for attendant care. 

(e)        The Independent Citizens Oversight Committee (“ICOC”) may waive the requirement
in subdivision (a) of this section if the ICOC determines, after a public hearing, that in the absence of the waiver, development and broad delivery of the Drug will be unreasonably hindered or that the waiver will provide significant benefits
that equal or exceed the benefits that would otherwise flow to the state pursuant to subdivision (a) of this section. To invoke this waiver provision, a Grantee, Collaborator or Exclusive Licensee must deliver a written request to the Chair of
the ICOC within 10 business days following final approval of the Drug by the federal Food and Drug Administration, unless the Chair of the ICOC agrees to an extension. The request must be accompanied by materials describing how development and broad
delivery of the Drug will be unreasonably hindered by compliance with subdivision (a) of this section, and/or how the waiver will provide significant benefits that equal or exceed the benefits that would otherwise flow to the state pursuant to
subdivision (a) of this section. The request shall be posted on CIRM’s website no fewer than ten (10) business days prior to the ICOC’s consideration. The ICOC may meet in closed session to review confidential or proprietary
material, or other material as allowed by Health and Safety Code section 125290.30, subdivision (d). 

  
 2 

			
	Eff. 4/18/12	  	OAL FINAL

 (f)        A Grantee, Collaborator, or an Exclusive
Licensee that is commercializing the Drug must provide a Drug, that resulted in whole or in part from CIRM-Funded Research, at a price as provided in the California Discount Prescription Drug Program (commencing with California Health and Safety
Code section 130500) (or a successor statewide prescription drug discount program) to eligible Californians under said program. 

(g)        A Grantee, Collaborator or its Exclusive Licensee that is commercializing the Drug must
sell a Drug, that resulted in whole or in part from CIRM-Funded Research, and which is purchased in California with Public Funds (as defined in Title 17, California Code of Regulations, section 100601, subdivision (cc)) at any benchmark price
described in the California Discount Prescription Drug Program or a successor statewide prescription drug discount program. 

(h)        This regulation is not intended, and this-regulation shall not be construed, to preempt or
prevent any other requirement under state or federal law or regulation, or agreement or contract, that would result in selling a Drug at a lower price than provided hereunder. Note: Authority cited: Article XXXV, California Constitution; and
Section 125290.40(j), Health and Safety Code. 
 Reference: Sections 125290.30 and 125290.80, Health and Safety Code. 

  
 3 

			
	Eff. 4/18/12	  	OAL FINAL

 § 100610. March-In Rights. 

 

	(a)	 CIRM may request that a Grantee, Collaborator or an Exclusive Licensee enter into a nonexclusive, partially
exclusive, or Exclusive License Agreement with respect to a CIRM-Funded Invention or CIRM-Funded Technology, in any field of use or territory with a responsible applicant or applicants, upon terms that are reasonable under the circumstances.

  

	(b)	 If a Grantee, Collaborator or an Exclusive Licensee refuses CIRM’s request to enter into a License
Agreement to a CIRM-Funded Invention or CIRM-Funded Technology as provided by this regulation, CIRM shall have the right to enter into such a license with an applicant on behalf of the Grantee or its Exclusive Licensee
(march-in) if: 

  

	 	(1)	 the Grantee, Collaborator or an Exclusive Licensee has not made reasonable efforts to achieve practical
application of a CIRM-Funded Invention and/or CIRM-Funded Technology, as applicable; 

  

	 	(2)	 the Grantee, Collaborator or an Exclusive Licensee have failed to provide or comply with a plan for access to a
Drug in accordance with Title 17, California Code of Regulations, section 100607; 

  

	 	(3)	 the Grantee, Collaborator or Exclusive Licensee has unreasonably failed to use a CIRM-Funded Invention or CIRM-
Funded Technology to alleviate public health and safety needs that constitute a public health emergency as declared by the Governor. 

  

	(c)	 One consideration in taking the action described in subdivision (b) of this regulation will be whether
doing so will impinge on the Grantee’s, Collaborator’s or Exclusive Licensee’s academic freedoms. 

  

	(d)	 CIRM will promptly notify a Grantee, Collaborator or an Exclusive Licensee of any adverse determination under
this provision and the basis therefore, as well as its intention to exercise march-in rights ( “March-In Notice”). 

 

	(e)	 CIRM will not exercise its march-in rights if the Grantee, Collaborator
or an Exclusive Licensee promptly takes action to cure the deficiency and such deficiency is cured sooner than one year from the date of the March-In Notice (or longer period by mutual agreement). With respect
to a deficiency described in subdivision (b)(3) of this regulation, however, CIRM may exercise such right at any time in the event of a public health or safety emergency declared by the Governor and where CIRM finds that exercise of march-in rights is likely to alleviate the circumstances or conditions that give rise to the emergency declaration. 

  

	(f)	 Within thirty (30) days of the date CIRM issues a March-In Notice,
the subject Grantee may appeal CIRM’s decision to the ICOC by notifying the President of CIRM in writing of its intent to appeal CIRM’s decision. Within sixty (60) days of the March-In Notice
date, the subject Grantee must submit a written statement of the reasons for the appeal and any supporting materials it wishes to have considered by the ICOC. Absent 

	 	 
extraordinary circumstances, the ICOC shall render a final determination on the appeal within one hundred twenty (120) days of the March-In Notice. In
cases where an appeal is filed, CIRM shall not effect a march-in unless and until the ICOC renders a final determination on the appeal. The ICOC may reverse the decision of the CIRM to exercise march-in rights under this regulation for any reason. 

  

	(g)	 Unless provided otherwise by CIRM, any applicant to receive a License or Assignment pursuant to this regulation
will be bound by this Chapter as if it were an original Grantee recipient of the funding that resulted in the applicable CIRM-Funded Invention or CIRM-Funded Technology. 

 EXHIBIT B 

ARTICLES OF INCORPORATION 

 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION 

OF 
 ONCTERNAL
THERAPEUTICS, INC. 
 (Pursuant to Sections 242 and 245 of the 

General Corporation Law of the State of Delaware) 

Oncternal Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of
the State of Delaware (the “General Corporation Law”), 
 DOES HEREBY CERTIFY: 

FIRST: That the name of this corporation is Oncternal Therapeutics, Inc. and that this corporation was originally incorporated
pursuant to the General Corporation Law on November 18, 2013 under the name Tokalas, Inc. 
 SECOND: That the Board of
Directors duly adopted resolutions proposing to amend and restate the Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and
authorizing the appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows: 

RESOLVED, that the Certificate of Incorporation of this corporation be amended and restated in its entirety as follows: 

ARTICLE I. 
 The name of
this corporation is Oncternal Therapeutics, Inc. (referred to herein as the “Corporation”). 
 ARTICLE II.

 The address of its registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, New Castle County,
Delaware 19801. The name of its registered agent at such address is The Corporation Trust Company. 
 ARTICLE III. 

The nature of the business and purpose of this corporation is to engage in any lawful act or activity for which corporations may be organized
under the General Corporation Law. 
 ARTICLE IV. 

A.        Authorization of Stock. The Corporation is authorized to issue two
classes of stock designated, Common Stock, par value $0.0001 per share (“Common Stock”) and Preferred 

  
 1 

 
Stock, par value $0.0001 per share (“Preferred Stock”). The Preferred Stock shall consist of three series, one of which shall be designated “Series A Preferred
Stock”, one of which shall be designated “Series B Preferred Stock”, and one of which shall be designated “Series B-2 Preferred
Stock”. The number of shares of Common Stock which this Corporation is authorized to issue is 200,000,000. The number of shares of Preferred Stock which this Corporation is authorized to issue is 143,560,000, of which 75,000,000 shares
shall be designated Series B-2 Preferred Stock, 55,000,000 shares shall be designated Series B Preferred Stock, and 13,560,000 shares shall be designated Series A Preferred Stock. 

B.        Preferred Stock. The following is a statement of the designations and
the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each series of Preferred Stock of this Corporation. Unless otherwise indicated, references to “Sections” or
“subsections” in this Part B of Article IV refer to sections and subsections of Part B of this Article IV. 

1.        Dividends. In the event dividends are paid on any share of Common Stock, the
Corporation shall pay an additional dividend on all outstanding shares of Preferred Stock in a per share amount equal (on an as-if-converted to Common Stock basis) to
the amount paid or set aside for each share of Common Stock. Such dividends shall be payable only when, as and if declared by the Board of Directors of the Corporation. 

2.        Liquidation. 

(a)        Preferences. 

(i)        In the event of any voluntary or involuntary dissolution, liquidation or winding up of the
affairs of the Corporation (a “Liquidation Event”), after payment or provision for payment of the debts and other liabilities of the Corporation, the holders of each share of Series B-2 Preferred Stock shall be entitled to receive on a pro rata basis out of the assets of the Corporation, whether such assets are capital, surplus or earnings, an amount equal to the Liquidation Value (as set forth
in Section 2(e)) of such share, which amount shall be paid prior to and in preference of any payment made or assets distributed on the Series B Preferred Stock, the Series A Preferred Stock, the Common Stock or any other class or series of
capital stock of the Corporation. 
 (ii)        In the event of a Liquidation Event, after payment
to the holders of Series B-2 Preferred Stock of the full amounts specified in Section 2(a)(i) above, the holders of each share of Series B Preferred Stock shall be entitled to receive on a pro rata basis
out of the assets of the Corporation, whether such assets are capital, surplus or earnings, an amount equal to the Liquidation Value (as set forth in Section 2(e)) of such share, which amount shall be paid prior to and in preference of any
payment made or assets distributed on the Series A Preferred Stock, the Common Stock or any other class or series of capital stock of the Corporation. 

(iii)        In the event of a Liquidation Event, after payment to the holders of Series B Preferred
Stock of the full amounts specified in Section 2(a)(ii) above, the holders of each share of Series A Preferred Stock shall be entitled to receive on a pro rata basis out of the assets of the Corporation, whether such assets are capital, surplus
or earnings, an amount equal to 

  
 2 

 
the Liquidation Value (as set forth in Section 2(e)) of such share, which amount shall be paid prior to and in preference of any payment made or assets distributed on the Common Stock or any
other class or series of capital stock of the Corporation. 
 (b)        Partial Payment. If
upon any Liquidation Event the assets of the Corporation distributable as aforesaid among the holders of the Series B-2 Preferred Stock, the Series B Preferred Stock or the Series A Preferred Stock, as
applicable, shall be insufficient to permit the payment to them of the full preferential amounts to which they are entitled, then the entire remaining assets of the Corporation so to be distributed shall be distributed ratably among the holders of
the Series B-2 Preferred Stock, the Series B Preferred Stock or the Series A Preferred Stock, as applicable, in proportion to the sum of their respective per share Liquidation Value; provided that no payments
shall be made to holders of the Series B Preferred Stock until the holders of the Series B-2 Preferred Stock have received the full preferential amounts to which they are entitled, and no payments shall be
made to holders of the Series A Preferred Stock until the holders of the Series B Preferred Stock have received the full preferential amounts to which they are entitled. 

(c)        Remaining Assets. After payment to the holders of Preferred Stock of the amounts
set forth in Section 2(a) above, the entire remaining assets and funds of the Corporation legally available for distribution, if any, shall be distributed ratably among the holders of the Common Stock and the holders of the Preferred Stock on
an as-converted to Common Stock basis at the then applicable conversion rate, until such time as each share of Preferred Stock has received an aggregate distribution of three times (3x) the applicable
Liquidation Value for such share of Preferred Stock (as adjusted for all stock splits, stock dividends, consolidations, recapitalizations and reorganizations) (which aggregate distribution amount shall include (i) distributions made pursuant to
Section 2(a) above and (ii) distributions made pursuant to this Section 2(c)), at which point no further payments shall be made to holders of the Preferred Stock by reason thereof and any remaining assets of the Corporation shall be
distributed ratably among the holders of the Common Stock. 
 (d)        Deemed Conversion.
Notwithstanding the above Sections 2(a), (b) and (c), for purposes of determining the amount each holder of shares of Preferred Stock is entitled to receive with respect to a Liquidation Event, each such holder of shares of Preferred Stock shall be
deemed to have converted (regardless of whether such holder actually converted) such holder’s shares of Preferred Stock into shares of Common Stock immediately prior to the Liquidation Event if, as a result of an actual conversion, such holder
would receive, in the aggregate, an amount greater than the amount that would be distributed to such holder if such holder did not convert such Preferred Stock into shares of Common Stock. If any such holder shall be deemed to have converted shares
of Preferred Stock into Common Stock pursuant to this Section 2(d), then such holder shall not be entitled to receive any distribution that would otherwise be made to holders of Preferred Stock. 

(e)        Liquidation Value. The “Liquidation Value” per share of Series A
Preferred Stock as of any particular date shall be the sum of (A) $0.25 (as adjusted for all stock splits, stock dividends, consolidations, recapitalizations and reorganizations) plus (B) all declared but unpaid dividends as of the date the
Liquidation Value of such share is determined. The Liquidation Value per share of Series B Preferred Stock as of any particular date shall be the 

  
 3 

 
sum of (A) $0.45 (as adjusted for all stock splits, stock dividends, consolidations, recapitalizations and reorganizations) plus (B) all declared but unpaid dividends as of the date the
Liquidation Value of such share is determined. The Liquidation Value per share of Series B-2 Preferred Stock as of any particular date shall be the sum of (A) $0.45 (as adjusted for all stock splits, stock
dividends, consolidations, recapitalizations and reorganizations) plus (B) all declared but unpaid dividends as of the date the Liquidation Value of such share is determined. The Liquidation Value as it applies to each series of Preferred Stock
is sometimes referred to herein as the “Liquidation Value.” 

(f)        Deemed Liquidation Events. 

(i)        Definition. For purposes of this Section 2, a Liquidation Event shall be
deemed to be occasioned by, or to include, the following (each, a “Deemed Liquidation Event”) unless the Requisite Holders elect otherwise: 

(a)        a merger or consolidation in which 

(i)        the Corporation is a constituent party, or 

(ii)        a Subsidiary of the Corporation is a constituent party and the Corporation issues shares
of its capital stock pursuant to such merger or consolidation, except any such merger or consolidation involving the Corporation or a Subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger or
consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (1) the
surviving or resulting corporation or (2) if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting
corporation (provided that, for the purpose of this Section 2(f)(i)(a), all shares of Common Stock issuable upon exercise of stock options of the Corporation outstanding immediately prior to such merger or consolidation or upon conversion of
convertible securities of the Corporation outstanding immediately prior to such merger or consolidation shall be deemed to be outstanding immediately prior to such merger or consolidation and, if applicable, converted or exchanged in such merger or
consolidation on the same terms as the actual outstanding shares of Common Stock are converted or exchanged); provided, that the preceding exception shall not apply (and such merger or consolidation shall be a Deemed Liquidation Event) to a merger
or consolidation involving the Corporation or a Subsidiary where such transaction is entered into with an entity that has its securities registered under the Securities Act of 1933, as amended, listed on a nationally recognized stock exchange or
market system, including without limitation The NASDAQ Global Select Market, The NASDAQ Global Market or The NASDAQ Capital Market, or quoted on an automated quotation system (including the Pink Sheets and the OTC Bulletin Board) or by a recognized
securities dealer; or 
 (b)        the sale, lease, transfer, exclusive license or other
disposition, in a single transaction or series of related transactions, by the Corporation or any Subsidiary of the Corporation of all or substantially all the assets of the Corporation and its Subsidiaries taken as a whole, or the sale or
disposition (whether by merger or otherwise) of one or more Subsidiaries of 

  
 4 

 
the Corporation if substantially all of the assets of the Corporation and its Subsidiaries taken as a whole are held by such Subsidiary or Subsidiaries, except where such sale, lease, transfer,
exclusive license or other disposition is to a wholly owned Subsidiary of the Corporation. 

(ii)        Effecting a Deemed Liquidation Event. 

(a)        The Corporation shall not have the power to effect a Deemed Liquidation Event referred to
in Section 2(f)(i)(a) unless the agreement or plan of merger or consolidation for such transaction provides that the consideration payable to the stockholders of the Corporation shall be allocated among the holders of capital stock of the
Corporation in accordance with Sections 2(a), (b), (c) and (d). 
 (b)        In the event of a
Deemed Liquidation Event referred to in Section 2(f)(i)(a)(ii) or 2(f)(i)(b), if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within 90 days after such Deemed Liquidation Event, then
(i) the Corporation shall send a written notice to each holder of Preferred Stock no later than the 90th day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant
to the terms of the following clause (ii) to require the redemption of such shares of Preferred Stock, and (iii) if the holders of at least a majority of the then outstanding shares of Preferred Stock so request in a written instrument
delivered to the Corporation not later than 120 days after such Deemed Liquidation Event, the Corporation shall use the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the
assets sold or technology licensed, as determined in good faith by the Board of Directors of the Corporation), together with any other assets of the Corporation available for distribution to its stockholders (the “Available
Proceeds”), to the extent legally available therefor, on the 150th day after such Deemed Liquidation Event, to redeem all outstanding shares of Preferred Stock at a price per share equal to the applicable Liquidation
Value. Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of Preferred Stock, the Corporation shall first redeem a pro rata
portion of shares of Series A Preferred Stock, Series B Preferred Stock and Series B-2 Preferred Stock in accordance with the liquidation preferences set forth in Sections 2(a) and (b) to the fullest
extent of such Available Proceeds, and shall redeem the remaining shares to have been redeemed as soon as practicable after the Corporation has funds legally available therefor. Prior to the distribution or redemption provided for in this
Section 2(f)(ii)(b), the Corporation shall not expend or dissipate the consideration received for such Deemed Liquidation Event, except to discharge expenses incurred in connection with such Deemed Liquidation Event or in the ordinary course of
business. 
 (iii)        Notice. The Corporation shall give each holder of record of
Preferred Stock written notice of such impending event described in Section 2(f)(i) not later than twenty (20) calendar days prior to the stockholders meeting called to approve such transaction, or twenty (20) calendar days prior to
the closing of such transaction, whichever is earlier, and shall also notify such holders in writing of the final approval of such transaction. The first of such notices shall describe the material terms and conditions of the impending transaction
and the provisions of Section 2, and the Corporation shall thereafter give such holders prompt notice of any material changes. The transaction shall in no event take place sooner than twenty (20)

  
 5 

 
calendar days after the Corporation has given the first notice provided for herein or sooner than ten (10) calendar days after the Corporation has given notice of any material changes
provided for herein. Notwithstanding anything to the contrary in subsection 2(f)(ii) or 2(f)(iii), the periods set forth in subsection 2(f)(ii) and 2(f)(iii) may be shortened and/or notice may be waived upon the Corporation’s receipt of written
consent of the Requisite Holders. 
 3.        Redemption. The Corporation shall not be
obligated to, and shall not have the right to, call or redeem any shares of the Preferred Stock, except in accordance with Section 2(f)(ii)(b) above. 

4.        Voting Rights; Directors. 

(a)        Generally. On all matters to come before the stockholders, the Preferred Stock
shall have that number of votes per share (rounded up to the nearest whole share) equivalent to the number of shares of Common Stock into which such share of Preferred Stock is then convertible determined by reference to the applicable Conversion
Price in effect at the record date of the determination of the holders of the shares entitled to vote or, if no such record date is established, at the date such vote is taken or any written consent of stockholders is first solicited. Each holder of
shares of Common Stock shall be entitled to one (1) vote for each share thereof held. Except as otherwise provided by law or this Amended and Restated Certificate of Incorporation, the holders of Preferred Stock shall vote together with the
holders of the outstanding shares of Common Stock, and not as a separate class or series. 

(b)        Directors. 

(i)        The authorized number of directors shall be seven (7) until this provision is amended
in accordance with the terms of this Amended and Restated Certificate of Incorporation. The holders of the outstanding shares of Series A Preferred Stock, voting as a separate class and to the exclusion of all other classes of capital stock of the
Corporation, shall be entitled to elect one (1) member of the Board of Directors (the “Series A Director”). The holders of the outstanding shares of Series B-2
Preferred Stock, voting as a separate class and to the exclusion of all other classes of capital stock of the Corporation, shall be entitled to elect two (2) members of the Board of Directors (the “Series B-2 Directors”, together with the Series A Director, the “Preferred Directors”). The holders of the outstanding shares of Common Stock, voting as a
separate class and to the exclusion of all other classes of capital stock of the Corporation, shall be entitled to elect three (3) members of the Board of Directors (the “Common Directors”). The holders of
the outstanding shares of Preferred Stock and Common Stock, voting together as a single class, shall be entitled to elect the remaining member of the Board of Directors (the “General Director”). For
administrative convenience, the initial Series B-2 Directors may also be appointed by the Board of Directors in connection with the approval of the initial issuance of Series
B-2 Preferred Stock without a separate action by the holders of the Series B-2 Preferred Stock. 

(ii)        In the case of any vacancy in the office of a director occurring among the Preferred
Directors or the Common Directors, by the affirmative vote of the holders of a majority of the shares of the class or classes entitled to vote on the election of the Preferred Directors or Common Directors, as the case may be, such holders shall
elect a successor or 

  
 6 

 
successors to hold the office for the unexpired term of the director or directors whose place or places shall be vacant. In the case of any vacancy in the office of a General Director, by the
affirmative vote of the holders of a majority of the shares of Preferred Stock and Common Stock, voting together as a single class, such holders shall elect a successor or successors to hold the office for the unexpired term of the director or
directors whose place or places shall be vacant. Any director may be removed during the aforesaid term of office, whether with or without cause, only by the affirmative vote of the holders of a majority of the shares eligible to vote in an election
for the seat occupied by that director (e.g., in order to remove a Series A Director, the holders of a majority of the shares of Series A Preferred Stock, voting as a separate class and to the exclusion of all other classes of capital stock of the
Corporation, must so vote). 
 (c)        Protective Provisions. In addition to voting
rights provided by law, so long as any shares of Preferred Stock shall be outstanding (as adjusted for all stock splits, stock dividends, consolidations, recapitalizations and reorganizations), the Corporation shall not, without the consent of the
holders of at least a majority of the outstanding shares of Preferred Stock, given in person or by proxy, either in writing or by vote at a meeting called for that purpose at which the holders of the Preferred Stock shall vote together as a separate
class and to the exclusion of all other classes of capital stock of the Corporation: 

(i)        declare or pay any dividends on any capital stock of the Corporation; 

(ii)        redeem or repurchase capital stock of the Corporation except in connection with the
repurchase of shares of Common Stock issued to or held by employees, consultants, officers and directors upon termination of their employment or services pursuant to agreements providing for the right of said repurchase, which agreements were
authorized by the Board of Directors; 
 (iii)        take any action which would result in a
Liquidation Event or a Deemed Liquidation Event; 
 (iv)        increase or decrease the total
number of authorized members of the Board of Directors; 
 (v)        authorize, create or issue
(whether by merger, consolidation, reclassification, amendment of this Amended and Restated Certificate of Incorporation, sale or otherwise) shares of any class or series of stock not authorized herein having rights, preferences or privileges
superior to or on parity with the Series B-2 Preferred Stock; or 

(vi)        take any action to amend or waive any provision of this Amended and Restated Certificate
of Incorporation or the Company’s Bylaws. 
 5.        Conversion. The rights of the
holders of shares of Preferred Stock to convert such shares into shares of Common Stock (as defined in Section 5(h) below) of the Corporation (the “Conversion Rights”), and the terms and conditions of such
conversion, shall be as follows: 

  
 7 

 (a)        Right to Convert; Automatic
Conversion. 
 (i)        Each share of the Preferred Stock shall be convertible, at the option
of the holder, in each case at the office of the Corporation or any transfer agent for the Preferred Stock or the Common Stock, into that number of the fully paid and nonassessable shares of Common Stock determined in accordance with the provisions
of Section 5(b) below. 
 (ii)        Before any holder of Preferred Stock shall be entitled
to convert the same into shares of Common Stock, the holder shall surrender the certificate(s) therefor, duly endorsed, at the office of the Corporation or of any transfer agent for the Preferred Stock and shall give written notice to the
Corporation at such office that the holder elects to convert the same (except that no such written notice of election to convert shall be necessary in the event of an automatic conversion pursuant to Section 5(a)(iv) hereof). The Corporation
shall, as soon as practicable thereafter, issue and deliver at such office to such holder of Preferred Stock certificate(s) for the number of shares of Common Stock to which such holder shall be entitled as aforesaid. Such conversion shall be deemed
to have been made immediately prior to the close of business on the date of such surrender of the shares of Preferred Stock to be converted; except that in the case of an automatic conversion pursuant to Sections 5(a)(iv)(A) and/or 5(a)(v)(A)
hereof, such conversion shall be deemed to have been made immediately prior to the closing of the offering referred to in Sections 5(a)(iv)(A) and/or 5(a)(v)(A), or in the case of an automatic conversion pursuant to Sections 5(a)(iv)(B) and/or
5(a)(v)(B) hereof, immediately prior to the close of business on the date of the election referred to in Sections 5(a)(iv)(B) and/or 5(a)(v)(B), and the Person or Persons entitled to receive the shares of Common Stock issuable upon such conversion
shall be treated for all purposes as the record holder or holders of such shares of Common Stock on such date. If the conversion is in connection with an underwritten public offering of securities registered pursuant to the Securities Act, the
conversion may, at the option of any holder tendering Preferred Stock for conversion, be conditioned upon the closing with the underwriters of the sale of securities pursuant to such offering, in which event any Persons entitled to receive Common
Stock upon conversion of Preferred Stock shall not be deemed to have converted such Preferred Stock until immediately prior to the closing of such sale of securities. 

(iii)        The Corporation shall, as soon as practicable after the surrender of the certificate or
certificates evidencing shares of Preferred Stock for conversion at the office of the Corporation or the transfer agent for the Preferred Stock or the Common Stock, issue to each holder of such shares, or its nominee or nominees, a certificate or
certificates evidencing the number of shares of Common Stock (and any other securities and property) to which it shall be entitled and, in the event that only a part of the shares evidenced by such certificate or certificates are converted, a
certificate evidencing the number of shares of Preferred Stock which are not converted. Such conversion shall be deemed to have been made immediately prior to the close of business on the date of such surrender of the shares of Preferred Stock to be
converted, except that in the case of an automatic conversion pursuant to Sections 5(a)(iv)(A) and/or 5(a)(v)(A) hereof, such conversion shall be deemed to have been made immediately prior to the closing of the offering referred to in Sections
5(a)(iv)(A) and/or 5(a)(v)(A), or in the case of an automatic conversion pursuant to Sections 5(a)(iv)(B) and/or 5(a)(v)(B) hereof, immediately prior to the close of business on the date of the election referred to in Sections 5(a)(iv)(B) and/or
5(a)(v)(B), and the Person or Persons entitled to receive the shares of Common Stock issuable 

  
 8 

 
upon such conversion shall be treated for all purposes as the record holder or holders of such shares of Common Stock at such date and shall, with respect to such shares, have only those rights
of a holder of Common Stock of the Corporation. 
 (iv)        Each share of Series A Preferred
Stock then outstanding shall be automatically converted into that number of fully paid and nonassessable shares of Common Stock determined in accordance with the provisions of Section 5(b) below upon the earlier of (A) the close of
business of the day immediately preceding the effective date of the Corporation’s registration statement filed in connection with a Qualified Public Offering (as defined in Section 6 below) or (B) the consent of the holders of at
least a majority of the outstanding shares of Series A Preferred Stock voting or consenting together as a separate class, given in person or by proxy, either in writing or by vote at a meeting called for that purpose at which the holders of Series A
Preferred Stock shall vote together as a separate class. 
 (v)        Each share of Series B
Preferred Stock and Series B-2 Preferred Stock then outstanding shall be automatically converted into that number of fully paid and nonassessable shares of Common Stock determined in accordance with the
provisions of Section 5(b) below upon the earlier of (A) the close of business of the day immediately preceding the effective date of the Corporation’s registration statement filed in connection with a Qualified Public Offering (as
defined in Section 6 below) or (B) the consent of the holders of at least a majority of the outstanding shares of Series B Preferred Stock and Series B-2 Preferred Stock, voting or consenting
together as a single class, given in person or by proxy, either in writing or by vote at a meeting called for that purpose at which the holders of Series B Preferred Stock and Series B-2 Preferred Stock shall
vote together as a single class. 
 (vi)        No fractional shares of Common Stock shall be
issued upon conversion of the Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as
determined in good faith by the Board of Directors of the Corporation. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Preferred Stock the holder is at the
time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion. 

(b)        Conversion of Preferred Stock. The Series A Preferred Stock shall be convertible
into the number of shares of Common Stock which results from dividing the Conversion Price (as defined herein) per share in effect at the time into $0.25 per share of Series A Preferred Stock being converted. The Series B Preferred Stock shall be
convertible into the number of shares of Common Stock which results from dividing the Conversion Price per share in effect at the time into $0.45 per share of Series B Preferred Stock being converted. The Series
B-2 Preferred Stock shall be convertible into the number of shares of Common Stock which results from dividing the Conversion Price per share in effect at the time into $0.45 per share of Series B-2 Preferred Stock being converted. 
 (c)        Conversion
Price. The conversion price per share for the Series A Preferred Stock shall initially be $0.25 (the “Series A Conversion Price”) and shall be subject to adjustment from time to time as provided herein. The conversion
price per share for the Series B 

  
 9 

 
Preferred Stock shall initially be $0.45 (the “Series B Conversion Price”) and shall be subject to adjustment from time to time as provided herein. The conversion price
per share for the Series B-2 Preferred Stock shall initially be $0.45 (the “Series B-2 Conversion Price”) and shall be subject to adjustment from
time to time as provided herein. Each of the Series A Conversion Price, the Series B Conversion Price and the Series B-2 Conversion Price are sometimes referred to herein as the “Conversion
Price”. 
 (d)        Adjustment for Stock Splits and Combinations. If
outstanding shares of the Common Stock of the Corporation shall be subdivided into a greater number of shares, or a dividend in Common Stock or other securities of the Corporation convertible into or exchangeable for Common Stock, shall be paid in
respect to the Common Stock of the Corporation, the applicable Conversion Price in effect immediately prior to such subdivision or at the record date of such dividend shall be proportionately reduced, and conversely, if outstanding shares of the
Common Stock of the Corporation shall be combined into a smaller number of shares, the applicable Conversion Price in effect immediately prior to such combination shall be proportionately increased. 

Any adjustment to a Conversion Price under this Section 5(d) shall become effective at the close of business on the date the subdivision
or combination referred to herein becomes effective. 
 (e)        Reorganizations, Mergers,
Consolidations or Reclassifications. In the event of any capital reorganization, any reclassification of the Common Stock (other than a change in par value or as a result of a stock dividend, subdivision,
split-up or combination of shares), the consolidation or merger of the Corporation with or into another Person (excluding a consolidation or merger described in Section 2(f)(i)(a) of this Article IV)
(collectively referred to hereinafter as “Reorganizations”), the holders of the Preferred Stock shall thereafter be entitled to receive, and provision shall be made therefor in any agreement relating to a
Reorganization, upon conversion of the Preferred Stock the kind and number of shares of Common Stock or other securities or property (including cash) of the Corporation, or other corporation resulting from such consolidation or surviving such merger
to which a holder of the number of shares of the Common Stock of the Corporation which the applicable series of Preferred Stock entitled the holder thereof to convert to immediately prior to such Reorganization would have been entitled to receive
with respect to such Reorganization; and in any such case appropriate adjustment shall be made in the application of the provisions herein set forth with respect to the rights and interests thereafter of the holders of the Preferred Stock to the end
that the provisions set forth herein (including the specified changes and other adjustments to the applicable Conversion Price) shall thereafter be applicable, as nearly as reasonably may be, in relation to any shares, other securities or property
thereafter receivable upon conversion of the Preferred Stock. The provisions of this Section 5(e) shall similarly apply to successive Reorganizations. 

(f)        Sale of Additional Shares. 

(i)        If at any time or from time to time following the date of the initial issuance of shares
of Series B-2 Preferred Stock, the Corporation shall issue or sell (or is deemed to have issued or sold) Additional Shares of Common Stock other than as a dividend or other distribution on any class of stock
and other than as a subdivision or combination of shares of 

  
 10 

 
Common Stock as provided in Section 5(d) above, for a consideration per share less than the then existing Series B-2 Conversion Price, then, and in
each such case, the then existing Series B-2 Conversion Price shall be reduced, as of the opening of business on the date of such issuance or sale, to the consideration per share received by the Corporation
for such issue or deemed issue of the Additional Shares of Common Stock; provided that if such issuance or deemed issuance was without consideration, then the Corporation shall be deemed to have received an aggregate of $0.001 of consideration for
all such Additional Shares of Common Stock issued or deemed to be issued; provided, however, that solely with respect to any shares of Series B-2 Preferred Stock issued in exchange for shares of Series B
Preferred Stock, the Series B-2 Conversion Price shall not be reduced pursuant to the foregoing, but shall instead be reduced in the manner described in Section 5(f)(ii) below (mutatis mutandis). 

(ii)        If at any time or from time to time following the date of the initial issuance of shares
of Series B-2 Preferred Stock, the Corporation shall issue or sell (or is deemed to have issued or sold) Additional Shares of Common Stock other than as a dividend or other distribution on any class of stock
and other than as a subdivision or combination of shares of Common Stock as provided in Section 5(d) above, for a consideration per share less than the then existing Series B Conversion Price, then, and in each such case, the then existing
Series B Conversion Price shall be reduced, as of the opening of business on the date of such issuance or sale, to a price determined by multiplying the Series B Conversion Price by a fraction, the numerator of which shall be the number of shares of
Common Stock outstanding immediately prior to such issuance (including shares of Common Stock issuable upon conversion of the Series B Preferred Stock and the number of shares of Common Stock which could be obtained through the exercise or
conversion of all other rights, options and convertible securities outstanding on the date immediately prior to such issuance) plus the number of shares of Common Stock that the aggregate consideration received by the Corporation for such issuance
would purchase at the then existing Series B Conversion Price; and the denominator of which shall be the number of shares of Common Stock outstanding immediately prior to such issuance (including shares of Common Stock issuable upon conversion of
the Series B Preferred Stock and the number of shares of Common Stock which could be obtained through the exercise or conversion of all other rights, options and convertible securities outstanding on the date immediately prior to such issuance) plus
the number of shares of Additional Shares of Common Stock actually issued in such issuance. 

(iii)        If at any time or from time to time following the date of the initial issuance of shares
of Series B-2 Preferred Stock, the Corporation shall issue or sell (or is deemed to have issued or sold) Additional Shares of Common Stock other than as a dividend or other distribution on any class of stock
and other than as a subdivision or combination of shares of Common Stock as provided in Section 5(d) above, for a consideration per share less than the then existing Series A Conversion Price, then, and in each such case, the then existing
Series A Conversion Price shall be reduced, as of the opening of business on the date of such issuance or sale, to a price determined by multiplying the Series A Conversion Price by a fraction, the numerator of which shall be the number of shares of
Common Stock outstanding immediately prior to such issuance (including shares of Common Stock issuable upon conversion of the Series A Preferred Stock and the number of shares of Common Stock which could be obtained through the exercise or
conversion of all other rights, options and convertible securities outstanding on the date immediately prior to such issuance) plus the number of shares of Common Stock that the 

  
 11 

 
aggregate consideration received by the Corporation for such issuance would purchase at the then existing Series A Conversion Price; and the denominator of which shall be the number of shares of
Common Stock outstanding immediately prior to such issuance (including shares of Common Stock issuable upon conversion of the Series A Preferred Stock and the number of shares of Common Stock which could be obtained through the exercise or
conversion of all other rights, options and convertible securities outstanding on the date immediately prior to such issuance) plus the number of shares of Additional Shares of Common Stock actually issued in such issuance. 

(iv)        For the purpose of making any adjustment in the applicable Conversion Price, or number of
shares of Common Stock issuable upon conversion of the applicable series of Preferred Stock, as provided above, the consideration received by the Corporation for any issue or sale of securities shall: 

(a)        To the extent it consists of cash, be computed at the net amount of cash received by the
Corporation after deduction of any expenses payable directly or indirectly by the Corporation and any underwriting or similar commissions, compensations, discounts or concessions paid or allowed by the Corporation in connection with such issue or
sale; 
 (b)        To the extent it consists of property other than cash, the consideration other
than cash shall be computed at the fair market value thereof as determined in good faith by the Board of Directors, at or about, but as of, the date of the adoption of the resolution specifically authorizing such issuance or sale, irrespective of
any accounting treatment thereof; provided, however, that such fair market value as determined by the Board of Directors, when added to any cash consideration received in connection with such issuance or sale, shall not exceed the aggregate market
price of the Additional Shares of Common Stock being issued, as of the date of the adoption of such resolution; and 

(c)        If Additional Shares of Common Stock, Convertible Securities (as defined below) or Rights
(as defined below) are issued or sold together with other stock or securities or other assets of the Corporation for consideration which covers both, the consideration received for the Additional Shares of Common Stock, Convertible Securities or
Rights shall be computed as that portion of the consideration so received which is reasonably determined in good faith by the Board of Directors to be allocable to such Additional Shares of Common Stock, Convertible Securities or Rights. 

(v)        For the purpose of making any adjustment in the applicable Conversion Price provided in
Section 5(f) hereof, if at any time, or from time to time, the Corporation issues any stock or other securities convertible into Additional Shares of Common Stock (such stock or other securities being hereinafter referred to as
“Convertible Securities”) or issues any rights or options to purchase Additional Shares of Common Stock or Convertible Securities (such rights or options being hereinafter referred to as
“Rights”), then, and in each such case, if the Effective Conversion Price (as hereinafter defined) of such Rights or Convertible Securities shall be less than the applicable Conversion Price in effect
immediately prior to the issuance of such Rights or Convertible Securities, the Corporation shall be deemed to have issued at the time of the issuance of such Rights or Convertible Securities the maximum number of Additional Shares of Common Stock
issuable upon exercise or conversion thereof and 

  
 12 

 
to have received in consideration for the issuance of such shares an amount equal to the aggregate Effective Conversion Price of such Rights or Convertible Securities. For the purposes of this
Section 5(f)(v), “Effective Conversion Price” shall mean an amount equal to the sum of the lowest amount of consideration, if any, received or receivable by the Corporation with respect to any one
(1) Additional Share of Common Stock upon issuance of the Rights or Convertible Securities and upon their exercise or conversion, respectively. No further adjustment of the applicable Conversion Price adjusted upon the issuance of such Rights
or Convertible Securities shall be made as a result of the actual issuance of Additional Shares of Common Stock on the exercise of any such Rights or the conversion of any such Convertible Securities. If any such Rights or the conversion privilege
represented by any such Convertible Securities shall expire without having been exercised, such applicable Conversion Price, as applicable, as adjusted upon the issuance of such Rights or Convertible Securities shall be readjusted to the Conversion
Price, as applicable, which would have been in effect had such adjustment been made on the basis that the only Additional Shares of Common Stock so issued were the Additional Shares of Common Stock, if any, actually issued or sold on the exercise of
such Rights or on the conversion of such Convertible Securities, and such Additional Shares of Common Stock, if any, were issued or sold for the consideration actually received by the Corporation upon such exercise, plus the consideration, if any,
actually received by the Corporation for the granting of all such Rights, whether or not exercised, plus the consideration received for issuing or selling the Convertible Securities actually converted plus the consideration, if any, actually
received by the Corporation (other than by cancellation of liabilities or obligations evidenced by such Convertible Securities) on the conversion of such Convertible Securities. No readjustment pursuant to this subsection (f)(v) shall have the
effect of increasing the applicable Conversion Price to an amount which exceeds the lower of (a) the applicable Conversion Price on the original adjustment date and (b) the applicable Conversion Price that would have resulted from any
issuance of Additional Shares of Common Stock between the original adjustment date and such readjustment date. 

(g)        Additional Shares of Common Stock. “Additional Shares of Common
Stock” as used in this Section 5 shall mean all shares of Common Stock issued or deemed to be issued by the Corporation, whether or not subsequently reacquired or retired by the Corporation, other than: 

(i)        shares of Series B-2 Preferred Stock and warrants
to purchase shares of Series B-2 Preferred Stock issued pursuant to the Purchase Agreement; 

(ii)        shares of Common Stock issued upon the conversion of, or as a dividend or distribution
on, any shares of the Corporation’s Preferred Stock; 
 (iii)        shares of Common Stock
issued or issuable to employees or officers or directors or outside consultants or contractors of the Corporation or any Subsidiary pursuant the exercise or conversion of options, warrants or other Convertible Securities issued pursuant to a plan,
agreement or arrangement duly approved by the Board of Directors; 
 (iv)        shares of Common
Stock issued or issuable pursuant to the exercise or conversion of options, warrants or other Convertible Securities outstanding as of the date hereof; 

  
 13 

 (v)        shares of Common Stock issued pursuant
to a Qualified Public Offering; 
 (vi)        shares of Common Stock issued to effect any stock
split, stock dividend or recapitalization of the Corporation; 
 (vii)        shares of Common
Stock and/or options, warrants or other Common Stock purchase rights issued in connection with the Corporation obtaining lease financing, whether issued to a lessor, guarantor or other Person, provided that such issuance is pursuant to an agreement
or arrangement duly approved by the Board of Directors; 
 (viii)        shares of Common Stock
and/or options, warrants or other Common Stock purchase rights issued in connection with any borrowings, direct or indirect, from a bank or other financial institution by the Corporation, provided that such issuance is pursuant to an agreement or
arrangement duly approved by the Board of Directors; 
 (ix)        shares of Common Stock and/or
options, warrants or other Common Stock purchase rights issued in connection with the acquisition of all or a substantial portion of the assets or the business of another entity by the Corporation, provided that such issuance is pursuant to an
agreement or arrangement duly approved by the Board of Directors; and 
 (x)        shares of
Common Stock and/or options, warrants or other Common Stock purchase rights issued in connection with any corporate partnering transaction, strategic alliance, technology transfer or similar transaction between the Corporation and any other Person,
provided that such issuance is pursuant to an agreement or arrangement duly approved by the Board of Directors. 

(h)        Common Stock. “Common Stock” as used in this
Section 5 shall mean any shares of any class of the Corporation’s capital stock other than the Preferred Stock. The Common Stock issuable upon conversion of the Preferred Stock, however, shall be the Common Stock of the Corporation as
constituted on the date hereof, except as otherwise provided in this Section 5. 

(i)        Certificate of Adjustment. In each case of an adjustment or readjustment of the
Conversion Price or the number of shares of Common Stock or other securities issuable upon conversion of any series of Preferred Stock, the Corporation, at its expense, shall cause the Chief Financial Officer or Treasurer of the Corporation to
compute such adjustment or readjustment in accordance with this Amended and Restated Certificate of Incorporation and prepare a certificate showing such adjustment or readjustment, and shall mail such certificate, by first-class mail, postage
prepaid, to each registered holder of such Preferred Stock at the holder’s address as shown on the Corporation’s stock transfer books. The certificate shall set forth such adjustment or readjustment, showing in detail the facts upon which
such adjustment or readjustment is based, including a statement of (i) the consideration received or to be received by the Corporation for any Additional Shares of Common Stock issued or sold or deemed to have been issued or sold; (ii) the
applicable Conversion Price at the time in effect for such Preferred Stock; and (iii) the number of Additional Shares of Common Stock and the type and amount, if 

  
 14 

 
any, of other property which at the time would be received upon conversion of such Preferred Stock. Such notice may be given in advance of such adjustment or readjustment and may be included as
part of a notice required to be given pursuant to Section 5(j) below. 
 (j)        Notices
of Record Date. In the event the Corporation shall propose to take any action of the type or types requiring an adjustment to the Conversion Price of any series of Preferred Stock, or the number or character of such Preferred Stock as set forth
herein, the Corporation shall give notice to the holders of such Preferred Stock as applicable in the manner set forth in Section 5(i) above, which notice shall specify the record date, if any, with respect to any such action and the date on
which such action is to take place. Such notice shall also set forth such facts with respect thereto as shall be reasonably necessary to indicate the effect of such action (to the extent such effect may be known at the date of such notice) on the
Conversion Price and the number, kind or class of shares or other securities or property which shall be deliverable upon the occurrence of such action or deliverable upon the conversion of the Preferred Stock. In the case of any action which would
require the fixing of a record date, such notice shall be given at least ten (10) days prior to the date so fixed, and in case of all other action, such notice shall be given at least twenty (20) days prior to the taking of such proposed
action. Notwithstanding the requirements of this Section 5(j), this Section 5(j) shall not be applicable and no such notice shall be required with respect to any action that is, or has been, approved by the Requisite Holders. 

(k)        Reservation of Stock Issuable Upon Conversion. The Corporation shall at all times
reserve and keep available out of its authorized but unissued shares of Common Stock, solely for the purpose of effecting the conversion of the shares of Preferred Stock, such number of its shares of Common Stock as shall from time to time be
sufficient to effect a conversion of all outstanding shares of Preferred Stock, and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of
Preferred Stock, the Corporation shall promptly seek such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such
purpose. In the event of the consolidation or merger of the Corporation with another corporation where the Corporation is not the surviving corporation, effective provisions shall be made in the certificate or articles of incorporation, merger or
consolidation, or otherwise of the surviving corporation so that such corporation will at all times reserve and keep available a sufficient number of shares of Common Stock or other securities or property to provide for the conversion of Preferred
Stock in accordance with the provisions of this Section 5. 
 (l)        Payment of
Taxes. The Corporation shall pay all taxes and other governmental charges (other than any income or other taxes imposed upon the profits realized by the recipient) that may be imposed in respect of the issue or delivery of shares of Common Stock
or other securities or property upon conversion of shares of Preferred Stock, excluding any tax or other charge imposed in connection with any transfer involved in the issue and delivery of shares of Common Stock or other securities in a name other
than that in which the shares of Preferred Stock so converted were registered. 

(m)        Status of Converted Stock. In the event any shares of Preferred Stock shall be
converted pursuant to Section 5 hereof, the shares so converted shall be canceled and 

  
 15 

 
shall not be issuable by the Corporation, and this Amended and Restated Certificate of Incorporation shall be appropriately amended to effect the corresponding reduction in the Corporation’s
authorized capital stock. 
 (n)        No Impairment. Subject to the right of this
Corporation to amend its Certificate of Incorporation or take any other corporate action upon obtaining the necessary approvals required by its Certificate of Incorporation and applicable law, the Corporation shall not amend this Amended and
Restated Certificate of Incorporation or participate in any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, for the purpose of avoiding or seeking to avoid the
observance or performance of any of the terms to be observed or performed hereunder by the Corporation, but shall at all times in good faith use its best efforts, and assist in carrying out all such action as may be reasonably necessary or
appropriate in order to protect the Conversion Rights of the holders of the Preferred Stock against dilution or other impairment. 

6.        Miscellaneous. 

(a)        Definitions. 

(i)    “Additional Shares of Common Stock” shall have that meaning set forth in
Section 5(g) hereof. 
 (ii)    “Common Stock” shall have that meaning set forth in
Section 5(h) hereof. 
 (iii)    “Conversion Price” shall have that meaning
set forth in Section 5(c) hereof. 
 (iv)    “Conversion Rights” shall have
that meaning set forth in Section 5 hereof.  
 (v)    “Convertible
Securities” shall have that meaning set forth in Section 5(f)(v) hereof.  

(vi)    “Effective Conversion Price” shall have that meaning set forth in
Section 5(f)(v) hereof. 
 (vii)    “Liquidation Value” shall have that
meaning set forth in Section 2(e) hereof. 
 (viii)    “Person” shall mean
an individual, a corporation, a partnership, a trust or unincorporated organization or any other entity or organization. 

(ix)    “Preferred Stock” shall have that meaning set forth in the first paragraph of this
Article IV. 
 (x)    “Purchase Agreement” means that certain Series B-2 Preferred Stock and Warrant Purchase Agreement, dated on or about the date of the filing of this Amended 

  
 16 

 
and Restated Certificate of Incorporation, by and among the Corporation and the Persons party thereto, as the same may be amended, restated or otherwise modified from time to time in accordance
with the terms thereof. 
 (xi)    “Qualified Public Offering” means a firmly
underwritten public offering of the Corporation’s Common Stock on a Form S-1 Registration Statement, or any similar form of registration statement, adopted by the Securities and Exchange Commission (the
“Commission”) from and after the date hereof, filed with the Commission under the Securities Act of 1933, as amended, with respect to which the Corporation receives gross proceeds of at least $25,000,000 (prior to deduction for
underwriters’ discounts and expenses relating to such public offering, including without limitation, fees of the Corporation’s counsel) and the price to the public is at least $1.35 per share (equitably adjusted for all stock splits, sub-divisions, stock dividends, combinations and the like with respect to such shares). 

(xii)    “Requisite Holders” shall mean the holders of at least (i) a majority of the then
outstanding shares of Series A Preferred Stock, voting or acting by written consent together as a separate class, (ii) a majority of the then outstanding shares of Series B Preferred Stock, voting or acting by written consent together as a
separate class, and (iii) a majority of the then outstanding shares of Series B-2 Preferred Stock, voting or acting by written consent together as a separate class. 

(xiii)    “Series A Conversion Price” shall have that meaning set forth in
Section 5(c) hereof. 
 (xiv)    “Series A Preferred Stock” shall have that
meaning set forth in the first paragraph of this Article IV. 
 (xv)    “Series B Conversion
Price” shall have that meaning set forth in Section 5(c) hereof. 

(xvi)    “Series B Preferred Stock” shall have that meaning set forth in the first paragraph of
this Article IV. 
 (xvii)    “Series B-2 Conversion
Price” shall have that meaning set forth in Section 5(c) hereof. 

(xviii)    “Series B-2 Preferred Stock” shall have
that meaning set forth in the first paragraph of this Article IV. 
 (xix)    “Subsidiary”
means any Person of which equity securities possessing a majority of the ordinary voting power in electing the board of directors are, at the time as of which such determination is being made, owned by the Corporation either directly or
indirectly through one or more Subsidiaries. 
 (b)        Notices. All notices referred to
herein, except as otherwise expressly provided, shall be made by registered or certified mail, return receipt requested, postage prepaid and shall be deemed to have been given when so mailed. 

  
 17 

 (c)        Conflicts. So long as any of the
Preferred Stock is outstanding, in the event of any conflict between the provisions of this Article IV and the remainder of this Amended and Restated Certificate of Incorporation or the Bylaws of the Corporation (both as presently existing or
hereafter amended and supplemented), the provisions of this Article IV shall be and remain controlling. 

C.        Common Stock. The rights, preferences, privileges and restrictions
granted to and imposed on the Common Stock are as set forth below in this Article IV C. 

1.        Dividends. Subject to the prior rights of holders of all classes of stock at the time
outstanding having prior rights as to dividends, the holders of the Common Stock shall be entitled to receive, when, as and if declared by the Board of Directors, out of any assets of this Corporation legally available therefor, any dividends as may
be declared from time to time by the Board of Directors. 
 2.        Liquidation Rights.
Upon the liquidation, dissolution or winding up of this Corporation, the assets of this Corporation shall be distributed as provided in Section 2 of Article IV B hereof. 

3.        Redemption. The Common Stock is not redeemable at the option of the holder. 

4.        Voting Rights. The holder of each share of Common Stock shall have the right to one
(1) vote for each such share, and shall be entitled to notice of any stockholders’ meeting in accordance with the Bylaws of this Corporation, and shall be entitled to vote upon such matters and in such manner as may be provided by this
Amended and Restated Certificate of Incorporation and law; provided, however, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to the Restated Certificate that relates solely
to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Restated
Certificate or pursuant to the General Corporation Law. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority
of the stock of this Corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law. 

5.        Directors. The holders of outstanding Common Stock shall be entitled to elect
directors as provided in subsection 4(b) of Article IV B. 
 ARTICLE V. 

Except as otherwise provided in this Amended and Restated Certificate of Incorporation, in furtherance and not in limitation of the powers
conferred by statute, the Board is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of this Corporation. 

ARTICLE VI. 

  
 18 

 Subject to any additional vote required by this Amended and Restated Certificate of
Incorporation, the number of directors of this Corporation shall be determined in the manner set forth in the Bylaws of this Corporation. 

ARTICLE VII. 
 Elections
of directors need not be by written ballot unless the Bylaws of this Corporation shall so provide. 
 ARTICLE VIII. 

Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws of this Corporation may provide. The books of
this Corporation may be kept (subject to any provision contained in the statutes) outside the State of Delaware at such place or places as may be designated from time to time by the Board or in the Bylaws of this Corporation. 

ARTICLE IX. 
 To the
fullest extent permitted by the General Corporation Law, a director of this Corporation shall not be personally liable to this Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General
Corporation Law is amended after approval by the stockholders of this Article IX to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of this Corporation shall be
eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended. 
 Any amendment, repeal or
modification of the foregoing provisions of this Article IX by the stockholders of this Corporation shall not adversely affect any right or protection of a director of this Corporation existing at the time of, or increase the liability of any
director of this Corporation with respect to any acts or omissions of such director occurring prior to, such amendment, repeal or modification. 

ARTICLE X. 
 This
Corporation reserves the right to amend, alter, change or repeal any provision contained in this Amended and Restated Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon stockholders
herein are granted subject to this reservation. 
 ARTICLE XI. 

This Corporation shall have the power to indemnify (and advance expenses to), to the fullest extent permitted by the General Corporation Law,
as it presently exists or may hereafter be amended from time to time, any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or
investigative (a “Proceeding”) by reason of the fact that he or she is or was a director, officer, employee or agent of this Corporation or is or was serving at the request of this Corporation as a director,
officer, employee or agent of another corporation, 

  
 19 

 
partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys’ fees), judgments, fines and amounts
paid in settlement actually and reasonably incurred by such person in connection with any such Proceeding, including in excess of the indemnification and advancement otherwise permitted by Section 145 of the General Corporation Law. 

Any amendment, repeal or modification of the foregoing provisions of this Article XI shall not adversely affect any right or protection of a
director, officer, employee, agent or other person existing at the time of, or increase the liability of any such person with respect to any acts or omissions of such person occurring prior to, such amendment, repeal or modification. 

ARTICLE XII. 
 To the
fullest extent permitted by applicable law, this Corporation renounces any interest or expectancy of this Corporation in, or in being offered an opportunity to participate in, an Excluded Opportunity; provided, that nothing herein is intended to
diminish the fiduciary duties of any director of this Corporation. An “Excluded Opportunity” is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise
comes into the possession of, (i) any director of this Corporation who is not an employee of this Corporation or any of its subsidiaries, or (ii) any holder of Preferred Stock, any Affiliate of such holder, or any partner, member,
director, stockholder, employee or agent of any such holder or Affiliate, in each case other than someone who is an employee of this Corporation or any of its subsidiaries (collectively, “Covered Persons”),
unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person’s capacity as a director of this
Corporation. 
 ARTICLE XIII. 

In connection with repurchases by this Corporation of its Common Stock from employees, officers, directors, advisors, consultants or other
persons performing services for this Corporation or any subsidiary pursuant to agreements under which this corporation has the option to repurchase such shares at cost upon the occurrence of certain events, such as the termination of employment,
Section 500 of the California Corporations Code shall not apply in all or in part with respect to such repurchases. In the case of any such repurchases, distributions by this Corporation may be made without regard to the “preferential
dividends arrears amount” or any “preferential rights amount,” as such terms are defined in Section 500(b) of the California Corporations Code. 

*        *        * 

THIRD:  The foregoing amendment and restatement was approved by the holders of the requisite number of shares of said
corporation in accordance with Section 228 of the General Corporation Law. 
 FOURTH:  That said Amended and
Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of this corporation’s Certificate of 

  
 20 

 
Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law. 

IN WITNESS WHEREOF, this Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of this
corporation on this 8th day of September, 2017. 
  

			
	By:	 	 /s/ James B. Breitmeyer

	Name: James B. Breitmeyer, M.D., Ph.D.
	Title: President and CEO

  
 21 

 EXHIBIT C 

PATENT RIGHTS 
 [***] 

  
 1 

 EXHIBIT D 

BIOSITE SERVICE AGREEMENT OBLIGATIONS 

  
 2 

 EXHIBIT A 

COMMERCIALIZATION TERMS 

Because Institution is committed to being a center of excellence in research, it will not directly commercialize the products resulting from
the research, and must rely on third parties for development and eventual commercialization. The following terms and conditions shall apply in the event that Institution, directly or through one or more Licensees (as defined below), elects to
develop a Product (as defined below) for commercialization: 
  

	1.	 Definitions. For purposes of this Exhibit A, the terms defined in this Section 1 shall have the
respective meanings set forth below. All capitalized terms not defined below shall have the respective meanings set forth in Section 1 of the Agreement. 

1.1    “First Commercial Sale” shall mean, with respect to any Product and any country,
the first sale of such Product by Institution, its licensee or their respective Affiliates to customers who are not Affiliates in such country after all applicable marketing and pricing approvals (if any) have been granted by the applicable
governing health authority of such country. 
 1.2    “License Agreement” means an
agreement into which Institution enters with a Third Party (“Licensee(s)”), for the purpose of (i) granting certain rights, (ii) granting an option to certain rights, or (iii) forbearing the exercise of any rights to
(a) use a method or composition or perform a service which would otherwise infringe, induce to infringe or contribute to infringement, of any pending or issued claim within patents that are assigned to Institution and claim an Antibody or the
use thereof; or (b) make, use or sell Products (whether or not there exist any patents that claim such Products or the use thereof). 

1.3    “Net Sales” shall mean, with respect to any Product, the gross sales price of such
Product invoiced by Institution’s Licensees or their respective Affiliates to customers who are not Affiliates (or are Affiliates but are the end users of such Product) less, to the extent actually paid or accrued by the selling party,
(a) credits, allowances, discounts and rebates to, and chargebacks from the account of, such customers for spoiled, damaged, ou-tdated and returned Product; (b) freight and insurance costs incurred
by the selling party in transporting such Product in final form to such customers; (c) cash, quantity and trade discounts, rebates and other price reductions for such Product given to such customers under price reduction programs that are
consistent with industry practices and price reductions given for similar products by such selling party; (d) sales taxes incurred on the sale of such selling party in final form to such customers; and (e) customs duties, surcharges and
other governmental charges incurred in exporting or importing such Product in final form to such customers. 

1.4    “Phase I Clinical Trial” shall mean a human clinical trial in any country that is
intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 CFR 312.21(a), or its foreign equivalent; 

1.5    “Phase II Clinical Trial” shall mean a human clinical trial in any country that is
intended to initially evaluate the effectiveness of a Product for a particular indication or indications in patients with the disease or indication under study or that would otherwise satisfy requirements of 21 CFR 312.21(b), or its foreign
equivalent; and 

  
 3 

 1.6    “Phase III Clinical Trial” shall
mean a pivotal human clinical trial in any country the results of which could be used to establish safety and efficacy of a Product as a basis for a BLA or that would otherwise satisfy requirements of 21 CFR 312.21(c), or its foreign equivalent.

 1.7    “Product” shall mean a product that directly or indirectly incorporates,
contains, uses, is based on or is derived from the Antibody or Antibody Fragment for the Target or the results of the use of the Antibodies. 
  

	2.	 CONSIDERATION 

2.1        Milestone Payments. The Institution shall require its Licensees to
pay to Biosite the following milestone payments with respect to each Product: 
  

															
	 [***]
	  	 [***]
	  		  		  		  		  		  	
	 [***]
	  	 [***]
	  		  		  		  		  		  	
	 [***]
	  	 [***]
	  		  		  		  		  		  	
	 [***]
	  	 [***]
	  		  		  		  		  		  	
	 [***]
	  	 [***]
	  		  		  		  		  		  	
	 [***]
	  	 [***]
	  		  		  		  		  		  	

 2.2        Royalties. For a period twelve
(12) years after the First Commercial Sale of each Product in each country, Institution shall require its Licensees to pay to Biosite [***] of Net Sales by such Licensees, their licensees and their respective Affiliates of such Product in such
country. Biosite shall be the third party beneficiary of such License Agreements. 
  

	3.	 PAYMENT REPORTS AND PAYMENT TERMS 

3.1        Payment Reports. Within ninety (90) days after the end of each
June 30th following the First Commercial Sale of a Product by the Licensees or their sublicensees, Institution or its Licensees shall furnish to Biosite a written report showing in reasonably
specific detail, on a Product-by-Product and country-by-country basis, (a) the gross
sales of all Products sold by the Licensees, their sublicensees and their respective Affiliates during the twelve (12) months preceding such June 30th and the calculation of Net Sales from
such gross sales; (b) the calculation of royalties, if any, that shall have accrued based upon such Net Sales; (c) the withholding taxes, if any, required by law to be deducted with respect to such sales; and (d) the exchange rates,
if any, used in determining the amount of United States dollars. With respect to revenues received by the Licensees, their sublicensees or their respective Affiliates and invoiced in United States dollars, all such amounts shall be expressed in
United States dollars. With respect to Net Sales of Products by the Licensees, their sublicensees or their respective Affiliates and invoiced in a currency other than United States dollars, all such amounts shall be converted into their equivalent
dollar value using such party’s standard accounting procedures and conversion methodology, which shall be consistent with Generally Accepted Accounting Principles. Institution, its Licensees, their sublicensees and their respective Affiliates
shall keep complete and accurate records in sufficient detail to enable the amounts payable hereunder to be determined. 

3.2        Audits. Upon the written request of Biosite and not more than once
in each calendar year, Institution and the Licensees shall permit an independent certified public accounting firm of nationally recognized standing, selected by Biosite and reasonably acceptable to Institution, at

  
 4 

 
Biosite’s expense, to have access during normal business hours to such of the records of Institution and the Licensees that Biosite has not had audited previously under this Agreement as may
be reasonably necessary to verify the accuracy of the payment reports hereunder for any year ending not more than twenty-four (24) months prior to the date of such request. If such accounting firm concludes that additional amounts were owed
during the audited period, Institution shall pay such additional amounts within thirty (30) days of the date Biosite delivers to Institution such accounting firm’s written report so concluding. The fees charged by such accounting firm
shall be paid by Biosite; provided, however, if the audit discloses that the royalties payable by Institution for such period are more than [***] of the royalties actually paid for such period, then Institution shall pay the reasonable fees and
expenses charged by such accounting firm. Biosite shall cause its accounting firm to retain all financial information subject to review under this Section 3.2 in strict confidence; provided, however, that Institution shall have the right to
require that such accounting firm, prior to conducting such audit, enter into an appropriate non-disclosure agreement with Institution regarding such financial information. The accounting firm shall disclose
to Biosite only whether the reports are correct or not and the amount of any discrepancy. No other information shall be shared. Biosite shall treat all such financial information as Institution’s Confidential Information (as defined in
Section 4.1 of the Agreement). 
 3.3        Payment Terms. 

3.3.1        Milestones. All amounts payable under Section 2.1 of this
Exhibit A shall be payable within ninety (90) days of the first June 30th following the occurrence of the applicable event. Payment of amounts in whole or in part may be made in advance of
such due dates. 
 3.3.2        Royalties. All amounts payable as indicated
by each payment report provided for under Section 3.1 of this Exhibit shall be payable within ninety (90) days of June 30th of each year under this Agreement and for the period ending on
those dates during the term of this Agreement. Payment of amounts in whole or in part may be made in advance of such due dates. 

3.3.3        Payment Method. All payments by a party to the other party under
this Agreement shall be paid in United States dollars and all such payments shall be originated from a United States bank located in the United States and made by bank wire transfer in immediately available funds to such account as the payee shall
designate before such payment is due. 
  

	4.	 INDEMNITY 

4.1        Indemnity. Institution shall, and shall require its Licensees to,
indemnify and hold Biosite harmless, and hereby forever releases and discharges Biosite, from and against all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and costs) resulting from all claims, demands, actions
and other proceedings by any Third Party to the extent arising from (a) the use of the Antibodies or the making, using or selling of Products by Institution, its Licensees or their Affiliates or sublicensees, (b) the use of any Target, or
the development, sale or delivery of an Antibody to the extent it is specific to any Target, by Biosite in performing the Services, or (c) the gross negligence or willful misconduct of Institution, its Licensees or their Affiliates or
sublicensees in the performance of its obligations, and its permitted activities, under this Agreement. Notwithstanding any other provision of this paragraph, Institution indemnifies Biosite hereunder, only in proportion to and to the extent that
all losses, liabilities, damages and expenses (including reasonable attorneys’ fees and costs) is caused by Institution, it directors, officers and 

  
 5 

 
employees. Additionally, Institution will require the same level of indemnification for Biosite in its commercial licenses, if any, arising from the Services hereunder as Institution obtains for
itself. 
 4.2        Procedure. Biosite shall promptly notify Institution of
any claim, demand, action or other proceeding for which Biosite intends to claim such indemnification. Institution shall have the right to participate in, and to the extent it so desires jointly with any other indemnitor similarly noticed, to assume
the defense thereof with counsel selected by Institution; provided, however, that Biosite shall have the right to retain its own counsel, with the fees and expenses to be paid by Institution, if representation of Biosite by the counsel retained by
Institution would be inappropriate due to actual or potential differing interests between Biosite and any other party represented by such counsel in such proceedings. Institution may not settle or otherwise consent to an adverse judgment in any such
claim, demand, action or other proceeding that diminishes the rights or interests of Biosite without the prior express written consent of Biosite, which consent shall not be unreasonably withheld or delayed. Biosite, its employees and agents, shall
reasonably cooperate with Institution and its legal representatives in the investigation of any claim, demand, action or other proceeding covered by this Section 4. 

4.3        Insurance. Institution or its Licensees hereunder shall maintain
such insurance with respect to the development, manufacture and sales of Products by Institution, its Affiliates or Licensees in such amounts as Institution, or its Licensees hereunder, customarily maintains with respect to the development,
manufacture and sales of its other products. Institution or its Licensees hereunder shall maintain such insurance for so long as it continues to develop, manufacture or sell Products, and thereafter for so long as it customarily maintains insurance
for itself covering the development, manufacture and sales of its other products. Biosite shall maintain liability insurance with financially sound and reputable insurers with insurance coverage against loss from such risks and in such amounts as is
customary for well-insured companies or institutions engaged in similar businesses or services, including comprehensive liability coverage with contractual liability coverage sufficient to cover its indemnification obligations under this Agreement.

  
 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]